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SU M M A RY
High myopia (more severe than -6.00 Diopters) is one of the leading causes of blindness and 
vision impairment in the world. Its prevalence has rapidly been growing and the estimated 
number o f myopic people worldwide is expected to be -2.5 billion by the year 2020.
My experimental work covered three topics: (1) characterization of the quantity and quality 
o f mouthwash-extracted DNA; (2) genetic association studies, and (3) evaluation o f an 
imprinting effect in high myopia.
Mouthwash-derived DNA is an important source o f human DNA for large-scale genetic 
studies. Thus, potential methods o f DNA quantification (spectrophotometry, fluorometry, gel 
electrophoresis and qPCR) and quality assessment (gel electrophoresis and PCR) were 
evaluated. Regarding DNA quantification methods, fluorometry compared favorably to the 
gold-standard qPCR. DNA quality assessments revealed that -10%  of collected buccal DNA 
samples were severely degraded -  a phenomenon that was shown to be partly 
subject-specific.
Myopia association studies were performed for: genes in MYP regions, the myocilin gene, 
the collagen type I alpha 1 gene and the collagen type II alpha 1 gene. These genes have been 
linked to myopia because of their function and/or previous positive findings. All tests were 
performed on a combined dataset o f complex high myopia pedigrees and cases/controls, 
applying likelihood ratio statistics and Bonferroni correction to account for multiple testing. 
The results suggested that none of the genes examined have an important influence on 
susceptibility to high myopia.
There is greater resemblance o f refractive error between siblings than between parents and 
offspring, implying the possibility o f imprinting in the aetiology of myopia. Thus, tests for 
imprinting were performed on “trio” pedigrees, applying Z-score and T2-test statistics and 
permutation to account for multiple testing. The results tentatively suggested that parent-of- 
origin effects and/or by maternal effects contribute to myopia development.
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INTRODUCTION
Originating from Aristotle, reports on myopia (shortsightedness) are known from 
about the last 2000 years [1]. Yet, centuries later, it still cannot be fully interpreted. 
Shortsightedness has been the subject of much discussion and has inspired a number of 
theories. However, there is still no satisfactory explanation for this condition.
The prevalence of myopia has rapidly been growing in some parts of the world [2-4]. 
The estimated number of 1.6 billion myopic people worldwide is expected to increase 
to approximately 2.5 billion by the year 2020 [2]. The World Health Organization has 
put myopia among the leading causes of blindness and vision impairment in the world
[3]-
Aiming to help the understanding of shortsightedness, the project named “The Family 
Study of Myopia” was started about 10 years ago. In 2005,1 joined the study as a PhD 
student and this thesis is the result of the work I have done under the guidance of my 
supervisor and in collaboration with 4 other myopia research groups. My project was 
focused on the genetic association studies and the scope of my activities included (1) 
subject recruitment (section 2.1); (2) processing (section 2.2) and assessing of 
participants’ DNA (chapter III.); (3) microsatllite genotyping (section 2.3) and (4) the 
actual statistical tests of various nature - replication, genome-wide association and 
imprinting (chapters IV-VII).
This work concerns high myopia, that is more severe than -6.0 Doiptres (section 2.4.4), 
as the higher degrees of the condition represent a particular threat by inducing 
pathological changes that can lead to blindness (section 1.2.3).
The aim of the first chapter is to provide the reader with background information on 
myopia and genetics that, in my opinion, is essential for the understanding of the later 
chapters. The following section on Materials and Methods introduces all of the 
techniques that I have used and is intended to serve as a reference for the technical 
parts later on. Finally, chapters III to VII report my findings.
1
There are many papers published on the subject of myopia. While it is often difficult to 
compare different studies, I have decided to include scientifically weaker ones, as well 
as the stronger ones, to show the reader the points of contradiction in the literature on 
myopia and the variety of theories intended to explain the mechanism of 
shortsightedness.
My first task was subject recruitment and DNA sample collection in the form of 
mouthwash (sections 2.1), followed by DNA extraction (section 2.2.1). As The Family 
Study of Myopia was an established and running project when I joined, there already 
was a databade of the previously recruited subjects and their extracted DNA. My 
contribution was the collection of additional 19 families (150 subjects), 60 cases and 
111 controls as well as their DNA.
The next section (section 2.2.2) describes the four methods - spectrophotometry, 
fluorometry, gel electrophoresis and polymerase chain reaction - that I utilized to 
perform a quantity and quality control on DNA extracted by me from the new samples 
that I have collected, as well as on the DNA that was already in the database of The 
Family Study of Myopia. This work is detailed in chapter III. Later on, I applied the 
developed quality control method to all mouthwash-extracted DNA that was 
genotyped for the association analyses.
This study concerns two types of DNA polymorphisms: microsatellites and SNPs. The 
first variants were genotyped by me using the technique described in section 2.3.1, 
while SNPs were genotyped by various companies (each of which is specified in an 
appropriate part of the thesis). Section 2.3.2 gives an overview of the SNP genotyping 
techniques. Once the variants were genotyped, I performed a quality check (section
2.3.3) on all data independently of whether it was obtained by me or by a genotyping 
company.
My work also involved the performance of a number of statistical analyses, that are 
described in section 2.4 of chapter II on materials and methods. This section first 
characterize such methods as generalized linear model and analyses of categorical 
outcomes, that I used to draw conclusions from experiments performed on the 
mouthwash-extracted DNA (chapter III.). Further sections on likelihood, statistics of
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association and the issue o f multiple testing intend to give the reader an idea about 
how the genetic softwares, I have utilized in chapters IV-VII, work and how did I 
decide whether each specific result was genuine or a false positive due to chance.
Finally, chapters IV-VII are designated to the association analyses I carried out to gain 
information about the genetic background o f severe myopia. The description o f the 
work is in the subsequent chapters on two replication studies (Myocilin and Collagen 
genes), one genome-wide association study and, finally, an examination of the possible 
epigenetic impact on high myopia. All these analyses were performed by me. The test 
o f collagen gene (chapter VI.) was carried out on the subjects recruited within The 
Family Study of Myopia only; while the genome-wide association (chapter V.), the 
myocilin gene replication (chapter IV.) and test o f epigenic effect (chapter VII.) 
involved participants collected by our collaborators. In addition, the relationship 
between collagen genes and high myopia was also examined by the research group of 
Prof. T. Young. I included their findings along with my own in chapter VI. to allow a 
comparison.
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CHAPTER I.
MYOPIA AND GENETICS BACKGROUND
1.1 Myopia
1.1.1 Myopia as a refractive error
1.1.1.1 Ocular Components and Myopia
The human eye is a delicately balanced visual system comprising several components 
(Figure 1.1). The interaction of these elements defines an ocular refractive status, with 
reference to an eye in which parallel rays of light from infinity are brought to a focus, 
with relaxed accommodation [4]. In an emmetropic eye, this focus is projected exactly 
upon the retina, while in ametropia (refractive error) it is in front (myopia) or beyond 
(hyperopia) the retina.
Figure 1.1 The Structure o f the Human Eye 
(Adopted from Mouroulis [5])
Refractive surfaces (refractive power):
- Cornea
- Lens 
Refractive Indices:
- Aqueous (anterior chamber)
- Vitreous (vitreous chamber) 
Linear Ditances:
- Anterior chamber depth
- Vitreous chamber depth
- Axial length
Emmetropia is the result of the development and maintenance of a precise optical 
arrangement and structure of the eye (emmetropization), any imbalance in which leads 
to refractive error. Ametropia arises if either refractive power (cornea, lens) or axial 
length deviates from the optimal (normal) state, while effects of refractive indices 
(aqueous, lenticular and vitreous) are usually invariant [6]. Thus, parallel rays o f light 
can be focused in front o f the retina (myopia) as a consequence of too great a refractive 
power or too great an axial length [7].
c o r n:
A VITREOUS
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Ocular axial length (Figure 1.2) has a high correlation with ametropia [8] and seems to 
be the major factor in the development [9] and progression of myopia [9, 10]. The 
radius of curvature of the cornea (Figure 1.3) and the power of the crystalline lens 
(Figure 1.4), on the other hand, appear to show a much weaker correlation with 
ametropia [8, 10].
Nonetheless, refraction is correlated with the combined effects of ocular power and 
axial length [10], engaging cornea, lens and the length of the eye together, in a 
complex interplay.
Figure 1.2 The Axial Length 
(Adopted from Mouroulis [5])
Length variation with age [11]:
- at birth: 17mm
- in adulthood: 24mm
Length variation with ametropia [12]:
- emmetropia: 24mm
- myopia: >26mm
Figure 1.3 The Cornea 
(Adopted from Mouroulis [5])
Refractive power [11]:
- at birth: 51 Dioptres
- in adulthood: 43 Dioptres
Figure 1.4 The Lens 
(Adopted from Mouroulis [5])
Refractive power [11]:
- at birth: 34 Dioptres
- in adulthood: 18 Dioptres
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1.1.1.2 Emmetropization and Myopia
Humans are usually bom with hyperopic errors - the eye is too short for the optical 
power of cornea and lens. Thus, during development in the early years o f life the eye 
elongates (emmetropization) to match the power of its optical components [13, 14]. 
Emmetropia is usually reached by about 6-7 years of age [15]. The failure to reach or 
maintain emmetropia results in ametropia.
Generally, there are two phases o f emmetropization: a “rapid” phase o f fast axial 
growth during infancy and a “slow” phase during school years [11, 16]. Most 
emmetropization takes place during the rapid growth phase, especially between 3 and 
12 months of age. The changes o f the eye in this phase are axial lengthening and the 
loss o f the power o f the cornea and the crystalline lens. The degree of eye elongation 
shows a strong negative correlation with the initial refractive error, suggesting an 
important visual effect in emmetropization [11, 12, 17].
Among the refractive components o f the eye, the crystalline lens appears to play the 
most important role in refractive development beyond the age of 6-7 years [18], while 
the cornea has a smaller role [11]. The contribution o f the cornea to emmetropization is 
inferior to that o f lens because the cornea’s development is virtually complete by the 
age o f 2 years and, thus, it is unlikely to play an active role in maintaining emmetropia 
during ocular growth in childhood [18]. Several longitudinal and cross-sectional 
studies have shown that corneal power alters little across the school years [16, 19, 20]. 
The crystalline lens, on the other hand, tends to flatten, thin and lose power in this 
period of development [20-22].
Myopia is mostly due to excessive elongation o f the axial length (particularly the 
vitreous chamber depth [23, 24]), while other dimensions of ocular size remain 
approximately constant. Elongation of the eye by merely 1 mm without other 
compensation will result in myopia o f -2.0 to -2.5 Dioptres (D) [24]. The two most 
striking differences in ocular component changes between children with persistent 
emmetropia and those who develop myopia is the axial length and vitreous chamber 
depth: myopes show a lack o f slowing in their growth [25].
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In some cases, the cornea may undergo a “paradoxal” steeping during the “slow” phase 
of axial elongation and lead to myopia acceleration. Thus, myopic eyes usually have 
greater mean corneal power than emmetropic eyes [16].
The mechanism of emmetropization is poorly understood. However, it is known that a 
vision-dependent mechanism guides refractive state towards emmetropia [11, 13, 23]. 
The requirement for vision for eye growth regulation was proven in animal 
experiments: various species are known to develop ametropia when deprived of form 
vision or of clearly focused vision [26, 27]. In addition, a nonvisual mechanism 
operates without the need for visual guidance with the eye approaching emmetropia 
simply as a result of increasing eye size [11, 28].
1.1.2 Aetiology of Myopia
The aetiology of myopia is multifactorial, meaning that both genes and the 
environment play important roles. Twin studies indicate a strong genetic influence and 
a weak environmental impact, while differing myopia prevalences in different 
population groups from the same gene pool point to the opposite [29].
1.1.2.1 Genetic Factors
There are several signs of genetic influence on myopia development. Firstly, Myopia 
shows high heritability in twin studies (Table 1.1). Furthermore, ocular component 
dimensions exhibit high heritability as well: axial length 59-92% [30-32], lens 
thickness 93% [30] and comeal curvature 50-90% [30-32]. There also is a significant 
effect of the number of myopic parents on the risk of developing high myopia (odds 
ratio > 5.5 (95% Cl: 3.2-12.6) if at least one parent is highly myopic) as well as strong 
association between axial length and parental myopic state [33].
Table 1.1 Recent Heritability in the Studies o f  Myopia (twin studies)
Heritability of myopia Source
84% Hammond et al [34]
94% Lyhne et al [30]
75-88 % Dirani et al [31]
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The genetic component of myopia is confirmed by the findings that the prevalence of 
shortsightedness in certain ethnic groups sharing the same environment is different: (1) 
in the USA: Asian and Jews have high, while Africans and African-Americans have a 
low myopia rate [35]; (2) in Hawaii: Chinese have greater prevalence of myopia than 
Koreans, Japanese or Caucasians [36] and (3) in Taiwan: the frequency of myopia 
among purely aboriginal children is smaller than that in Chinese children [37].
Finally, the genetic background of myopia is also supported by the number of 
successful segregation and candidate gene analyses (section 1.4).
1.1.2.2 Environmental Factors
Evidence of an increase in the prevalence of myopia brings attention to environmental 
factors in the aetiology of myopia [38-40].
One of the environmental effects that has been much discussed is near work. The 
strong correlation between education and myopia [38, 41, 42] supports the idea that 
excessive accommodation produces myopia. A higher risk of myopia is observed in 
students when they are engaged in excessive near work (University term time), 
compared to when taking summer or winter vacations (breaks from near work) [43]. In 
addition, an interesting study conducted in Israel found that boys studying in orthodox 
school have higher myopia prevalence as compared to boys of identical ethnic 
background studying in general school. The authors attribute this difference to unique 
study habits of orthodox school and to the fact that the printed letters in the 
commentaries studied may be as small as 1mm in height [44].
However, attempts to reduce myopia progression with reading glasses or contact lenses 
have been disappointing [45]. Thus, near work is likely to be a weak risk factor for 
myopia, or else these interventions are not having the expected effects.
Moderate to severe myopia can be induced by optical alterations during 
emmetropization in the developing eye [6]. Visual impact on emmetropia development 
has been proved in several animal studies [11, 13, 23]. However, the applicability of 
these studies to human myopia is uncertain: for example, patients with form
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deprivation, such as unilateral ptosis or congenital cataract, do not always develop 
myopia [46].
Apart from near work, several other environmental factors -  such as education, 
diet/nutrition, psychology/personality, season of birth, maternal age and birth order, 
premature birth, low birth-weight and outdoors activities - have been proposed to be 
important in myopia development. These factors are summarized in Table 1.2.
In conclusion, myopia is a multifactorial disorder as both environmental factors along 
with genetics lead to its development.
Table 1.2 Environmental Aetiology o f  Myopia
Environmental Factor Support Reference
Near work The greater the amount of near work, the 
higher the myopia degree or the more it 
progresses
[43, 44, 47, 48]
Education Linear correlation between education and 
myopia
[35,38,41,42]
Diet/Nutrition Role of vitamins and minerals in growth 
and development
[49, 50]
Season of Birth Significant association between season of 
birth and high myopia
[51,52]
Maternal Age and Birth 
Order
Significant association of reduced vision 
with these factors
[53]
Premature Birth Prematurely boms have a higher risk of 
developing myopia in latter life
[54]
Low Birth-Weight Low birth-weight presents a risk factor 
for myopia development in latter life
[55]
Family Income The prevalence of myopia increases as 
family income rises
[35]
Out-door activities Out-door activities reduce the prevalence 
of myopia
[56]
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1.1.3 High Myopia as a Significant Problem
High, or pathologic, myopia usually refers to refractive error worse than -6.0 Dioptres. 
This form of myopia is a health issue not only due to the need of glasses or contact 
lenses, but also because of its association with high level of ocular morbidity.
Pathological myopia carries an increased risk of additional eye disorders (Table 1.3). 
Some of these changes occur in the myopic eye only, whereas others can occur 
regardless of refractive error but have a greater prevalence in myopic eyes [57]. 
Pathologic transformations of posterior pole can reduce central vision to blindness. In 
addition, changes in retinal periphery are an even greater threat to vision because of the 
possibility of retinal detachment, resulting in complete loss of vision [57].
High myopia complications are recognized as a significant cause of visual impairment, 
especially because myopia-related blindness often affects people earlier in life when 
they still can be active professionally [24].
Table 1.3 Pathologic Changes in Myopic Eye 
(Taken from Grosvenor and Goss [57])
Anterior Fundus
Optic Nerve Crescents Due to pulling away the choroid and 
pigment epithelium from the optic nerve 
head, allowing scleral tissue to be seen
Posterior Staphyloma Formation Outward bulging of the eye over a restricted 
area due to localized weakness of the 
underlying sclera
Retinal Hemorrhages Small, round hemorrhages near the macular 
area; a variable degree of vision loss may 
occur
Subretinal Neovascularization Neovascular membrane is formed beneath 
the retinal pigment epithelium; the newly 
formed vessels are prone to leak
Posterior Fundus
Vitreous Detachment Characteristically occurs at the optic nerve 
head and can lead to retinal detachment
Retinal detachment Sensory retina separates from the pigment 
epithelium; due to retinal breaks or tearing 
that are common in myopic eye
Fuchs’ Spot A lesion in macular (paramacular) area; is 
due to breaks in Bruch’s membrane; may be 
cause of loss of central vision
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1.2 Genetics
1.2.1 The Human Genome at a Glance
1.2.1.1 Chromatin
Nuclear DNA is packaged into a complex referred to as chromatin (with proteins 
called histones) [58]. The DNA is wound around a core of basic histones to form a 
structural unit called the nucleosome [59]. Chromatin structure is dynamic, 
accommodating the need for DNA to participate in various functions that require it as a 
template [60].
Traditionally, chromatin has been divided into hetero- and euchromatin depending on 
its accessibility for transcription. However, the genome is now known to be modified 
during gene expression to a higher degree than was previously anticipated (see below). 
In addition, transcription is now known to arise from intergenic regions, intron 
sequences and other non-coding genetic regions [61].
1.2.1.1.1 Euchromatin
Euchromatin represents areas o f “active” chromosomal DNA available for 
transcription. A gene can be considered as a functional unit encoded in the genome, 
transcripts of which can be used directly (e.g regulatory RNA) or be interpreted in 
peptide (e.g. messenger RNA) [62].
Each gene has a specific position on a chromosome called its locus. Most genes consist 
of coding (exon) and non-coding (intron) regions. At the junctions between introns and 
exons there are highly conserved sequences (e.g. at the 5’ and 3’ ends of the inrons GT 
and AC dinucleotides occur), that are critical for normal splicing of messenger RNA 
(mRNA) [63].
At the 5’ flanking region of the gene there are typically 3 “boxes” of homology: the 
CACCC box, the CCAAT box and the TATA box. All three boxes are conserved 
sequences and are generally required for accurate and efficient initiation of 
transcription - that is they are the major promoter regions for structural genes. At the 3’
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non-coding region a polyadenylation signal (e.g. AATAAA) serves to recruit the 
machinery for end processing and polyadenylation of the 3’ end of mRNA. [63].
Exons constitute three regions within the gene: (1) a region for RNA transcription; (2) 
a region translated to amino acid sequence; and (3) a region for the termination of 
translation [64].
Introns account for at least 30% of the human genome and may be a significant source 
of regulatory RNA [65]. Although the role of introns is still far from clear, non-coding 
RNA may determine many of our complex characteristics, play an important role in 
disease and contribute to genetic variation [66].
1.2.1.1.2 Heterochromatin
Heterochromatin refers to transcriptionally “inactive” stretches of DNA. Some areas of 
heterochromatin remain condensed throughout the organism’s lifetime (constitutive or 
permanent heterochromatin), while others can be assembled when needed (facultative 
or optional heterochromatin) [67].
Regions important for the genome integrity (e.g. bands of satellites present next to 
centromeres [67]), repetitive and noncoding sequences, are kept stably as constitutive 
chromatin [68]. Despite their condensed state, transcription from these regions is 
possible. However, transcript levels are low and do not match those of euchromatin 
[69].
Similarly, permanently condensed chromatin, facultative chromatin is also inert to 
transcription, but maintains the potential to convert to euchromatin [69]. The major 
components of heterochromatin are the regulatory factors of DNA and histone 
methylation, transcriptional repressors and functional RNA [67].
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1.2.1.2 Gene Expression and its Control
The general concept of gene expression is that of a pathway from DNA to a 
polypeptide via chromosome structure, primary transcript, mRNA processing and 
translation [70]. However, genomic expression is not as tightly related to protein 
formation as had been thought [71]. The classical model of most genetic information 
being translated into proteins is now challenged by recent evidence suggesting that the 
majority of the genome is transcribed into so-called non-coding RNA (ncRNA) [66].
The control of gene expression can occur on 2 major levels: transcriptional and post- 
transcriptional regulation [72] (Figure 1.5). The majority of regulatory events, 
however, happen at transcription [62].
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Figure 1.5 Steps o f Gene Expression Control in Eukaryotes 
(Taken from Raven &Johnson [72]).
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Firstly, for transcription initiation, DNA needs to be accessible: a gene may exist in 
either of two structural conditions and, thus, the change between permissive and non- 
permissive chromatin states leads to activation or repression of transcription. The 
alteration in structure is associated with histone acetylation and gene methylation [59]. 
The alteration in structure is associated with so-called epigenic control (section
1.3.1.3).
Once nucleosomic DNA is made accessible, transcription can start. This requires a 
close collaboration of transcription factors (/ram-acting proteins) and regulatory DNA 
sequences (c/.v-acting modules).
7><mv-acting transcription factors (TF) assemble into a complex with RNA polymerase 
and cis-acting DNA sequences in such a way that transcription can be initiated and 
tightly controlled at the same time. These factors can be divided into 2 groups: (1) 
constitutively active, basal factors which stabilize and guide RNA polymerase binding 
to a promoter; (2) regulatory - so-called coactivators, enhancers and repressors -  
factors that interact with regulatory DNA modules and other proteins [73]. The first 
group are essential for transcription, but cannot by themselves increase or decrease its 
rate. The latter, on the other hand, positively or negatively affect the pace of 
transcription by binding to governing cis-elements [72].
C/T-acting expression-control DNA sequences may be located within genes or in 
intergenic regions [74]. These modules can also be divided into 2 groups: (1) 
promoters; (2) transcription rate controlling enhancers and silencers [73]. In contrast to 
promoters, the positions o f the latter sequences are variable with regards to the genes 
they are regulating. Located upstream or downstream of a gene, enhancers activate 
transcription in a distance- and gene-independent manner. Silencers, on the other hand, 
increase the probability that a gene is repressed in any given cell [75].
Post-transcriptional control o f gene expression can occur via the processing o f a 
primary transcript (RNA splicing), selective degradation of mRNA or translation rate 
control [72]. An example o f such regulation is the occurrence of a premature 
termination codon that precludes the synthesis of a full-length protein, resulting in a 
non-functional, truncated gene product. Approximately 33% of inherited and acquired
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Mendelian diseases are attributable to a premature termination codon [76].
The expression level o f many genes shows natural variation, which is probably due to 
polymorphisms in DNA sequence. This variation is likely to account for a substantial 
part of human diversity and has a heritable component [74]. It can, therefore, 
contribute to differences that are important for understanding the aspects o f the 
susceptibility to complex diseases [77].
1.2.1.3 The Human Epigenome
The epigenome refers to chemical modifications o f DNA bases and histone proteins, 
forming a complex regulatory network that modulates chromatin structure and genome 
function, influencing how the genome is made manifest across a diverse array of 
developmental stages, tissue types and disease states. Although these chemical changes 
and are not encoded in the nucleotide sequence, they are potentially heritable [78].
Epigenic modifications fall into two main categories: DNA methylation and histone 
modification. In humans, DNA methylation occurs almost exclusively in the context of 
so-called CpG islands [82, 83]: regions o f DNA with a high G and C content and high 
frequency o f CpG (phosphodiester bonded C and G nucleotides) dinucleotides relative 
to the rest o f the genome [79]. Such islands cover about 0.7% of the human genome 
[80] and are associated with about 60% of human gene promoters [78]. A methylated 
cytosine base can promote or preclude the recruitment of gene expression regulatory 
proteins through methyl-CpG binding proteins. The preservation (or inheritance) of 
methylation is thought to be mediated by a methyl-transferase enzyme, which has 
specificity for hemi-methylated CpG dinucleotides: the enzyme methylates a newly 
synthesized DNA strand based on the presence of methylation in the CpG dinucleotide 
in the complementary template strand [82, 83].
The core histones are subject to more than 100 different post-translational 
modifications, including acetylation, methylation, phosphorylation and ubiquitination 
[78]. The vast majority o f these modifications (including their inheritance), however, is 
still poorly understood.
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DNA methylation has been implicated in a number of such cellular functions and 
pathologies as tissue-specific gene expression, cell differentiation, genomic imprinting, 
regulation of chromatin structure, carciogenesis and aging [81]. In cancer 
development, for example, characteristic epigenetic changes include hypermethylation 
of the tumor suppressor genes’ promoters, which typically results in their silencing 
[82].
Another example of epigenetic control is imprinting: the phenomena of gene 
expression being dependant on the sex of the parent from whom the gene was inherited 
(parent-of-origin effect). Imprinted loci are characterized by the reduced or absent 
expression of either the paternally- or maternally-derived allele [83]. Approximately 
1% of all human genes are thought to be imprinted [84].
Imprinting syndromes are a group o f medical conditions that result from the altered 
expression of genes. These alterations, however, can be derived not only from epigenic 
control, but also from such changes in DNA sequence as (1) large deletions or 
duplications of chromosomal regions that contain imprinted genes; (2) DNA mutations 
and (3) uniparental disomy [85]. One of the most well observed imprinting syndromes 
is Prader-Willi syndrome (PWS), which results from the absence o f paternal 
expression of a cluster o f non-coding RNAs [85]. The underlying molecular 
mechanism in the great majority o f PWS patients is either a 4-6 Mb chromosome 
deletion at 15q (70%) region or maternal disomy of chromosome 15 (25%). The rest 
(5%) may be accounted for by epigenetics in the form of hypomethylation o f the 
paternally inherited allele [85].
1.2.1.4 Heterogeneity of The Human Genome
Each copy of the human genome is unique and differs in sequence from any other copy 
in the population. Despite the fact that 99.9% of the DNA sequence in two randomly 
selected individuals is identical, the variability in remaining 0.1 % of DNA sequence is 
enough to influence human diversity in physical appearance, susceptibility to a disease 
or response to a medical treatment [86]. Although the relative contribution to complex 
human traits of DNA variants that alter protein structure, versus variants that alter the 
pattern of gene expression, is unknown [87], what is certain is that all variable human
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traits are likely to have at least som e genetic contribution [88].
The diversity in nucleotide sequence can occur in intergenic regions as well as within 
genes. Given the diploidy o f humans, each locus is represented by 2 alleles (genotype) 
that can either be the same (homozygosity) or differ (heterozygosity). Polymorphic 
alleles that co-occur on a chromosome are called haplotypes.
In studying human genetic variation in its totality, it is crucial to sample subjects of 
diverse ethnogeography, as chromosomes sampled from different populations have 
substantial differences [89]. Performing genetic association studies, on the other hand, 
typically utilise participants of the same ethnicity to avoid spurious results due to allele 
frequency diversity between populations (section 1.3.4.2.3).
DNA sequencing and analysis has revealed several types of variability in the human 
genome: microsatellites, single nucleotide polymorphisms and structural variants, each 
of which is detailed below.
1.2.1.4.1 Microsatellites
Microsatellites, or tandem repeat loci, are characterized by numerous contiguous 
repeats o f the same short sequence unit, typically ranging from 1 to 6 nucleotides in 
size. At these sites, the number of repeated copies varies greatly: many microsatellites 
have 5-10 alleles [90].
Approximately 3% o f the human genome is occupied by microsatellites [91]. Detailed 
examination of repeat loci has revealed that mononucleotide repetitions are the most 
abundant class of microsatellites, while trinucleotide alleles are about three times less 
frequent than di- and tetranucleotide repeats [92]. The distribution of microsatellites 
within the genome is not random: typically, longer alleles occur within non-coding 
regions [93, 94].
Microsatellites located in promoter regions, untranslated regions and introns can be 
important regulators of such aspects of gene expression as translation rate, RNA 
stability and splicing efficiency [95, 96]. Microsatellites occurring in intergenic
19
regions may also have functional role: it has been suggested that tandem repeats can 
alter chromatin organization and may be associated with recombination hotspots [94],
Microsatelittes have been used for disease gene mapping since the late 1980s [97] as 
their alleles can be easily and rapidly distinguished on the basis of variations in 
electrophoretic movement of fluorescent-labelled PCR products [90].
Because microsatellites are highly polymorphic and contribute to gene regulation, 
observation of changes in the length o f their alleles may provide a large pool of 
heritable variance. Indeed, allele length polymorphisms of microsatelites are 
implicated as genetic risk factors for such complex diseases as cystic fibrosis [98, 99] 
and breast cancer [100].
1.2.1.4.2 Single Nucleotide Polymorphism
Single nucleotide polymorphisms (SNPs) are the substitution of a single base and are 
the most common form of DNA variation [87]: there are about 15 million SNPs in the 
human genome [89].
The presence or absence, as well as the frequencies, of SNPs vary considerably among 
gene regions and among populations. A number of population-specific SNPs with 
minor allele frequency (MAF) substantially above 5% have been observed in one 
population but not in another, demonstrating an appreciable variation in SNP 
frequencies among human populations (Figure 1.6) [88]. The largest number of 
population-specific SNPs has been found in individuals of African origin [88, 89, 91].
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Figure 1.6 Population Distribution o f37582 SNPs among Individuals o f Different 
Ethnic Origin
(AF: African-American; AS: Asian; CA: Caucasian; HL: Hispanic-Latino). The 
degree of population sharing is indicated in color. Over 2/3 of the polymorphisms 
observed were variable among AF individuals, whereas between 37 and 47% of the 
SNPs were variable in each of the other populations (Taken from Schneider et al. 
[88]).
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Regions of DNA that affect gene expression are highly variable, containing 0.6% 
polymorphic sites [89]. The distribution o f SNPs in various genomic regions suggests 
that there is conservation of the coding region (Figure 1.7): the average gene contains 
about four SNPs in its coding sequence, with allele frequencies of at least a few 
percent [101]. However, the SNP density varies less than 2-fold among all regions and 
could be even higher in large introns or in intergenic regions [88].
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Figure 1. 7  SNP Distribution per kilobasepair o f Functionally-defined Genomic
Regions o f 1630 genes
(Taken from Schneider et al. [88])
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A large proportion of SNPs in the human genome show a minor allele frequency of 
less than 1% (Figure 1.8): most SNPs observed in ENCODE regions have MAF < 5% 
and 9% of them were only observed in a single individual (Figure 1.8). Although the 
majority of polymorphisms in the population are rare, most heterozygous loci within 
any individual are due to common SNPs [102] and it is frequently suggested that SNPs 
whose MAF > 5% are of most interest in disease gene mapping (see below) [101].
SNPs represent a great interest in human genetics. Found in a functional gene region, a 
SNP may encode a difference in protein sequence or expression, which in turn can lead 
to a disease or other phenotype. It may also mark the presence of other, perhaps less 
easily detected, sources of genetic diversity that cause a phenotype of interest [101].
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Figure 1.8 Minor Allele Frequency Distribution o f SNPs in the ENCODE Regions
Polymorphic SNPs are shown according to their MAF (blue). The sum of contribution 
of each MAF bin to the overall heterozygosity is shown in orange. SNPs that are 
heterozygous in one individual only are marked as grey (Taken from International 
HapMap Consortium [102]).
Minor allele frequency
1.2.1.4.3 S tructural V ariants
Structural variants are defined as genomic alterations that involve segments of DNA of 
1000 bases (1 kb) or larger [103].
In contrast to SNPs that affect only a single nucleotide, structural variants can affect 
from one kilobase to several megabases of DNA per event (deletion, insertion, 
duplication and complex rearrangements of genomic regions), adding up to a 
significant effect on phenotypic variability. Table 1.4 comprises a brief description of 
commonly encountered types o f structural variants.
The discovery of structural variants demonstrates the plasticity of the human genome 
and might help to explain phenotypic discrepancies in genetic traits and/or in the 
severity of the resulting phenotype. It may also provide new leads for the molecular 
basis of complex disorders [104].
23
Table 1.4 Structural Variation Definitions 
(Adopted from [103] and [104])
Structural Variant Definition
Copy-number Variant 
(CNV) or 
Polymorphism
A segment o f DNA that is lkb or larger and is present at a variable 
copy number in a specific chromosomal region. If its population 
allele frequency is less than 1%, it is referred to as a rare variant; if 
its frequency exceeds 1%, the term copy number polymorphism 
may be used.
Segmental 
duplication or low- 
copy repeat
A segment o f DNA > 1 kb in size that occurs in two or more copies 
per haploid genome and the different copies share >90% sequence 
identity. They are often variable in copy number and can therefore 
also be CNVs.
Inversion A segment o f DNA that is reversed in orientation with respect to 
the rest of the chromosome and to a specific reference genome.
Translocation A change in position o f a chromosomal segment within a genome 
that involves no change in the total DNA content. Translocation 
can be intra- or inter-chromosomal.
1.2.1.5 Utilization of Genetic Variation in Genetic Studies
The ability to genetically map complex disorders is facilitated by identifying and 
genotyping DNA polymorphisms termed “markers”. These DNA variations used in 
genetic analyses can be divided into 5 groups: (1) restriction fragment length 
polymorphisms (RFLP); (2) variable number o f tandem repeats (VNTR); (3) 
microsatellite or short tandem repeats; (4) SNP and (5) copy number variations (CNV). 
The type o f polymorphism utilized in human genetics has been changing with time.
Until recently, analyses have been based on widely spaced (usually ~10 cM) 
microsatellite markers, but it is now possible to genotype a dense map o f SNP markers 
at low cost. In addition, construction of the international SNP database (HapMap) 
enables the performance o f not only genome-wide analyses, but also o f candidate gene 
studies facilitating the choice o f so-called tagging SNPs (section 1.3.3.2). Apart from 
SNPs, copy number variations are o f particular interest in current human genetics. 
However, development o f novel techniques and statistical methods is needed to 
capture this new form of genetic variation in a meaningful manner [105].
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There has been a debate whether it is better to use microsatellites or SNPs in genetic 
studies. Although SNPs are somewhat less informative than microsatellites, the current 
trend is to use single nucleotide polymorphisms: it is technically easier and less 
expensive to genotype SNPs because they have only 2 alleles and require less DNA 
[106]. Furthermore, microsatellites have a disadvantage of being prone to mutation, 
which makes their use more challenging compared to SNPs. It is noteworthy, however, 
that because of large genetic variability o f microsatellites, the chance of finding 
disease causative allele in linkage disequilibrium (section 1.3.3.2) with such marker is 
much higher than with SNP markers.
1.2.2 Phenotype and its Inheritance
1.2.2.1 Phenotype as the Result of a Genotype
A phenotype is the observable expression of an individual’s genotype [107]. While 
genotypes act through proteins and different molecular pathways remaining mostly 
stable over the lifetime o f an individual, phenotypes are observed through signs, 
symptoms and visible traits and are often dynamic. Therefore, genetic studies need to 
pay particular attention to issues o f phenotype definition and measurement: the 
phenotyping needs to be standardized to increase the quality of research and the 
reproducibility of linkage and association studies [108].
The presence (affected) or absence (non-affected) of a certain trait depends in part on 
an individual’s nucleotide sequence: a genetic variant shared by all affected (but not by 
non-affected) subjects is likely to be responsible for the trait examined. When such a 
variant is found, the probability that a randomly selected individual who caries the 
variant will be affected can be estimated as the phenotype penetrance [109]: for 
example, the ratio o f risks for developing a phenotype between those with and those 
without the susceptibility genetic factor (allele, genotype or haplotype). These ratios 
are often used as a criterion o f association between a trait and a genetic variant 
(genotype relative risk).
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A number of different factors (of both genetic and environmental origin) determine the 
relationship between genotype and phenotype: two individuals with identical genotype 
at a given locus can experience different clinical symptoms due to a differing genetic 
background [110]. Such elements include the pattern of inheritance, allelic 
heterogeneity, locus heterogeneity, variable penetrance, epistasis as well as 
environmental variables (Table 1.5).
Table 1.5 Sources o f Heterogeneity in Susceptibility to Complex Diseases 
[111] , [112]
Heterogeneity Explanation
Locus Heterogeneity Phenotypically indistinguishable diseases caused by mutation in one 
o f two or more separately located genes.
Allelic Heterogeneity Different mutations or deletions within a single gene may cause a 
common disease phenotype.
Epistasis 
(Gene Interaction)
The possession o f a certain mutation or genotype will confer 
susceptibility to a degree dictated by the presence of other mutations
or genotypes.
Environmental
Vulnerability
Phenotypes are influenced by environmental stimuli.
Gene x Environment 
Interactions
Gene or genes have their effects only in the presence of particular 
environmental stimulus. Strictly, a genotype leads to a different 
phenotype depending on the environment in which it occurs.
1.2.2.2 Phenotype in a Genetic Study: Discrete and Continuous Traits
In genetic studies, traits are classified as discrete or continuous. The term discrete 
phenotype applies to those traits that are either present or absent: such as cancer or 
retinitis pigmentosa.
A continuous phenotype, on the other hand, has a range of possible values and these 
values are often used directly. Such quantitative traits include for example body weight 
and height, blood pressure and refractive error. Continuous traits can also be 
categorized as dichotomous by using a predefined threshold value; sometimes, 
especially for genetic studies, only individuals in the extremes of the frequency 
distribution are used in order to maximize power and obtain a definitive distinction 
between diseased and nondiseased individuals [107].
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1.2.2.3 Inheritance of a Phenotype: Mendelian and Complex Traits
To be able to understand the spectrum of human genetic disease, it is essential to 
consider the way in which genes may be inherited. Some inherited disorders follow a 
simple Mendelian form of transmission. Complex or multifactorial traits, on the other 
hand, are determined by a number o f genetic and environmental factors [111]. In 
contrast to monogenic Mendelian phenotypes that are controlled by single genes, 
complex traits are defined by multiple genes and are therefore called multigenic traits 
[113]. Many Mendelian phenotypes vary in diverse biological features such as age of 
onset or severity, suggesting that genetic background tends to modify the phenotypic 
expression leaving few if any Mendelian disorders to be truly monogenic. Common 
diseases are almost always genetically complex [114], since otherwise robust selection 
wold be expected to reduce the risk allele frequency in a population.
A phenotype is considered dominant if it appears in the heterozygote in whom only 
one allele is defective. Dominant mutations often result in a clinical symptom by 
giving rise to reduced or abnormal expression of a gene product. In a recessive 
disorder, both alleles must be mutant (homozygous state) for a phenotype to become 
apparent. A recessive allele does not necessarily lead to a disease trait: production of 
50% of the normal level o f the gene product in a heterozygote may be sufficient to 
avoid clinical symptoms [110].
Mendelian dominant or recessive inheritance can also be either autosomal or sex- 
linked, depending on which chromosome the mutant allele appears on. In case o f an X- 
linked recessive trait, males are affected more commonly since they do not carry a 
homologous X-chromosome which can serve to mask clinical expression of the 
disorder in females. By contrast, in X-linked dominant disorders, the mutation is 
manifested more equally in females and males, although the absence o f a normal allele 
often results in males being more severely affected than females [110].
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1.2.2.4 Common Disease Traits: the Genetic Challenge
Identification o f the genes that contribute to complex traits poses a special challenge 
because o f their high genetic heterogeneity. To address this issue, two main hypotheses 
have emerged regarding the genetic susceptibility to common diseases: the common 
disease-causing variant hypothesis and the rare variant hypothesis [115].
The common disease-common variant (CDCV) hypothesis posits that a few common 
allelic variants (defined as having a MAF > 1% [116]) account for much o f the genetic 
variance in disease susceptibility [117]. DNA variants leading to monogenic diseases 
are usually rare due to natural selection. By contrast, because variants in genes 
involved in polygenic traits do not act alone to produce the phenotype, selection 
against them will only occur when they are present in the disease-causing combination. 
Thus, these variants may exist at a high frequency in the population [118].
An alternative, although not mutually exclusive, hypothesis is that genetic 
susceptibility to common disorders is due to summation of the effects o f a series of 
rare variants in different genes, each contributing a more substantial increase in 
relative risk [115]. Such rare variants will mostly be population specific because of 
founder effects resulting from genetic drift [119].
A critical feature shared by common and rare variants is that they do not necessarily 
give rise to a familial concentration o f cases (as opposed to familial segregation of 
Mendelian traits). This is because the penetrance of such variants is low. Most o f the 
common alleles found so far are associated with risk ratios o f only between about 1.2 
and 1.5, while rare variants, on average, show risk of 2 or more. Only when 
penetrances are well above 50% does one approach a familial concentration that begins 
to look like a standard Mendelian segregation [119]. Other, general and individual 
properties of these variants are listed in Table 1.6. Whether common disorders are 
primarily caused by common or rare variant is still an open question. The current 
literature suggests that both these hypotheses are correct, depending on the gene and 
disease examined.
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Table 1.6 Characteristics o f Common and Rare Variants 
(Taken from Bodmer and Bonilla [119]).
Common Disease Variants Rare Disease Variants
Discovery Population association studies DNA sequencing of candidate 
genes
Minor Allele Frequency > 5 % >0.1%  to 2-3%
Risk Ratio 1 .2 -  1.5 > 2 .0
Familial concentration 
of cases
None None
Contribution to Disease 
Aetiology
Hard to find functionally 
relevant variant
Functionally relevant, often 
obvious variants
1.2.3 Independent Assortment and Linkage Disequilibrium
1.2.3.1 Independent Assortment of Gametes and Recombination
A diploid organism, such as human, produces a large number o f genetically unique 
gametes. Cells undergo two processes to produce this diversity: independent 
assortment and recombination [120].
Independent assortment is the random distribution of maternal and paternal 
chromosomes into gametes during meiosis. Once the first gamete is drawn from an 
individual, the second one still has an equal chance that its chromosomes stem from 
either parent. In humans, independent assortment yields 223 (over 8 million) unique 
ways to distribte the 23 pairs of chromosomes [120].
Recombination is the result o f “crossing over”, which occurs early in meiosis when the 
homologous chromosomes exchange DNA, such that each caries some paternally and 
some maternally derived genetic material (Figure 1.9) [120]. Genes on the same 
chromosome are physically linked and thus tend to be co-transmitted from one 
generation to the next, each serving as a marker for the other. However, meiotic 
recombination can lead to segregation o f these alleles to different germ cells, so that an 
individual may inherit a new combination o f alleles. When recombination fails to 
cause segregation of these alleles, they are said to be in linkage disequilibrium [118].
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Diploid Cell
Meiosis
No Recombmalior Reoombinaiion
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Figure 1.9 Meiotic Segregation o f  
DNA Variants
(Taken from Schafer et al. [118]) 
A/a and B/b are alleles at two loci. 
“A” and “B” (as well as “a” and 
“b”) are physically linked on two 
chromosomes. Recombination 
between chromosome pairs can 
result in chromosomes with A/b 
on one chromosome and B/b on 
another. When recombination fails 
to cause segregation of the alleles, 
they are said to be in linkage 
disequilibrium.
1.2.3.2 Linkage Disequilibrium and its Estimation
Linkage disequilibrium (LD) refers to the non-independence of alleles at two or more 
loci. When a sample of chromosomes is drawn from a population, all the chromosomes 
are related by some ancestral genealogy. Thus, genetic markers that are very close 
together on a chromosome have either the same or similar genealogies and this induces 
dependence between them. Markers that are further apart may have different ancestry 
because of recombination and, for this reason, the strength of LD between pairs of 
markers decreases as a function of genetic distance between them [121]. Nonetheless, 
local variation in LD overwhelms this “rule” over short distances: markers that are 
adjacent to each other on a chromosome may be statistically independent, whereas 
those that are further apart can be highly correlated [122].
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With most human recombination occurring in recombination hotspots, the breakdown 
o f LD is often discontinuous creating a “block-like” structure. However, the tendency 
towards co-localisation o f recombination sites does not imply that all haplotypes break 
at each recombination hot spot [123].
Although genealogy and recombination provide insight into why nearby SNPs are 
often correlated, it is redundancy among genetic variants (e.g.SNPs) that are o f central 
importance for the design and analysis o f genetic studies. A truly comprehensive 
association study must consider all putative causal alleles and test each for its potential 
role in a disease. If a casual variant cannot be directly tested in the sampled population, 
its effect can nonetheless be examined indirectly if it is in strong linkage 
disequilibrium with a directly tested SNP. When two variants are perfectly correlated, 
testing one is exactly equivalent to testing the other. Thus, taking the number of 
distinct combinations of SNP alleles (haplotypes), it is possible to select a 
parsimonious set of SNPs that would capture the information o f all variants that are in 
strong LD with these selected, so-called tagging SNPs and, therefore, distinguish the 
haplotypic variation in a population [124].
Various statistical measures can be used to assess LD between a pair o f loci, but in
■y
practice only two, namely D ’ and r are widely used.
In what follows, the discussion will be restricted to a marker and a disease locus each 
having two alleles: disease alleles “A” and “a”; and marker alleles “B” and “b”. Thus, 
the haplotypes for the disease and the single marker can be arrayed in 2x2 table with 
marginal probabilities p a , pa, Pb and pb for each allele of these 2 loci (Table 1.7).
In principal, D’ and r2 measures of LD reflect the difference between the observed and 
the expected (under independence) frequencies o f haplotypes bearing the disease and 
normal alleles: D = p » A ~  (P b  x  P a )  [125]. The so-called D’ measure can be obtained by 
normalizing this D value by the absolute maximum D that could be achieved given the 
table margins [126]; while raising D to the power of 2 and dividing it by the multiple 
o f all marginal frequencies will result in r2 (r2 = D2/pA x pa x pe x pb ) [121]. Both D’ 
and r2 have the same scale from zero to one: zero implies independence and one means 
complete LD between the two loci [122].
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Although the mathematical interpretation of these measures may seem to be the same, 
it is important to understand the difference in their practical meanings: r equals one 
only when the two loci have identical allele frequencies and every occurrence o f an 
allele at each o f the markers perfectly predicts the allele at the other locus. By contrast, 
D’ can reach a value o f one when the allele frequencies vary, as it reflects the 
correlation only since the most recent mutation [122]. Thus, D’ can be large even when 
one o f the alleles is very rare (Figure 1.10), which is usually of little practical interest 
in disease gene mapping [127].
Table 1.7 Layout and Notations for Sample Haplotype Frequencies.
(p denotes the frequencies and marginal probabilities o f the haplotypes in the sample)
Disease Allele “A” Disease Allele “a” Total
Normal Allele “B” P ba PBa P b
Normal Allele “b” PbA Pba Pb
Total P a Pa 1
32
Figure 1.10 A Hypothetical Allele Frequencies and Haplotype Set o f Different 
Situations o f LD Between a Disease and Marker Loci 
(Adopted from Zondervan and Cardon [122])
Haplotype frequency Allele frequency D  !>*■■**. T) (^marker. 7)
A «> a •► a < a < A =0.30 0.21 1.0 1.0
T <> t < t ( t < 7" =0.30
6 <► B i > o <► t> < B =0.70 0.0Q 1.0 0.18
C <> C < c  <> c < C = 0.00 0.03 1.0 0.05
0.30 0.40 0.20 0.10
Consider a diallelic locus in which allele “T” is associated with a complex disease. The 
population frequency of “T” is 0.3 (thus, the frequency of “t” will be 1 -0.3 = 0.7). 
Cases and controls are collected for the study of the disease, but the disease 
polymorphism is not genotyped. Instead, three surrounding SNPs (A/a, B/b and C/c) 
with different allele frequencies and different LD relationships with the disease allele 
are typed. Note that the haplotypes carrying the “T” allele will be over-sampled in 
cases relative to its frequency in the population as a whole. The trait allele “T” is 
present only in one haplotype, ABC, which has a frequency of 0.3 in the population. 
Marker allele “A” is also present only on ABC, and therefore has the frequency of 0.3. 
Allele “B” occurs on ABC and on aBC, with a total frequency of 0.7, whereas “C” 
occurs on ABC, aBC and abC with a total frequency of 0.9. All three marker alleles 
“A”, “B” and “C” are in complete LD with the disease allele “T” in terms of D’, but 
not all B or C alleles are co-inherited with “T”. Thus, marker allele “A” is the only one 
with an r2 value of one.
Allele frequencies of marker B/b are identical to those of marker A/a, as well as for the 
trait locus. The D’ values between “B” and “T” and between “A” and “T” are both 
one. However, the “B” allele is not the one that matches the disease allele frequency: it 
is the frequency of the other allele “b” that does, but it never occurs on the haplotype 
with the disease allele. For equal statistical power, it would take a sample size 5.5 
times greater to detect a disease association with “B” than with “A” (1/r2 = 1/0.18 = 
5.5). This shows that markers with equal MAF and high D’ are not sufficient to ensure 
high power; they must match in phase as well [122].
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In Table 1.7, the observed proportions o f gametes in a population sample o f size N, the 
2  * • 2X test for association between the loci would be: D N/pA x pa x pe x pb [128]. 
Replacing D2/pA x pa x pe x pb with r2, the test statistic for independence o f haplotype 
counts will be r2 multiplied by the sample size. Consequently, r2 reflects the power to 
detect LD between two loci. If  disease risk is multiplicative across alleles and Hardy 
Weinberg Equilibrium (section 1.3.3.3) holds, the reciprocal of r2 gives the sample size 
that would have been required to detect the disease association by directly typing the 
casual polymorphism, relative to the sample size required to achieve the same power 
when typing the marker (Figure 1.10) [127].
The performance of D’ and r greatly depends on variation in marker allele frequencies 
and on the configuration of markers surrounding the disease locus (Figure 1.10). The 
value of D’, for example, is independent from the marginal allele frequencies in 
mathematical terms, but it is not in any other general sense (e.g. the force o f equal 
recombination rate on different populations with different allele frequencies will result 
in unequal D’ values for these populations) [128].
The correlation between a causal mutation and haplotype on which it arose -  linkage 
disequilibrium -  has great value for both fine-mapping and genome-wide genetic 
association studies. However, the actual degree o f disequilibrium between two loci is 
drawn from a probability distribution that results from the evolutionary process: LD 
can be influenced by other phenomena besides recombination, namely mutation, drift, 
mating choice and selection. These population genetic phenomena can mask the 
impact o f recombination, leading to a large variance in LD values [125].
1.2.3.3 Hardy-Weinberg Equilibrium
Hardy-Weinberg equilibrium implies constant genotype frequencies from generation to 
generation in a population whose members are mating randomly, with no selection or 
migration. Under such an equilibrium, the genotypic frequencies at an autosomal locus
with two alleles (“A” with relative frequency “p” and “a” with relative frequency “q”)
• 2 2 will be expected to be p for genotype “AA”, 2pq for genotype “Aa” and q for
genotype “aa”. In addition, all three genotypic proportion will sum to one, as will the
allele frequencies [129]. HWE, thus, depends on a series of assumptions about the
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tested population, including, for example, that no new mutations arise, no selection 
occurs and mating is random [130]. Departures from HWE, if not due to a change or 
violation of these assumptions, may therefore point to genotyping error, population 
admixture or a true non-independence o f alleles in the population (e.g. due to the 
influence o f an allele on disease prevalence) [131, 132].
The most common two ways of assessing HWE are through a goodness-of-fit chi- 
square test and an exact Fisher’s test (section 2.4.2.3). The performance o f both tests 
depends on the sample size and minor allele counts. However, x2 tests tend to 
overestimate the significance level, especially in smaller samples, while the exact 
statistic never exceeds the nominal significance level [133, 134].
1.2.4 Genetic association
1.2.4.1 Transmission Disequilibrium and the Concept of Genetic Association 
Studies
Under the law of Mendelian assortment, alleles at a locus will be transmitted randomly 
and with equal probability from parents to an offspring. Deviation from the random 
occurrence of an allele regarding disease phenotype (transmission disequilibrium) is 
considered to be genetic association. Allelic association reflects sharing o f ancestral 
chromosomes: alleles at loci tightly linked to disease susceptibility locus will be shared 
among affected individuals more often than expected by chance.
Classically, association can be examined with the transmission disequilibrium test 
(TDT), which compares the observed number of alleles transmitted to affected 
offspring with those expected in Mendelian transmissions in terms of chi-square 
statistics [135]. Originally, TDT was used to test for linkage in the presence of 
association. However, because its null hypothesis assumes both no linkage and no 
association, the TDT is now typically used as a test for association.
With time, several types o f association studies have been developed. The next section 
o f this chapter summarizes the current methods according to the markers utilized
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(direct and indirect studies), aim (hypothesis generating and hypothesis testing studies) 
and the nature o f examined cohort (family-based and case/control studies).
1.2.4.2 Testing for Genetic Association 
1.2.4.2.1 Direct and Indirect Association Approaches
Most association studies rest on the assumption that linkage disequilibrium exists and, 
thus, the causal variant can be examined either directly (direct association) or by the 
means of a polymorphism in LD with it (indirect association). Commonly, the casual 
variant will not be typed in the study. Nonetheless, a well-designed experiment will 
have a good chance o f including one or more genotyped polymorphisms that are in 
strong LD with a common casual variant and be able to detect the indirect association 
between marker locus and disease phenotype [127].
The limitation of association studies being indirect can be overcome by exploiting the 
block-like structure o f LD, characterized by the existence o f genomic regions with 
little evidence for historical recombination and limited haplotype diversity. Within 
such regions, genotypes o f common SNPs can be inferred from only a few so-called 
tag SNPs (sections 1.3.3.2 and 1.3.4.3.2) [136-138]. Moreover, because LD is a short 
range phenomena, if  association exists, it will define a small candidate region in which 
to search for a susceptibility gene.
1.2.4.2.2 Hypothesis-generating and Hypothesis-testing Association Studies
Association analyses can be used for the genome-wide, genetic exploration o f a disease 
(hypothesis-generating) or for the identification o f candidate polymorphisms 
(hypothesis-testing) (Table 1.8). This classification, however, is not precise: some 
candidate gene studies may involve many genes and are similar to genome-wide scans 
[127].
Genome-wide, exploratory, hypothesis-generating analyses present an opportunity to 
identify associations between genetic polymorphisms and a complex trait. For this kind 
of test, a large number of SNPs is typed throughout the genome (a high SNP density is
36
essential for mapping a putative association region). High-throughput genotyping 
makes this a realistic and affordable strategy.
Once the region of interest is known, the next step is to test the hypothesis and fine 
map the exact polymorphism responsible for a disease-related phenotype. In this case, 
markers can span a gene (candidate gene) or a locus on a chromosome (e.g. a linkage 
peak).
Table 1.8 Types o f Population Association Studies 
(Taken from Lewontin [127])
Type of an Association Study Description
Candidate Polymorphism Study Focuses on an individual polymorphism that 
is suspected to be the causal one.
Candidate Gene Study Focuses on candidate gene (or genes) and 
involves the genotyping o f several 
polymorphisms within that gene (or genes).
Fine Mapping Focuses on a candidate region that has been 
identified by previous studies; may involve 
several genes with genotyping o f hundreds 
of polymorphisms.
Genome-Wide Study Focuses on identifying common casual 
variants throughout the genome.
1.2.4.2.3 Case/control and Family-based Analyses
Genetic association for complex traits can be assessed either with a case/control study 
of unrelated people or with a family-based design. Although these are two 
fundamentally different approaches, which have their own strengthes and weaknesses, 
these analysis should be viewed as complementary and not competitive in the effort to 
overcome the challenges o f association studies [139]. Thus, combined case/control and 
family association studies can also be performed.
The classic case/control design compares allele frequencies of genotypes in a sample 
o f unrelated affected and a sample of unrelated unaffected individuals [140]. The 
major criticism of these studies is the potential for spurious association due to 
population stratification: the existence of genetically different groups in the population 
under study. A false positive association can arise because allele frequencies and
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disease prevalence vary across human populations (Figure 1.11).
The first attempt to solve this problem was the haplotype relative risk (HRR) 
approach [141]: the comparison o f frequencies of marker alleles among cases and 
pseudocontrols (created from non-transmitted alleles). It is argued that the HRR 
method reduces, but not eliminate the possibility of population stratification [142]. 
Several other techniques have been proposed to deal with this issue: genomic control 
[143], structured association [144] and the use of principal components [145]. 
However, they all suffer from the same major disadvantage: they require a number 
(preferably >100) of widely spaced null SNPs that have been genotyped in cases and 
controls in addition to the candidate SNPs.
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Figure 1.11 Example o f True and False Association in Case/Control Study 
(Taken from Hirschhom et al. [146])
Shapes in red are the carries of a putative causative allele. In both figures (A. and B.) 
the fraction of individuals with the causative allele in cases is twice of that in controls. 
The upper part (A.) of the figure represents a true association: the frequency of risk 
allele is greater in cases than in controls in both populations. The bottom part (B.) of 
the figure represents a false positive association: the frequency of risk allele is identical 
in cases and controls in both populations, but because ethnic group 1 is 
overrepresented in cases and the risk allele is prevalent in ethnic group 1 only, the 
allele tested is overall twice as frequent in cases than in controls, leading to spurious 
association.
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Unlike case/control studies, family-based analyses are robust against population 
substructure. Being “immune” to population stratification, the limitation of family- 
based TDT is the pedigree structure it can manage. Parents with an affected offspring 
(trios) are the recommended family structure for this test, since its chi-square statistic 
assumes that all observations are independent and this may not hold for pedigrees with 
multiple affected relatives [142], It also requires knowledge of the genotypes o f both 
parents, which in practice is not always feasible. Thus, TDT’s original method has 
been expanded to suit diverse types o f pedigrees. The new alternatives integrate the 
information carried by unaffected offspring to overcome the issue of missing parents 
by estimating their genotypes or by comparing the transmissions to affected offsrings 
with that to unaffected ones [147, 148]. The primary null hypothesis of no association 
and no linkage has been changed to “no association in the presence of linkage” to 
account for the non-independence o f transmissions in cases of multiple affected 
relatives [147, 149]. Finally, splitting large pedigrees into nuclear families can be 
introduced to allow the analysis of pedigrees with multiple generations [147],
Extensions to TDT not only adjust the test to different sizes and types of pedigrees, but 
also make it possible to integrate a case/control study with a family-based analysis 
[147]. Such synthesis takes advantage o f the strength of both approaches and 
represents a flexible alternative for association studies of complex traits.
1.2.4.3 Design and Interpretation of Genetic Association Studies
1.2.4.3.1 The Power of an Association Study
The probability o f a study to obtain a significant result (power) is a critical aspect in 
the design o f any genetic association analysis. It is, therefore, important to understand 
and evaluate the parameters influencing this statistical power, which include (1) the 
frequency and degree o f risk attributed to a disease allele; (2) the sample size; (3) the 
degree of LD and allele frequency matching between a marker and a disease allele; (4) 
the mode of inheritance; (5) the prevalence of the disease and (6) the type of an 
association study. There is a complex interplay between all o f these factors and one 
cannot be considered in isolation: the sample size required for a study, for example, 
greatly depends on the disease allele frequency and its relative risk [122, 150].
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Under a family-based or case-control design of an association study, it is equally 
important to evaluate the disease allele parameters (direct study) and its degree o f LD 
with a marker allele (indirect study) as they are the major determinants of the power 
through the sample size of a study: the greater the LD between a marker and disease 
allele, the greater the similarity between their population frequencies, and the greater 
the genotypic relative risk, the greater will be the power of an association test [150],
In indirect studies, the dominant feature o f the relationship between a disease allele 
and a marker allele, however, is not LD but marker allele frequencies. Under the rare 
allele hypothesis, even if LD is complete, at least 1/3 of the true effect is lost with 
markers of 10% minor allele frequency or greater. The detection of a frequent disease 
allele suffers similarly from marker-related decay in effect size, but in the opposite 
direction: a marker with a minor allele frequency of 20% or less leads to very low 
effect sizes that can not be detected even with a vast sample size [122]. Thus, the 
minimum sample size is achieved when the frequencies of the disease allele and 
associated marker allele are equal [150].
The importance o f equality between disease and marker allele frequencies becomes 
more apparent when the effect size o f a disease allele is taken into consideration. In the 
situation of a disease with a common allele o f small relative risk, a “common” marker 
allele with MAF as high as 50% will still result in a pronounced drop in effect size 
and, thus, power of an association study. The situation of a rare disease allele that also 
has small effect size will suffer from an even greater loss of power as the combination 
of the low effect size and rare MAF would lead to unfeasibly large sample size 
requirement to allow the detection o f association[122].
1.2.4.3.2 Marker Selection for an Association Study
Performing any association analysis requires a selection o f polymorphisms. However, 
this selection is not a simple matter. Firstly, for the powerful detection of a target 
polymorphism, all the variants in the population of interest should be represented, but 
in practice with current 300,000 to 1,000,000 SNPs genotyping platforms -20%  of 
common SNPs are only partially tagged or not tagged at all, and rare variants are 
generally missed out [116]. Secondly, the current maximum genotyping panel is one
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million SNPs, while the estimated number of SNPs in the human genome is 15 million 
[89]. Thus, in actuality, markers are chosen based on LD patterns.
Based on the r2 measure of LD, an r2 > 80% is generally considered to be sufficient for 
tag SNP mapping to obtain a good coverage of untyped SNPs and relatively small loss 
in power [151]. The optimal number o f variants for an association study is defined as 
the smallest number of SNPs that needs to be genotyped to cover the other SNPs at an 
r2 of 0.8 or greater [138, 152]. If the LD between SNPs is strong, this could result in up 
to 70-80% less genotyping. In contrast, if LD in the region of interest is low, almost 
every SNP may need to be genotyped.
Testing the hypothesis of a gene being a disease-causing candidate, the SNP selection 
can also be led by the within-gene position of a polymorphism (a variant, for example, 
can be chosen from an intronic region that is conserved, and therefore, may present a 
functionally important regulatory sequence [153]) or by the virtue o f its function 
(polymorphisms that alter function through nonsynonymous protein-coding changes, 
or through effects of translation [154]).
The above approaches are primarily aimed at surveying common variants (MAF > 
5%). Rare polymorphisms require a more comprehensive analyses: considerably larger 
sample size and resequencing [155].
1.2.4.3.3 Interpretation of Results from an Association Study
An additional challenge o f association studies is their interpretation. Most of the 
reported significant associations appear to be poorly reproducible (section 1.4). The 
possible explanations o f this inconsistency are false-positive reports, misinterpretation 
or true heterogeneity between studies.
It is crucial to understand the nature o f the association test performed (hypothesis 
generating or hypothesis testing), assess its power and correct for multiple testing 
(where applicable) before drawing conclusions.
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In a hypothesis-generating genome-wide test, a number of polymorphisms are tested 
and the results can be considered significant only after appropriate correction for these 
multiple tests. It also should not be forgotten that these analyses are exploratory and 
their replication in an independent sample is necessary to distinguish false positives 
from true associations.
In candidate gene analysis (replication or hypothesis testing), it is important to choose 
the appropriate test according to the available sample of cases/controls or pedigrees. 
The wrong null hypothesis or method of family-based studies as well as the neglection 
of population stratification in case/control approach may all lead to false positives.
1.3 Myopia and Genetics
The link between myopia and genetics has been long recognized. Firstly, several 
familial studies report that myopia occurs more often in the children o f myopic parents 
than non-myopic parents [156-159]. Yap et al noted that the prevalence o f myopia in 
7-year-old children increases up to 45% when both parents are myopic compared to 
7.3% when neither parent is myopic [159].
Further, strong evidence for the role of genetics in myopia is also provided by twin 
studies: identical (monozygotic) twins display higher similarity in their refractive 
status and ocular components than dizygotic twins [30, 31, 34, 160].
Multiple familial studies (linkage and association) support the importance of a genetic 
effect on myopia. To date, 14 MYP regions linked to myopia are listed in the Online 
Mendelian Inheritance in Man (OMIM) and several novel intervals have been 
identified (Table 1.9). Determination of these loci has generally been based on just a 
few families with little replication of linkage by other investigators, except for the 
MYP3 region on chromosome 12, which has been replicated in 3 independent studies 
including one conducted by the International High Myopia Consortium with the largest 
dataset yet assembled [161]. Familial occurrence of myopia has been mostly 
described as a discrete, segregating trait based on the distinction of low and high 
grades of myopia, showing autosomal dominant inheritance in the majority of studies.
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Although segregation analyses suggest the involvement of multiple genes, high 
myopia is more likely to result from a major effect mutation than are lower grades of 
refractive error [162].
The genetic intervals identified by linkage analysis harbour a number o f loci encoding 
possible myopia genes. Several association studies -  in which linkage peaks have been 
fine-mapped as well as candidate-gene analysis -  have been carried out in an attempt 
to identify genetic variants that confer susceptibility to myopia (Table 1.10). 
Unfortunately, many of the initial reports of association proved to be false positives 
[163-169], leaving the majority of myopia susceptibility genes still to be discovered.
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Table 1.9 Overview o f Myopia Linkage Analysis Studies
(Abbreviations: AD: autosomal dominant; XR: X-linked, recessive; QTL: quantitative trait locus)
Locus Original Finding Replication
Location Ethnicity  o f  the C ohort M yopia
C riteria
M ode o f  
Inheritance
R eference Ethnicity M yopia
C riteria
M ode o f  
Inheritance
C onfirm ation R eference
MYP1 X q28 C aucasian XR [1 7 0 ,1 7 1 ]
MYP2 18pl 1.31 C aucasian < -6 D AD [172] C aucasian < - 6  D AD N o [173]
C aucasian < -  1 D QTL N o [174]
A sian (C hinese) < -6 D AD Yes [175]
C aucasian < - 6  D AD Yes [176]
C aucasian < - 5  D AD N o _ [177]
C aucasian < - 1 D AD N o [1781
MYP3 12q21-q23 C aucasian < - 6  D AD [160] C aucasian < - 6 D AD Yes [173]
C aucasian < - 1 D Q TL No [174]
C aucasian < - 5  D AD Yes [179]
C aucasian < - 5  D AD Yes [177]
C aucasian < -  1 D AD No [1781
MYP4 7q36 C aucasian  and 
A frican-A m erican
< - 6 D AD [180]
MYP5 17q21-q22 Caucasian < - 6 D AD [181] C aucasian < - 6 D AD No [173]
MYP6 2 2 q l2 Caucasian < - 1 D AD [178] C aucasian < -1 D AD Yes [182]
C aucasian Continuous QTL Yes [183]
C aucasian < -  1 D AD No [184]
MYP7 1 1 p 13 Caucasian < -1 D QTL [185] C aucasian < -1 D QTL N o [186]
MYP8 3q26 Caucasian < -1 D Q TL [185] C aucasian < -1 D QTL Yes [186]
MYP9 4q 12 C aucasian < -1 D Q TL [185] C aucasian < -1 D QTL No [186]
VIYP10 8p23 C aucasian < -1 D QTL. [185] C aucasian < -1 D QTL N o [186]
C aucasian < - 1 D AD Yes [184]
MYP11 4q22-q27 A sian (C hinese) < - 6  D AD [187]
MYP12 2 q 3 7 .1 C aucasian < - 6  D AD [188] C aucasian < - 0.5 D AD Yes [189]
MYP13 Xq23-q25 A sian (C hinese) XR [190] A sian (C hinese) XR Yes [191]
\1YP14 lp36 Caucasian < - 1 D Q TL [192]
Novel i q C aucasian C ontinuous Q TL [183]
Novel 7p21 C aucasian C ontinuous QTL. [183]
Novel 5pl 5 A sian (C hinese) < - 6  D AD [193]
Novel 7 p l5 A frican-A m erican < -1 D QTL. [194]
Table 1.10 Overview o f Myopia Candidate Gene Analysis 
(Abbreviations: TF: transcription factors) _________
Gene
Symbol
Gene Name Reason for the Study Cohort Ethnicity Myopia
Criteria
Analysis Type Significant
Finding
Reference
T E X 28 T estisE xpressed28 Location  w ithin MYP1 5 Fam ilies C aucasian < - 5  D Screen ing  o f  sequence Suggestive [195]
N YX N yctalopin M yopia in congenital s tationary 
n igh t b lindness
52 Cases A sian  (C hinese) < - 6 D Screening  o f  sequence Suggestive [196]
TGIF
T ransform ing  G row th p- 
induced Factor
Location in M YP2 and role in eye 
grow th
71 C ases /1 0 6  C ontrols A sian (C hinese) < - 6 D A ssociation  o f  screened 
m utations
Yes [197]
204 C ases /  112 C ontrols A sian (C hinese) High SN P analysis o f  exons No [164]
10 C ases /  10 C ontrols C aucasian < - 6  D Screening  o f  sequence N o [1651
330 C ases /  330 C ontrols A sian  (Japanese) <-9 .25D A ssociation N o [1671
288 cases /  208 controls A sian (C hinese) < - 6  D A ssociation  Study No [1981
257 C ases /  294 C ontrols C aucasian < - 0 .5  D A ssociation No [199]
10 C ases /  10 C ontrols C aucasian < - 6  D Segregation  o f  sequenced 
polym orphism s
No [200]
10 C ases / 10 C ontrols C aucasian < - 6 D S egregation o f  sequenced 
polym orphism s
No [201]
CLUL1 C lusterin -like l Location in M YP2 10 C ases / 10 C ontrols C aucasian < - 6  D Segregation  o f  sequenced 
polym orph ism s
No [200]
EM ILIN 2 E lastinM icrofiblril Interfacer 
2
ZFP161 Zinc Finger Protein 161
M YOM 1 M yom esin 1 10 C a s e s /  10 C ontrols C aucasian < - 6  D Segregation  o f  sequenced 
polym orphism s
No [201]
M RCL2 /3 M vosinR egulatorvL igt C hain 
2 /3  '
DLGAP1 D rosophilaH om olog 
A ssociated  Protein 1
LPIN2 Lipin 2 Location in M Y P2 w ith highest 
LOD o f  9 .59[172]
10 C ases / 10 C ontrols C aucasian < - 6  D Segregation  o f  sequenced 
polym orphism s
No [200]
7 cases / 6 controls C aucasian < - 6  D Exam ination  o f  genom ic 
structure, expression  and SNPs
Potential 
regulatory  
e lem ents for 
TF
[202]
DCN D ecorin Location in M YP3 and role in 
collagen structure
10 C ases / 10 C ontrols C aucasian < - 6  D Segregation  o f  sequenced 
polym orphism s
No [201]
120 C ases / 137 C ontrols A sian(T aiw anese) < -10 D A ssociation  test N o [203]
EPYC E piphycan Location in M YP3 and role in 
collagen structure
10 C ases /  10 C ontrols C aucasian < - 6  D Segregation o f  screened 
polym orphism s
No [201]
Table 1.10 Overview of Myopia Candidate Gene Analysis (Continuation) 
(Abbreviations: TF: transcription factors)
Gene
Symbol
Gene Name Reason for the Study Cohort Ethnicity Myopia
Criteria
Analysis Type Significant
Finding
Reference
LUM Lum ican Location in M YP3 and role in 
collagen structure
10 C ases /  10 C ontrols C aucasian < - 6  D Segregation  o f  screened 
polym orphism s
No [201]
10 C ases / 5 C ontrols C aucasian < - 6  D Polym orphism  analysis o f  
screened sequences
N o [166]
125 C ases / 308 C ontrols; 
4 Fam ilies
C aucasian < - 6 D A ssociation  and segregation  tests 
o f  screened variations
Yes [204]
120 C ases / 137 C ontrols A sian(T aiw anese) < -10 D A ssocia tion  Studv Yes [203]
288 cases / 208 controls A sian (C hinese) < - 6  D A ssocia tion  Study N o [198]
FM O D Fibrom odulin Role in collagen structure 125 C ases /  308 C ontrols; 
4 Fam ilies
C aucasian < - 6  D A ssocia tion  and segregation  tests 
o f  screened variants
Suggestive [204]
10 C ases / 5 C ontrols C aucasian < - 6 D Screening  o f  sequence No [166]
O PTC O pticin Role in collagen structure 125 C ases / 308 C ontrols; 
4 Fam ilies
C aucasian < - 6  D A ssocia tion  and segregation  tests 
o f  screened variations
Yes [204]
C O L 1A I C ollagen. 
Type 1. A lpha 1
Location w ithin M YP5 and 
relation to collagen
471 C ases / 623 C ontrols A sian(T aiw anese) < - 6 D A ssocia tion  studv No [1691
330 C ases / 330 C ontrols A sian (Japanese) <-9.25 D A ssocia tion  Study Yes [205]
141 Fam ilies C aucasian < - 5  D A ssocia tion  Study N o [177]
COL2A1 C ollagen. Type 2. A lpha 1 R elation to collagen 123 Fam ilies C aucasian <-0.75 D A ssocia tion  Studv Significant [1631
PAX6 Paired Box 6 Location w ithin M YP7 and role in 
eye developm ent
221 D izygotic Tw in Pairs C aucasian < -1 D L inkage and A ssociation Linkage O nly [185]
123 Fam ilies C aucasian <-0.75 D A ssocia tion  Study N o [1631
164 Fam ilies A sian (C hinese) < - 6  D A ssocia tion  Study Yes [206]
188 C ases / 85 C ontrols A sian(C hinese) < - 6  D A ssocia tion  Study No r207]
596 Subjects C aucasian A ssociation  Study No [1681
4 Pedigrees C aucasian < - 5  D A ssocia tion  Study Suggestive [208]
SOX2 SexD etem iin ingR egionY B ox
2
Location in M Y P8 and role in eye 
developm ent
596 Subjects C aucasian A ssocia tion  Study No [168]
S 0 X 2 0 T SOX2 overlapp ing  transcript Location in M Y P8 and role in eye 
developm ent
1430 cases/ controls C aucasian < -1 D A ssociation  Study Yes [186]
T G F pi T ranscrip tion  grow th factor 
beta 1
Possible role in axial e longation 330 cases / 330 controls A sian (Japanese) <-9.25 D A ssociation  Studv No [2091
201 cases / 86 controls A sian (C hinese) < - 6 D A ssociation  Study Yes [210]
288 cases / 208 controls A sian  (C hinese) < - 6  D A ssociation  Studv N o [1981
HGF H epatocyte G row th Factor Possible role in axial e longation 128 fam ilies A sian (C hinese) < -  1 0 D A ssociation  Studv Yes [211]
288 cases / 208 controls A sian (C hinese) < - 6  D A ssociation  Study N o [198]
M M P3/
TIMP1
M a tr ix  M e ta l lo p e p t id a s e  3 /T IM P  
M e ta l lo p e p t id a s e  In h ib i to r  1
Possible role in axial e longation 366 cases / 736 controls A sian(T aiw anese) < - 6  D A ssociation  Study N o [212]
M YO C M yocilin Location in linkage region lq  and 
possible role in m yopic a lterations
70 cases / 69 controls A sian (C hinese) < - 6 D A ssociation  Studv No [213] .
162 fam ilies A sian (C hinese) < - 6  D A ssociation  Study Yes [214]
97 cases /  92 controls A sian (C hinese) < - 8  D A ssociation  Studv Yes [215]
EGR1 Early G row th R esponse 1 Involvem ent in ocular grow th 96 cases A sian (C hinese) < - 6  D M utation Screening No [216]
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2.1 Recruitment and Sample Collection
Subject recruitment \sas carried out with ethical approval granted by Cardiff University 
Human Sciences Research Ethics committee (Cardiff, Wales, UK) and followed the 
principles of Declaration of Helsinki. Signed, informed consent was obtained from each 
participant.
Idle project aimed to recruit ( I ) families where high myopia is present and (2) unrelated 
individuals with or without high myopia (cases/controls). In order to recruit subjects, 
information about The family Study o f Myopia was placed online and sent out to 
optometrists/ophthalmologists. Patients o f the Eye Clinic operating at Cardiff University 
were also approached.
Potential participants were sent an information pack (Appendix 1). containing detailed 
information about the project, a questionnaire and a consent form. Once subjects agreed to 
take part in the study, their subjective refraction was obtained from their 
optometrists/ophthalmologists and DNA samples were collected in the form o f saline 
mouthwashes via post.
Each potential subject was routinely asked to perform two mouthwashes first thing in the 
morning (before eating, drinking or brushing teeth) in order to obtain maximum DNA 
yield [217], The participants were requested to perform the mouthwash rinses twice, 
immediately one after the other, and to then post the mouthwashes back to our laboratory 
as soon as possible, f urther details are given below.
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2.2 Mouthwash as a Source of Human DNA
2.2.1 DNA Extraction from Mouthwashes
Participants were mailed 50ml skirted tubes containing 15-20 ml of sterile 0.9 % NaCl, 
and were asked to swish this vigorously in the mouth for 20-30 seconds, before spitting it 
back into the same tube.
On arrival back to laboratory, mouthwash samples were refrigerated for at least 40 
minutes, and then centrifuged at 3500 rpm for 5 minutes in a Boeco C-28 centrifuge 
(Boeckel & Co, Hamburg, Germany). The supernatant was discarded, and the buccal cell 
pellet resuspended in 480 pi of Extraction Buffer (10 mM tris-HCl, pH 8.0, ImM EDTA, 
0.5% SDS) and frozen at -20°C until processed further. Upon thawing, 20pl of proteinase- 
K (10 mg/ml) was added to each cell suspension and incubated in a waterbath with 
continuous shaking (-100 rpm) at 37°C for 2 hours. To separate insoluble material, tubes 
were centrifuged at 14000 rpm for 3 minutes and the supernatant was transferred to a fresh 
Eppendorf tube containing ~25pl high vacuum grease (Dow Coming Ltd). The vacuum 
grease served as a barrier between the aqueous (DNA-containing) and organic (protein- 
containing) phases after phenol/chloroform (phenol:chloroform:isoamyl alcohol -  
25:24:1) extraction was performed. Phenol-chloroform extraction was repeated up to twice 
more until the supernatant was clear. After the addition of 17pl 5M NaCl and 1ml 100 % 
ethanol, the DNA was precipitated overnight at -20°C and then centrifuged at 14000 rpm 
for 10 minutes. The supernatant was removed and the DNA pellet was washed with 1 ml 
ice-cold 70% ethanol. After air-drying for 3 minutes, the DNA pellet was dissolved in 
50pl of TE (10 mM tris, 1 mM EDTA, pH 8.0) and incubated at 37°C for 30 minutes with 
periodic gentle mixing (full protocol is in Appendix 2).
To quantify DNA concentrations, spectrophotometry, fluorometry, UV transillminator gel 
imaging system and Polymerase Chain Reaction (PCR) can be used. To test the quality of 
DNA, gel imaging system and PCR may be applied. These techniques are described 
below.
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2.2.2 Assessment of Mouthwash-extracted DNA
2.2.2.1 Spectrophotometry
Spectrophotometry measures the amount of light that a sample absorbs. A 
spectrophotometer operates by passing a beam of light through the compound in question 
and measuring the intensity of light reaching a detector. Different molecules absorb 
energy (light) at different wavelengths. For DNA, Ultra Violet (UV) light is applied. This 
UV wavelength can be absorbed by a number of molecules present in a sample. Hence, the 
absorbance method does not distinguish nucleotides, single stranded DNA or 
contaminants (e.g. proteins and trace amounts of phenol) from good quality double 
stranded DNA. Moreover, it is relatively insensitive and is not well suited for testing small 
volumes or concentrations of DNA [218-221]. Typical sensitivity is 150 ng/ml of double 
stranded DNA [222].
To quantify DNA, absorbance is usually measured at three different wavelengths: 
260(A260), 280(A280) and 320(A320) nm. Light of 260 nm is the one absorbed most 
strongly by DNA and its value is important in the calculation of the concentration of DNA 
in a sample. The absorbance of a DNA solution with a concentration of 50 pg/ml at 260 
nm is one unit, so the concentration of an unknown sample can be calculated by 
multiplying measured units of its absorbance by 50 and a dilution factor [222].
The A280 is used in a ratio of A260:A280 to determine the purity of DNA. Ratios below 
1.8 signal the presence of contaminating chemicals (e.g. proteins, phenol). Absorbance at 
320 nm (A320) provides information about proteins in a sample, since proteins absorb 
light of this wavelength, but DNA does not.
Spectrophotometry is probably the most widely applied method for DNA quantification, 
but is limited by requirement of large sample volumes (-100 pi), poor detectability and 
lack of DNA specificity. Free nucleotides, single-stranded nucleic acids (e.g. ribonucleic 
nucleic acid) and proteins may exhibit significant absorbance at A260 and any 
contamination of sample preparation by these agents will result in over-estimation of the 
DNA concentration [223]. In addition, it has been shown that such factors as pH or
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presence of phenol in the sample solution have a significant effect on the A260/A280 ratio 
[224, 225]. Therefore, only highly purified DNA preparations can be accurately quantified 
by spectrophotometry.
2.2.2.2 Fluorometry
2.2.2.2.1 The Principle of Fluorescence and Florometry
Fluorometry is the measurement of fluorescence, which is the phenomenon of light 
emission by “excited” molecules. Fluorescent molecules (fluorophores) absorb light at one 
wavelength and emit light at another. When fluorophores absorb light of a specific 
wavelength, their electrons rise to a higher energy level (the excited state). Electrons in 
this state are unstable and return to the ground level, releasing energy in the form of light. 
This emission of energy is fluorescence [226].
Analytical tools based on fluorescence are very useful because of their sensitivity and 
selectivity. When an analyte is fluorescent, direct fluorimetric detection is possible by 
means of a spectrofluorimeter operating at appropriate excitation and observation 
wavelengths. However, most molecules, including DNA, are not fluorescent and an 
indirect method of a fluorescent complex formation is applied in their analyses [226].
2.2.2.2.2 Fluorophores
Fluoresce-based analyses of nucleic acids are an integral part of many molecular biology 
procedures: fluorometry, agarose gel electrophoresis and real-time PCR.
The most commonly used fluorophore is ethidium bromide (EtBr), which is reported to 
have a sensitivity limit of lng/band for double stranded DNA (dsDNA) in agarose gels 
[227]. However, EtBr is potentially carcinogenic, posing handling and disposal problems. 
Furthermore, it easily photobleached and has a low fluorescence enhancement upon DNA 
binding, leading to high background readings [228, 229]. To address these issues, a series 
of cyanine dyes -  such as SYBR green [230], PicoGreen [218, 229] and SYBR gold [231]
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- have been developed. As a group, these dyes are characterized by having specific and 
high binding affinity to nucleic acids (up to 4x more than EtBr [231]), a low intrinsic 
fluorescence and large fluorescence enhancements upon binding to dsDNA [218, 228- 
231]. When bound to dsDNA, little background occurs since the unbound dye has 
virtually no fluorescence.
There are, however, certain limitations in their use as well. Cyanine dyes, for example, are 
not human-specific as they cannot distinguish between DNA molecules of different 
nature.
2.2.2.3 Ultraviolet (UV) Transillminator Gel Imaging System
2.2.2.3.1 Concept of DNA Gel Electrophoresis
Gel electrophoresis is a method that separates macromolecules on the basis of size, 
electric charge and other physical properties. The process of electrophoresis refers to the 
electrical charges “carried” by the molecules [232].
Nucleic acids are negatively charged. Under the influence of an electric field they migrate 
towards the positive electrode. The medium (e.g. agarose gel) they move through and their 
overall shape both affect their progress. It follows that different sizes and forms of nucleic 
acids move at different rates, providing the basis for their separation [232].
The basic protocol for DNA agarose gel electrophoresis can be divided into three steps:
(1) a gel is prepared with agarose concentration appropriate for the size of DNA 
fragments; (2) the DNA samples are loaded into the wells of a gel and are run at a voltage 
and for time period that will achieve optimal separation; (3) the gel is stained or, if the dye 
was incorporated into the DNA sample, visualized directly upon illumination with UV 
light [233].
Agarose gel electrophoresis can be used as a quantifying and/or quality assessment 
method. To calculate the concentration o f nucleic acid in an agarose gel, an image analysis
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computer program is applied. DNA quality can be evaluated by examining the size and 
shape of bands. The next two sections describe the methods of DNA staining, 
visualization and evaluation in electrophoresed agarose gel.
2.2.2.3.2 Staining methods for DNA Gel Electrophoresis
In order to detect DNA bands in electrophoresed gel, such methods are applied as 
fluorescence and staining with silver or visible organic dyes.
Fluoresce-based visualization of nucleic acids is an integral part of digital fluorescent 
imaging is widely used for both documentation and analysis of electrophoretic separations 
of DNA. Fluorophores that aid such examination of DNA are described in section 
2.2.2.2.2. Ethidium bromide and cyanine dyes are most widely used fluorescence 
reporters. It is possible to load the dyes directly to the DNA sample or agarose gel, 
avoiding the step of staining after a gel has been electrophoresed. However, all of the 
different types of dye can alter electrophoretic mobility and, thus, DNA size estimates 
[231,234].
Silver staining [235, 236] requires a large number of laborious processing steps involving 
accurate timing [237]. Although it has been reported to be more sensitive than EtBr [235], 
silver staining is still less sensitive than SYBR green and also is expensive [238].
Organic visible dyes are simple and safe to use, but a long destaining step (more than one 
hour) to detect distinct DNA bands and low sensitivity (2- to 4-fold less than EtBr) limits 
their application in molecular biology [239]. Nonetheless, these dyes could be a plausible 
alternatives as their inclusion in agarose gels allows observation of DNA bands in ambient 
light, eliminating the application of damaging UV light required by fluorophores.
2.2.2.3.3 DNA Quantification with UV TRansilluminator System
Quantification of the amount of DNA in a sample is a critical step in wide selection of 
molecular biology experiments. One of the ways of measuring DNA quantity in a sample
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is the densitometric analysis of bands with unknown DNA concentration run on a gel 
alongside standards of known concentration. The DNA can be quantified by constructing 
a “standard curve” and use of linear regression (section 2.4.1.2).
Fluorescence of the DNA-dye complex can be detected with an ultraviolet transilluminator 
system. This instrument represents a “dark room” where the gel is exposed to high 
intensity UV light and the induced fluorescence is captured by an attached digital camera. 
The image of fluorescent bands can be recorded on a disc and analyzed later using image 
analysis software.
Digital fluorescent imaging has a number o f advantages, including (1) DNA specificity, 
because of the dye used to visualize DNA; (2) the ability to show the quality of DNA (if it 
is degraded, there will be fragments of different sizes after separation) and (3) application 
to a wide range of stains, as most of DNA fluorophores have excitation peaks with UV 
light. However, this method also has some drawbacks: variation in such factors as gel 
thickness, sample loading volume and DNA fragment size can have a relatively large 
effect on the fluorescent signals seen with equivalent amounts of DNA [240].
2.2.2.4 Polymerase Chain Reaction (PCR)
2.2.2.4.1 Conventional PCR
DNA molecules can be “mass-produced” from incredibly small amounts with the 
Polymerase Chain Reaction (PCR) technique. This discovery allows a researcher to mimic 
the cell's own natural DNA replication process in a test tube.
The PCR method uses specially designed DNA oligonucleotides (primers) that are 
complementary to the part of sample DNA to be amplified. The sample DNA is denatured 
by heating and upon cooling this allows the primers to bind to their target sequences, if 
present. In the presence of a suitably heat-stable DNA polymerase and DNA precursors 
(the four deoxynucleoside triphosphates - dNTPs), the bound primers initiate the synthesis
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of new DNA strands which are complementary to the individual DNA strands of the target 
segment [241].
The PCR is a chain reaction because newly synthesized DNA strands act as templates for 
further DNA synthesis in subsequent cycles. After about 25 cycles of DNA synthesis, the 
products of PCR will include enough (about 105) copies of the specific target sequence to 
be easily visualized as a band of particular size when submitted to agarose gel 
electrophoresis [242].
PCR can provide information about DNA quantity (section 2.2.2.4.3) and quality. To get 
successful amplification one needs to have a DNA of a good quality: nicked or degraded 
DNA will not serve as a template for PCR.
2.2.2A2 Real Time PCR
Conventional polymerase chain reaction has several limitations. In terms of DNA 
quantification, the biggest issue is that the reaction reaches a “plateau” phase, after which 
the PCR yield remains constant [243]. The ideal solution to this problem is a real-time 
PCR -  a method that allows the detection of DNA sequences simultaneously with their 
amplification, first developed by Higuchi et al [244].
During the course of a real-time PCR reaction, detection of PCR products is made 
possible by including in the reaction a fluorophore (section 2.2.2.2.2) that reports the 
amount of DNA (this will yield a proportional increase in the fluorescent signal with the 
number of cycles). The information obtained is an amplification curve (Figure 2.2). This 
curve reflects two main phases o f fluorescence: (1) an exponential growth phase when the 
product approximately doubles providing the efficiency of the reaction is 100%, and (2) a 
plateau phase when the reaction saturates and no increase in fluorescence can be detected 
(Figure 2.1). In a typical real-time PCR all curves saturate at the same level and, thus, the 
end point of a reaction can provide no information about the initial DNA concentration. 
The growth phase, on the other hand, provides information regarding the original 
concentration of template. The number of cycles needed to accumulate enough product to
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raise the fluoresce signal above the background level is called the threshold cycle (Cj). 
Measurement of C j is the quantitative basis of real-time PCR [243].
Apart from being able to monitor amplification, real-time PCR can also provide 
information about the PCR product itself, by means of melting it and registering the 
decrease in florescence as the dye is released from denaturing dsDNA. The temperature 
dependence of the fluorescence reduction is represented as a melting curve (Figure 2.2). 
The melting temperature of a product (Tm) is defined as the point at which 50% of DNA is 
double stranded and 50% is single stranded, and is a function of product size and base 
composition [245]. Tm can also be identified as a peak value in the negative derivative 
melting curve (Figure 2.2). The melting curve analysis can be used for quantification (as 
the area under the curve of the peak is proportional to the amount of product [246]) or for 
confirmation of the correct target sequence (non-specific products have different length 
and therefore deviating melting temperatures [245]).
Figure 2.1 Real-time PCR Amplification Curve 
(Taken from Kubista et al [243])
During the exponential growth phase the 
amount of PCR product approximately 
doubles in each cycle. Flowever, as the 
reaction proceeds, the amplification slows 
and enters the plateau phase.
Initially, the fluorescence remains at the 
background level and its increase is not 
detectable. The time needed to accumulate 
enough product to yield a detectable signal is 
dependent on the initial DNA concentration 
and, thus, is different for each sample (Cji 
and CT2), providing the basis for the 
quantitative aspect of real-time PCR.
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Figure 2.2 Melting Curve o f a Real-Time PCR 
(Taken from Kubista et al [243])
The figure shows the drop in fluorescence as the product/primer-dimer (PD) melts. The Tm 
is determined as the inflection point of the curve, which is easier to identify as the 
maximum peak in the negative first derivative of the melting curve.
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2.2.2.4.3 Kinetics of Polymerase Chain Reaction and DNA Quantification
The basic equation describing PCR in simple terms is Nc = N0 x (E+l)c , where “c” is the 
number of thermocycles, “E” is the efficiency of a reaction, Nc is the amount of new 
product and N0 is the initial number of template molecules. This equation reflects the 
kinetics of PCR: each cycle produces an increase in Nc in proportion to amplification 
efficiency [247]. Since extension products are complementary to and capable of binding 
primers, each successive cycle essentially doubles the amount of DNA synthesized in the 
previous cycle. This results in exponential accumulation of amplicon, approximately 2n, 
where n is the number of cycles [248]. Therefore, 100% efficiency produces a doubling in 
specific target fragment.
The exponential growth in PCR product is not an unlimited process. Eventually, there will 
be more primer-template substrate accumulated than the amount of enzyme present is
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capable of completely extending in the amount of time allowed. When this occurs, the 
efficiency of reaction declines and reaches a plateau phase when the product accumulates 
in a linear rather than exponential manner [248]. In addition, as the PCR reaction 
progresses and the initial molar excess of primers present starts to reduce, template- 
template re-annealing can out-compete the primer-binding, leading to the plateau of a 
reaction.
Rearrangement of the PCR equation to N0 = Nc / (E+l)c provides the mathematical 
relationship upon which the quantitative PCR is based. Thus, quantification of Nc allows 
the calculation of N0 if amplification efficiency is known.
As described above, calculation of the initial DNA quantity in a sample with real-time 
PCR can be achieved using the Cj method, in which individual reactions are compared at 
the point when they contain identical amounts of product: at the Cj threshold Nc becomes 
constant and, thus, N0= NT/ (E+l)Ct [249].
The efficiency of a PCR assay (as well as the concentration of unknown samples) can be 
estimated from a standard curve based on serial dilutions of a standard sample. The C j 
values of diluted standards are read out and plotted against the logarithm of their 
concentrations or dilution factor. The mathematical basis of a standard curve can be 
derived by taking the logarithm of the C j method equation: log(N0 ) = log(NT) -  
log[(E+l)u ], which can be rewritten as log(N0) -  -log(E+l)xCj + log(Nj). Assuming that 
E and N r are constant, this standard curve equation will be linear and, therefore, plotting 
log(N0) versus C j will produce a line with a slope of -log(E+I) and intercept of log(NT). 
Hence, PCR efficiency can be calculated from the slope of a standard curve as ]0 'I/Slope 
[247]. Amplification efficiency is also frequently presented as a percentage: the percent of 
template that was amplified in each cycle. To convert E into a percentage the following 
equation can be used: Efficiency(%) = (E-l)xl00%  [250].
For proper comparison and quantification of DNA, all samples should have similar 
amplification efficiency during the exponential phase of a reaction: even as small a 
difference as 5% will result in a 3-fold difference in the amount of DNA after 25 cycles of
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exponential amplification [251]. In addition, Cy values generated from different runs can 
be compared directly only if an identical threshold was used for each run. Finally, the 
relationship between Nyand threshold values is dependent on amplicon size because the 
DNA fluorescence that underlines the determination of a threshold has a linear 
relationship with DNA mass [247].
The accuracy of DNA quantification in biological samples is often difficult because of 
their complex nature: they may contain inhibitory substances that are not present in 
purified standards. These inhibitory factors include carry-over chemicals from DNA 
purification, detergents, antibiotics, buffers, enzymes, fats and proteins [252]. The 
presence of an inhibitor may result in apparent increase in efficiency: samples with the 
highest concentration of template also have the highest amount of inhibitors, which causes 
a delayed Cy; whereas samples with lower template concentration have lower levels of 
inhibitors, so their Cy is minimally delayed. As a result, the absolute value of slope 
decreases and calculated efficiency appears to increase [250].
2.3 Genotyping
2.3.1 Microsatellite Genotyping
Precise and reproducible sizing of DNA fragments generated by PCR has become a 
fundamental technology in microsatellite genotyping. The procedure essentially involves 
two steps: amplification and electrophoresis [97]. DNA polymorphisms are amplified with 
end-labelled primers and visualized after separation on denatrating polyacrilamide 
sequencing gels [97]. The original polyacrilamide gel has been replaced by capillary 
electrophoresis in small diameter tubes [253] as it has benefits of automated filling of the 
capillary with separation medium and automated sample loading, allowing for full 
automation of the process.
One of the most widely used systems for microsatellite genotyping is the ABI 310 Genetic 
Analyzer. On this system, polymorphic loci are amplified with one unlabelled and one 
fluorescently 5’-labelled primer. Denaturated PCR products are then electrophoresed with
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an internal size standard (DNA fragments of known size labelled with a different 
fluorophore). Multiplex products are sequentially injected into a single capillary and 
detected in real time as they pass by a laser-detection window during their electrophoresis. 
The laser-induced fluorescence is captured with a CCD camera. The collected data is then 
analyzed by software that manually or automatically determines allele sizes on the basis of 
a standard curve from the internal size standards [254].
Precise scoring of microsatellite alleles, regardless of repeat unit size (2, 3 or 4 
nucleotides), holds a number of requirements. Genotyping errors may arise in several 
ways: low quality/quantity template DNA, unreliable PCR amplification or incorrect 
calling of alleles. Therefore, quality control is an essential step in accurate microsatellite 
genotyping (section 2.3.3).
2.3.2 SNP Genotyping
SNP genotyping is a major part of any large-scale genetic study and, thus, an appropriate 
genotyping method is crucial. The ideal assay should be sensitive, robust, automated and 
cost-effective. The majority of protocols involve the following steps: (1) allelic 
discrimination chemistry (hybridization, flap endonuclease discrimination, primer 
extension, allele specific digestion and oligonucleotide ligation); (2) allele detection 
(monitoring of the light emitted by products, measuring the mass of products or detecting 
a change in electrical property when the product is formed) and (3) allele calling. The 
challenge of high-throughput genotyping lies in pairing the right chemistry assay with the 
right detection system to maximize efficiency with respect to accuracy, speed and cost.
Hybridisation chemistries coupled with fluorescent plate reader detection currently offer 
the simplest route to a high-throughput genotyping platform. In this method allele-specific 
probes are immobilized on a solid support to capture amplified, labelled target DNA 
samples, and the hybridization event is visualized by detecting the label after the unbound 
targets are washed away. Knowing the location of the probe sequence on the solid support 
allows inference of the genotype of the target DNA. Hybridization assays differ in their 
way of reporting allele-specific binding: (1) TaqMan monitors the cleavage event of a
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specific probe during PCR [255]; (2) with molecular beacons, detection is based on the 
fluorescence of a stem-loop structure upon binding to the target DNA [256]; (3) in the 
Ulight-up" technique, fluorescence of the target DNA - oligomer probe complex reports 
the hybridization [257].
Allele-specific hybridization is the basis for an elegant genotyping assay: a complete 
system to generate a large number of short PCR products for each SNP in multiplex 
amplification and to automate hybridization, data scanning and analysis, allowing the 
screening of a large number of SNPs in parallel (e.g. Illumina or Affymetrix genotyping 
platforms). The major advantage of performing genotyping reactions on solid supports 
(e.g. latex bead, glass slide or silicon chip) is that many markers can be interrogated at 
once, saving time and reagents. Common hybridization conditions used for multiplexing, 
however, pose a problem of not being specific for all of the genotyped SNPs, with 
subsequent implications for data quality (section 2.3.3).
2.3.3 Genotyping Errors and their Prevention/Detection
Pinpointing genetic associations relies heavily on the accuracy of the underlying genotype 
data. High-throughput genotyping errors may occur for a number of reasons: low 
quality/quantity of template DNA, unreliable PCR amplification, electrophoresis artefacts, 
assay non-specificity, incorrect calling o f alleles and data entry errors.
Erroneous PCR amplification can be caused by deficient template DNA, poor primer 
design or suboptimal reaction conditions. Under any of these circumstances it is possible 
that one allele of a heterozygote will not be detected and that false allele calls will arise 
[258, 259]. Two particular problems are often experienced with microsatellite genotyping:
(1) stuttering (minor products preceding the primary allele peak on electopherogram) and
(2) an extra adenine base (A) added to the 3’ end of the amplified product by Taq 
polymerase. Both of these artefacts can cause difficulties in allele calling, particularly 
when analyzing dinucleotide repeats.
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Nonrandom genotyping failure, which involves an individual’s SNP genotype that is 
either incorrectly called or more commonly not called at all, can be a source of 
confounding in genome-wide association analysis. If such failure is non-random with 
respect to genotype (e.g. some genotypes are more likely to be uncalled) and to phenotype 
(e.g. cases have lower genotyping rates than controls) then false positive association can 
occur [260]. Therefore, it may be beneficial to exclude those SNPs or subjects that show a 
high genotyping failure rate.
Quality control and accurate quantification of DNA samples, as well as reproducibility 
checking by running replicates of samples o f known genotypes, may prevent faulty 
genotyping. To account for an extra A when dealing with microsatellites, a high single­
base resolution genotyping method is required.
To detect genotyping errors, Mendel consistency tests and HWE checking can be 
performed. Alleles showing non-Mendelian behaviour in families or out of HWE among 
unrelated subjects should be re-called (e.g. in pedigrees) or excluded from further 
analyses.
2.4 Statistical Analyses
2.4.1 Generalized Linear Model
One of the most widely used tools of statistical analyses is the generalized linear normal 
model, exemplified by analysis o f variance (ANOVA) and by regression analysis (sections
2.4.1.1 and 2.4.1.2).
Any statistical test of pattern requires a model against which to test the null hypothesis 
of no pattern. A linear model analyzes the relationship between two variables: one 
independent (or explanatory) and one dependent (or response). A model often comes in 
the form of a numerical function of input variables. Apart from the independent (input) 
variable, the function also contains some numerical parameters that need to be adjusted
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to the data by some type o f  algorithm.
The generalized normal linear model requires four basic assumptions: (1) the 
dependent variable is normally distributed, (2) the variance of the dependent variable 
remains constant over the range of values of the independent variable to be considered,
(3) the mean of the dependent variable is a linear function of any parameters introduced 
and (4) the observations of the independent variable are independent [261]. Thus, 
before applying any linear model to a data set, normality and homogeneity of variances 
must be addressed.
2.4.1.1 Analysis of Variance (ANOVA) and Post-Hoc Tests
ANOVA aims to identify whether there is any significant difference between the means of 
two or more groups of data. However, it does not compute the differences between means 
of the groups directly. Instead, ANOVA focuses on the variability in the data, examining 
if the variance between the group means is greater than would be expected by chance 
[262]. Thus, ANOVA is termed analysis of variance.
The statistic of ANOVA is the F-ratio or F-statistic: the value is obtained from the ratio of 
the variance between the groups and the variance within the groups [263] . A variance is 
the measure of variability, taking account of the size of the dataset.
The variability in a set of data quantifies how different the individual observations are 
from the mean of the overall population in general. Therefore, before performing an 
ANOVA test, it is crucial to assure the homogeneity of variances in groups of data wished 
to be analyzed (e.g. Levene’s test).
To calculate the variance, first the grand mean of the population is calculated, then the 
differences of each point from the mean: deviations will be both positive and negative, and 
the sum will be zero. This will hold regardless of the size or the amount of variability of 
the dataset. Thus, the raw differences are not useful as a measure of variability. If the 
measures are squared before summation, on the other hand, then this sum is a better
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estimate of variability: it will increase the greater the scatter of the data point around the 
mean. This quantity is called the sum o f squares (SS) and is the basis of the F-statistic 
[262).
The total sum of squares can be divided into two parts: SS between groups (SSb) and SS 
within groups (SSw). SSb is calculated based on the squared deviations between the group 
means and the grand mean of the sample population (all groups together). SSw is 
calculated based on the squared deviations between each individual in a group and that 
individual's group mean [262).
The SS, however, cannot be used as a comparative measure between groups because it 
will be influenced by the number o f datapoints in the group: the more datapoints the 
greater the SS. Therefore, SS is converted to a variance or the mean square (MS) by 
dividing SS by degrees o f freedom [262).
In statistics, degrees o f freedom represent the number of independent pieces of 
information in a population o f size n required to obtain a given grand mean. Since all 
deviations must sum up to zero by definition, it is known what the final value must be and, 
thus, there are only n-l independent observations or degrees of freedom [262, 263).
The mean square between the groups ( M S b ) is the sum of squares between groups ( S S b ) 
divided by the degrees of freedom between groups ( D F b ), and, similarly, the mean square 
within the groups is SSw divided by degrees of freedom within the groups (DFw). Degrees 
of freedom between the groups is one less than the number o f groups, while DFW is the 
difference between the total degrees o f freedom ( n-l ) and DFb. The F-statistic is then the 
ratio of the mean square between groups and the means square within groups (F= MSb / 
MSw) or it is between groups mean square divided by the error mean square [262, 263).
Being a type of general linear model analysis, ANOVA is analogous to the regression 
situation with the mean o f the independent variable forming the fitted value and the 
following equation: total deviation = deviation explained by independent variable + 
unexplained deviation (residual) [263J.
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If the p-value of the F-ratio or ANOVA test is less than 0.05, it only indicates that there is 
significant discrepancy between groups and does not give any information on which 
specific means are different. To uncover the source of significance, so-called post-hoc 
tests need to be performed [262].
The appropriate post-hoc examination is dependent upon the number and type of 
comparisons planned. The only post-hoc analysis used in this study is Dunnetf s test, 
which is used for comparability of groups with a chosen reference group, such that there 
are one less comparisons than the total number of groups [262].
2.4.1.2 Linear Regression
The purpose of linear regression analysis is to evaluate the impact of a predictor 
(independent) variable on an outcome (dependent) variable [264].
A simple, univariate regression model contains only one independent (explanatory) 
variable (x) and is linear with respect to the dependent variable. Mathematically, the 
model is expressed as Y = a + bx + e, where “Y” is the outcome variable; “x” is dependent 
variable; “a” and “b” are parameters of the model, representing the intercept on y axis and 
slope of the regression respectively; and “e” is the random error [264] . The slope is the 
average change in Y if x were to change by one unit and the intercept is the Y value when 
x equals zero [265] (Figure 2.3).
The main goal of linear regression is to fit a straight line through the datapoints, that 
would best explain the relationship between the two examined variables. This regression 
line is obtained using the method of least squares. Any line drawn through the datapoints 
would give a predicted or fitted value of Y for each observed value of x in the data set. 
The vertical difference between the observed and fitted value of y for a particular point x 
is known as the deviation or residual. The method of least squares finds the values of “a” 
and “b” that minimise the sum of the squares of all deviations [264, 266].
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The fraction of the variability in Y (with a range of 0-1) that can be explained by 
variability in x through their linear regression is referred to as the R-square measure. 
[264].
Several hypotheses can be tested by linear regression. The most common one is to test 
whether the slope of the regression line is zero (there is no linear relationship between Y 
and x). However, it is important to understand that linear regression should not be 
interpreted as causation and should not be used to estimate outside the range of the 
independent variables [264].
Figure 2.3Graphical Representation o f Linear Regression 
(Taken from Zou et al [264])
Blue squares represent the datapoints, across which a line was fitted using linear 
regression. The expectation of the dependent variable Y is linear in the dependent variable 
x, with an intercept a = 1.06 and a slope b = 1.8.
Regression equation: Y=1.8 + 1 06X
10
Corresponding Increase in Y 
Slope (b) = 1.8
Unit Increase inX
Y value when x=0 
Intercept (a) 1.06
O 2 4 6 8 10
Independent Variable (X)
67
2.4.2 Analysis of categorical outcomes
2.4.2.1 Statistics of Contingency Tables
2.4.2.1.1 Concept of Contingency Tables
When using categorical (qualitative) variables in an investigation of statistical relationship 
between groups, the data can be summarized in form of frequency or counts of 
independent observations in each category. If a statistical test is restricted to the 
association between two dichotomous variables, then the counts can be presented in a 2x2, 
or contingency, table [267, 268] (Table 2.1). It is important to assure that the outcome for 
each individual is independent of the outcome for other individuals in order not to violate 
the assumption of independent observations of the statistics of contingency tables.
Table 2.1 Contingency Table (Example)
(Taken from Sistrom and Garvan [268])
Both dependent (outcome) and independent (risk) variables are dichotomous. Counts of 
observations are calculated for each o f the two categories of each variable. N is the sum of 
all observations.
Outcome (Dependent) 
Variable
Total
Category
One
Category
Two
Risk
(Independent)
Variable
Category
One
a b a + b
Category
Two
c d c + d
Tota a + c b + d N
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2.4.2.1.2 Measures of the Effect of a Risk Variable in Contingency Tables
The probability of the occurrence of a particular event equals the proportion of times that 
the event would (or does) occur in an examined population. For example, the probability 
of death in five years following diagnosis of prostate cancer would be defined as the 
proportion of times death would occur among a large number of men diagnosed with 
prostate cancer. This probability is then said to be the risk of death in the five years 
following the diagnosis of prostate cancer [269].
The probability has a value between 0 and 1: 0 if the event never occurs and 1 if it is 
certain to occur. It can also be expressed as a percentage, taking a value between 0% and 
100%.
The odds of an event A are defined as the probability that A does happen divided by the 
probability that it does not happen: Odds(A) = prob(A) / 1 -prob(A). The odds are always 
bigger than the probability since 1 -  prob(A) is less than one: for example, when the 
probability is 0.5, the odds are one (0.5/( 1-0.5)). In contrast to the probability, which lies 
between 0 and 1, odds take the rage from 0 (when prob(A) = 0) and infinity (when 
prob(A) = 1). When the probability is small (<0.1), the odds are very close to the 
probability because l-prob(A) would be very close to one [269].
The effect of a certain risk variable can be assessed using probability and odds in three 
ways: risk difference, relative risk (RR) and odds ratio (OR) (Table 2.2).
The risk ratio is more commonly used to measure the strength of an association than is the 
difference in risks. This is because the amount by which a risk factor multiplies the risk of 
an event is interpretable regardless of the size of the risk. A risk ratio of one occurs when 
the risks are the same in the two groups and is equivalent to no association between the 
risk factor and the outcome. A risk ratio greater than one occurs when the risk of the 
outcome is higher among those exposed to the risk factor than among the non-exposed 
[269].
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An odds ratio of 1 occurs when the odds, and hence the proportions, are the same in the 
two groups and refer to no association between a risk factor and an outcome variable. As 
the risk in the group with no risk becomes larger, the maximum possible value for of the 
risk ratio becomes constrained, because, by definition, it must not be more than one. Odds 
ratio, on the other hand, is not constrained in this matter since there is no upper limit to its 
value [269].
Both risk ratio and odds ratio reflect the ratio of proportions and, thus, the hypothesis of it 
being equal to one or not can be tested. If the calculated ratio's 95% confidence interval 
does not include one, it means that the OR or RR show a significant effect of the 
examined risk variable [270].
Table 2.2 Measures o f the effect o f a risk variable in a contingency table 
(Adopted from Kirkwood and Sterne [269])
The notations “a”, “b’\  “c” and “d" are the same as in Table 2.1.
Measure of comparison Formula
Risk Difference a/b -  c/d
Risk Ratio (Relative Risk) a / b
c / d
Odds Ratio (OR) a x d
b x c
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2.4.2.1.3 Chi-square and Fisher Tests in Contingency Tables
In order to test for association in two categorical variables organized in a contingency 
table, the X  (chi-square) or Fisher's test can be performed. The X  test makes comparison 
between the observed or collected data versus the data one expects to find: X  = 
X(observed-expected)2/expected. In other worlds, the test examines if the difference 
between observed and expected values is due to random chance or some factor influencing 
the results [267].
The use o f the “chi-square distribution’' in tests of association is an approximation that 
relies on large expected frequencies and, thus, the cell counts cannot be less than five 
[267, 270]. To overcome this limitation, the relationship can be tested by Fisher’s exact 
test, which evaluates the probability o f obtaining the particular, observed cell counts, 
considering the total number of all possible tables with the given marginal totals and 
assuming the null hypothesis of no association [267, 270].
For large sample sizes the two statistics give very similar results, but for smaller samples 
Fisher’s test is preferable, although being more conservative (Fisher’s test produces larger 
p-values with less probability to conclude significant association between studied 
variables [270]).
2.4.2.2 Logistic Regression
The basis of the simple logistic regression is derived from the odds ratio (OR) of an 
examined risk factor: Odds in exposed group = Odds in unexposed group x Odds ratio. 
This model expresses the odds in each group in terms of two model parameters: baseline 
and odds ratio. The term baseline refers to the group against all other groups will be 
compared, while odds ratio expresses the effect of a risk factor on an outcome variable. 
Because confidence intervals or odds ratios are derived by using the log function, logistic 
regression models are fitted on a logarithmic scale. Thus, the previous equation can be 
rewritten as log(Odds) = log(Baseline) + log(Odds Ratio), transforming it from 
multiplicative to an additive (or linear) one [269].
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The general form of the logistic regression model is similar to that of the linear regression: 
log(Odds) = p0 + Pix, where po and Pi are the regression coefficients, and x is an 
independent (or exposure) variable. For comparing two exposure groups the exposure 
variable would equal one for those in the exposed group and zero for those in the 
unexposed group (269].
The likelihood ratio statistic in the logistic regression is the so-called Wald test, which is 
based on a quadratic approximation o f the exact log likelihood ratio, chosen to have the 
same value and curvature at the maximum likelihood estimate [269] (section 2.4.3)
2.4.3 Likelihood and Likelihood Ratio
The likelihood gives a comparative measure o f how compatible is an examined dataset 
with each particular value of a probability. For example, after testing 12 households for 
tuberculosis, 3 tested positive and 9 tested negative. Using the notation of Table 2.1, (a + 
c) would equal 3 and (b+d) would equal 9. The sample proportion, thus, would be 0.25. 
The likelihood would give the value o f the most likely probability o f trasmitting a 
tuberculosis infection given the sample proportion o f 0.25 [269].
The approach used to calculate the probability (n), or likelihood, is the maximum 
likelihood estimation (MLE) and is derived by differentiating the binomial likelihood 
equation of n (a+c) x (1- 7t)(b+d) to find the value that maximizes it. The result is 
(a+c)/(a+c+b+d). which is (a+c)/N and in this example is 0.25 [269].
As well as concluding that 0.25 is the most likely value for the true probability n of the 
risk of household transmission of tuberculosis in this example, it is useful to know what 
other values o f n are compatible with the data. The likelihood for any other probability 
will be less than MLE. Flow much less likely is assessed using the likelihood ratio (LR): 
LR = Likelihood for n / Likelihood at MLE. By definition, the likelihood ratio equals one 
for the MLE and less than one for all other values [269].
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Because the confidence interval for the likelihood ratios is derived using logarithmic 
function, in practice log(LR) is calculated instead of the actual ratio. Provided the sample 
size is sufficiently large, the curvature o f log(LR) can be approximated by a quadratic 
equation, which is easier to handle mathematically.
Likelihood is usually used for hypothesis testing and there are three types o f tests based on 
the log likelihood: the likelihood ratio test (LRT), Wald test and score test. The likelihood 
ratio test (LRT) is based on the value of the log likelihood ratio at the null value of the 
parameter and equals -2 x ln(Likelihood at null parameter -  Likelihood at MLE) [269].
The Wald and score tests are both based on the value of a fitted quadratic approximation. 
The Wald test uses the approximation to the log likelihood ratio at the null value of the 
parameter of interest rather than the actual value o f the log likelihood ratio at this point. 
The quadratic approximation of the Wald test is chosen to meet the log(LR) at the MLE 
point and to have the same curvature as the log(LR) at this point. It is symmetrical around 
MLE and its maximum value is zero [269].
The score test, on the other hand, uses an alterative approximation, chosen to have the 
same value, gradient and curvature as the log likelihood ratio at the null value of the 
parameter rather than at its MLE [269].
2.4.4 Statistical Methods for Detection of Genetic Association of Refractive Error
2.4.4.1 Refractive Error as a Categorical Outcome
Refractive error can be assessed both as categorical or continuous variable: continuous 
tests would provide information on refractive error as such; while performing association 
tests on dichotomized -  affected (highly myopic) and non-affected (emmetropic) -  
refractive error would reveal the possible candidate variants that may account for the trait 
in affected (in this case severely shortsighted) group only. Since this study is aiming to 
disclose the genetic background of high myopia, refractive error in all association analyses 
reported in this thesis was treated as a dichotomous phenotype.
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Refractive error shows a leptokurtotic distribution that is skewed towards myopia: the 
errors are clustered near zero and their prevalence falls exponentially moving away from 
zero in either direction (Figure 2.4). Based on the bimodality of the myopic limb of the 
refractive error curve (Figure 2.4), the criteria used to determine affectation status was 
historically set to be more or equal to -6.0 Dioptre [271]. Several genetic studies on high 
myopia have adopted this threshold [172, 175, 176, 180] and, therefore, analyses reported 
in this thesis were performed using this criterion.
The distribution of refractive error changes with age. The average refractive error of 
newborns is around +3.0 dioptres of hyperopia, shifting towards +1.0 dioptres by one year 
of age [272]. Based on studies of mostly Caucasian children, myopia typically appears 
between 6 and 12 years of age [48, 273, 274]. If an association study examines refractive 
error in form of a dichotomous variable, determining affectation status as high myopia (in 
this case more or equal to -6.0 Dioptres), it is important to take into account the age of the 
participants as young children may develop severe shortsightedness after their refraction 
was acquired for the analyses. The Family Study o f Myopia recruits mostly adults over 18 
years of age. There are no children younger than 6 years of age and only one participant 
was aged 12 years of age at the time the association analyses of this study were performed.
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Figure 2.4 The Distribution Curve o f Refractive Error 
(Taken from [271]).
2.4.4.2 The Statistic of an Association Test
The statistic of an association test can vary depending on whether it is a family-based or 
case/control study. Most analyses are either likelihood based ratio/score tests or x2/ Fisher 
tests of independence.
Family-based association studies originally involved a so-called transmission 
disequilibrium test (TDT) only [135]. This method can be considered to be a version of a 
X2 test of independence: the test statistic is calculated based on 2 x 2 table constructed with 
counts of alleles that are transmitted or non-transmitted to affected offspring in a small trio 
(mother, father and child) family. However, the original TDT test has several limitations 
(section 1.3.4.1).
Many family-based association tests are based on the regression model: Y = p + Pg 8 +  
pxx, where Y is the observed trait, /j. is the population mean, pg is the additive effect for
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each allele, g  is a genotype score, fix is a vector of covariate effects and x reflects the 
covariate status of each subject. To test for association, a multivariate likelihood test can 
be performed. First the likelihood is maximized under the null hypothesis of no 
association and under the constraint that is zero (Lo). Then the procedure is repeated 
without constrains on parameters to obtain Li. A likelihood ratio test (LRT) statistic to 
evaluate the evidence of association would then be equal to 21nLj -  21nLo. Such an LRT 
statistic requires that Lo and L| be maximized for each SNP. That can become 
computationally challenging on a genome-wide scale [275].
An alternative approach is to first fit a simple model without pg for each family and then to 
calculate a so-called score statistic, where, along with the expected genotype g  vector 
determined based on the available marker data, an additional E(g) vector with identical 
elements is created to give the unconditional expectation of each genotype score. [275].
Both LRT and score statistics asymptotically follow a chi-square distribution with one 
degree of freedom. However, it is important to note that the distribution of the score 
statistic will deviate from x2 when a linked major gene effect is large. Therefore, score 
statistics should be used for an initial phase of genome-wide analysis and LRT should be 
used for re-evaluation of statistical findings in screening steps, to avoid an excess of false 
positive results in the regions of strong linkage [275].
Although it is possible to restrict analyses to complete data only, such an approach would 
result in loss of power in comparison to one that would accommodate it [147]. Missing 
data can originate because the recruitment o f both parents is not always feasible in 
practice or because of failed/incorrect genotyping. To overcome the missingness of 
parents, information from siblings can be used if available [148, 276]. Alternatively, 
maximum likelihood can offer solution for any kind o f missing data [147, 277, 278].
Case/control association analyses are usually based on tests for independence (%2or Fisher 
test) at both allelic and genotypic levels as well as on calculation of odds ratios and 
relative risks. In addition, logistic (binary trait) or linear regression (quantitative trait) can 
also be applied [127].
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2.4.5 Multiple Testing and its Correction
Association studies involving many markers give rise to the problem of multiple testing, 
which results in an increased number of false positives, thus necessitating a correction in 
the nominal significance level. In genetic studies the risk of false discovery is very high 
because only few among all tested markers will have an effect in the case of a complex 
disease. Indeed, it has been speculated that out of 20 reported association studies, 19 are 
false [279].
Typically, a test is declared significant if the calculated p-value is less than a chosen 
threshold value. A type I error is the situation o f rejecting the null hypothesis when it is 
true. This produces a false discovery or a false positive result.
The traditional approach for controlling false discoveries is to maintain a desired 
probability that a study produces no more false positives than a specified error rate. This 
method controls the error rate for the whole set o f tests (e.g. genome-wide tests) [280]. 
One of the most well known procedures in this group is the Bonferroni adjustment: the cut 
off p-value is divided by the number of tests performed [281]. This one-step method has, 
however, been proven to be conservative, leading to loss in the power of a study. In 
addition, it performs well only when all markers are independent [280]. If more than one 
marker has an effect, a step-wise procedure is preferred. The main idea is that if one of the 
null hypotheses is rejected, it cannot be considered true anymore. Therefore, the correction 
can be made to the number of tests minus one, rather than the number of tests as such 
[282].
Rather than focusing on the risk of false discoveries, it can be argued that it may be better 
to calculate the ratio of false positives: the probability that a randomly selected marker 
among significant ones is false [283]. This ratio is called the false discovery rate (FDR) 
and is fundamentally different from traditional approaches. Firstly, because the risk of 
false discoveries in genome-wide analyses is high, the traditional correction will heavily 
penalize test statistics by imposing very small threshold p-values. However, a large 
association study is also likely to discover more true positives. Thus, FDR will reward it 
by focusing on the proportion of false discoveries divided by all rejected tests (including
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false but also true positives). Due to their small effect sizes, the power to detect genes 
responsible for complex diseases is already low, thus, it may be more advantageous to 
allow an occasional false discovery to improve the chances of finding an effect instead of 
further sacrificing power. Furthermore, because there will be multiple significant genes 
with small effects, the consequences of false discovery may not be as severe as in a single 
gene analyses where a discovery implies a strong claim that the cause has been found 
[280].
A second important difference is that in contrast to traditional methods, FDR does not 
concentrate on the number of tests performed. Instead, it is based on the so-called pG -  
value: the proportion of markers with no effect on a disease or, in other words, the 
probability that a randomly selected marker has no effect. The higher this proportion the 
more likely it is that a discovery is false [280]. This provides a better basis for comparison 
of different studies (e.g. replication analyses): the number of tests performed by different 
researchers is arbitrary and may depend on such factors as budget or genotyping capacity, 
whereas parameter pG is not arbitrary and applies similar standards to different studies 
[280].
It is noteworthy, however, that FDR, as any method, has its disadvantages as well. The 
major limitation is that the p0 -value and effect size are unknown. The pG -value 
commonly is assumed to be one, which results in a conservative test because the high pQ 
will produce a low threshold value. To avoid this bias, p0 can also be estimated from the 
data [284].
Finally, correction for multiple testing can also be done by the use of permutation [285]. 
Random permutations of the data are obtained by sampling from the same set of 
observations without a replacement. The limitation of this procedure is that the number of 
permutations should be large enough (preferable exceed 100/threshold p-value) to be able 
to estimate low p-values.
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CHAPTER m .
QUANTITY AND QUALITY OF DNA 
EXTRACTED FROM MOUTHWASHES
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In large-scale genetic linkage and association studies there is a need for a cost-effective, 
safe and efficient method of obtaining DNA. An attractive approach is to use buccal cells 
as, in comparison to blood, they offer a non-invasive and more easily collected source of 
cellular material. Various methods of buccal cell collection have been proposed, such as 
mouthwash, cytobrush and type cards [286, 287]. Among these procedures mouthwash 
can be performed by study participants without supervision, has the advantage of being 
collected via mail [288, 289] and yields the highest amount of DNA [286].
Despite these numerous advantages, there is a need for caution in using DNA extracted 
from buccal cells because of the presence o f non-human DNA in mouthwash samples, e.g. 
from oral bacteria or food remnants. Once the DNA is extracted, the biggest issue is to 
distinguish between different origins of DNA and accurately estimate the quantity/quality 
of human DNA.
The following three sections describe three experiments performed in order to gain insight 
into quantification and quality assessment o f mouthwash-derived DNA.
3.1 Experiment 1. Quantification of Mouthwash-extracted, Human DNA
3.1.1 Introduction
Correct DNA quantification is essential for many genetic applications, e.g. efficient high- 
throughput genotyping and sample conservation. Inaccuracy in DNA quantification can 
result in the unnecessary consumption of DNA [290], can lead to lower confidence in 
scoring genotype by increasing the variability in the amount of PCR product used by most 
genotyping technologies [291], and can give rise to wrong allele frequency estimations 
when such samples are pooled [292].
Conservation of original DNA samples is important to validate previous studies and to 
allow for future studies, representing a critical goal for the efficient utilization of research 
resources [290].
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In light of the above, an accurate and reliable method for DNA quantification is essential 
for any genetic study. Several methods have been developed to quantify DNA: basic UV 
spectrometry, gel-based techniques, fluorometry and amplification (PCR). Early 
techniques (spectrometry, gel electrophoresis, fluorometry) simply measured total DNA, 
but newer PCR can specifically measure human DNA. In addition, spectrophotometry 
usually overestimates the amount of human DNA not only because of the presence of non­
human DNA, but also because its measurements are influenced by UV-absorbing 
contaminants like proteins and phenol, which may interfere with the quantification results 
[293, 294]. In addition, the DNA concentration must be at least 3ng/pl in order to give 
reliable results with UV spectrophotometry [295]. Quantification of human DNA can also 
be inaccurate when estimated by DNA-specific dye based fluorometry or gel 
electrophoresis as a fluorophore dye cannot distinguish between DNA of different origins 
[294].
Performing conventional PCR for DNA quantification is time-consuming, while real-time 
reaction requires an expensive machine and reagents that may not be available in every 
laboratory. This experiment, thus, assessed classic and newer DNA quantification 
techniques and compared their performance to that of qPCR.
3.1.2 Materials and Methods 
3.1.2.1 Subjects and DNA samples
Subjects who took part in this experiment were volunteers from the School of Optometry 
and Vision Sciences. Each of the participants was asked to provide three mouthwashes.
3.1.2.2 Spectrophotometry
The principal of spectrophotometry is described in section 2.2.2.1. To calibrate the 
spectrophotometer, TNE (lOmM Tris, 100 mM sodium chloride (NaCl), 1 mM EDTA, pH 
= 8.0) was used as reference (blank) and calf thymus DNA solution of known 
concentration (50 pg/ml) was used as a standard. Samples were diluted in TNE 1:100 in 
triplicate, i.e. every sample was measured 3 times. The ratio of A260/A280 for each
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assessment was determined and those with less than 1.79 or greater then 2.10 were 
rejected. The concentration of DNA in a sample was ascertained as described in the 
section 2.2.2.1.
3.1.2.3 Fluorometry
The principle of fluorometry is described in section 2.22.2.
A dilution of stock SYBR-green in TE (10 mM Tris, ImM EDTA) 1:10 000 was prepared. 
A linear range of standard, human placenta DNA (Sigma) dilutions from 1 to 2 pg/pl were 
used as standards. Two micro litres o f samples and prepared standards were diluted in 
2000 micro litres of SYBR-green-TE (1:1000). Dilutions were produced in triplicates. A 
mixture of dye and TE was measured without any DNA as a blank.
The instrument settings were set according to the results of previously carried out tests 
with calf thymus DNA of known concentration. The wavelengths of excitation and 
emission were taken from the SYBR-green manufacturer’s package inserts and were 
verified from the literature [221]. The fluorimeter was set as follows: exciting wavelength 
= 497 nm, emission wavelength = from 500 to 540 nm, scan speed = 240 nm, the 
excitation monochromators were adjusted to a band width of 5 nm and the emission’s to
2.5 nm.
Using Microsoft Excel, a standard curve for samples with known concentration and their 
units of fluorescence was established by performing linear regression (section 2.4.1.2). 
The equations of regressions for each measurement were used to determine the 
concentration of DNA in the test samples.
3.1.2.4 Ultraviolet Transilluminator Gel Imaging System
The agarose gel electrophoresis procedure is described in section 2.2.2.3.I.
One percent agarose gels were run using boric acid-sodium hydroxide buffer. Samples for 
agarose gel electrophoresis were prepared in the following way: I pi of a purified, 
mouthwash-derived DNA sample was mixed with 2.4 pi of SYBR-green-ficoll (15%
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Ficoll 400, 0.5% xylene cyanol FF, lOmM EDTA, 1:50 dilution of stock SYBR Green I 
(Molecular Probes Ltd, Paisley, UK) solution) and 8.6 pi of water. Ten microliters of this 
mixture were loaded into the gel.
Calf thymus DNA was used as a standard. A calibration curve was prepared with a linear 
range of dilutions from 0.5 to 2 pg/pl. Electrophoresis was performed at a voltage of ~60 
Volts for 40 minutes. Every sample and standard was run 4 times (two gels with duplicate 
samples and standards). As a control, one well of the gel was loaded only with dye and 
water and no DNA. A DOC-008.XD (UVItec Ltd, Cambridge, UK) camera system 
coupled to an ultraviolet transilluminator was used to take a digital photograph of the gel 
and Quantity One software package was applied to determine the density of the DNA 
fragments. A standard curve was constructed (amount of DNA in standards versus their 
density) in Windows Excel. Linear regression analyses were performed for each gel and 
regression equations were adopted to calculate the amount of DNA loaded in each well of 
each gel.
3.1.2.5 Quantitative Polymerase Chain Reaction (qPCR)
For this experiment, conventional PCR amplification of microsatellite marker D7S3056 
(forward 5’ CAA TAG CCC TGA CCT TAT GC, reverse 5’ TAC CTA CCT ACC TAC 
CTC TAT GGC) was carried out. The principle of PCR is described in section 2.2.2.4.
Triplicate dilutions of each DNA sample were prepared to achieve ~5ng/pl concentration. 
Human placenta DNA was used as a standard and a linear range of concentrations from 1 
to 5 ng/pl was also prepared. Essential reagents for PCR were mixed to reach the 
following final concentrations of lx HotStar PCR buffer (Qiagen Ltd, Crawley, UK), 1.5 
mM MgC12, 0.2 pM each dNTP and 1 pM of each primer. Each reaction contained 0.5U 
HotStar Taq polymerase (Qiagen Ltd, Crawley, UK). Initial step of 15 minutes at 95°C 
served to activate the HotStarTaq polymerase enzyme. Amplification was achieved by 25 
cycles of the following steps: denaturation at 94°C for 1 minute, annealing at 60°C for 1 
minute and extension at 72°C for 1 minute. Ficoll-EDTA (15% Ficoll 400, 0.5% xylene 
cyanol FF, lOmM EDTA solution) was added to PCR products, and agarose gel
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electrophoresis was performed in a 2% agarose gel at the voltage of ~60 Volts for 40 
minutes. To visualize the DNA, ethidium bromide staining was performed. The optical 
density of gel bands was analyzed as described above.
3.1.2.6 Statistical Analyses
Yields of DNA in each sample, calculated using four methods described above, were 
tested with ANOVA and compared with Dunnetf s test to see whether there was any 
significant difference between results of qPCR and the three other procedures. Each 
dataset for each quantification method was weighted by its average. PCR results were 
treated as a reference group for Dunnett’s test.
3.1.3Results
3.1.3.1 Subjects and DNA samples
In total, five subjects took part in the experiment and, thus, 15 DNA samples were 
available for analysis.
3.1.1.2 DNA Quantification and Statistical Analyses
Each sample was quantified three times with each of the four methods examined: 
spectrophotometry, fluorometry, gel electrophoresis and qPCR (180 measurements in 
total; Table 3.1). Out of analyzed five subjects, two had only one acceptable 
spectrophotometry reading.
84
Table 3.1. Results (DNA yield) o f four Potential Quantification Methods.
Each sample was measured three times. Mouthwash two of subject two and mouthwash 
two of subject four had only one acceptable spectrophotometry reading (A260/A280 less 
than 1.79 or more than 2.10). SD is the abbreviation for standard deviation.
Subject Mouthwash DNA Yield (pg) measured by
Spectrophotom etry Fluorometry Electrophoresis PCR
1 1 94.50 77.59 66.19 71.08
87.75 70.83 62.50 51.64
87.25 72.43 42.80 61.36
Mean (SD) 89.83 (4.05) 73.62 (3.53) 57.16(12.58) 61.36 (9.72)
1 2 8.50 11.55 7.06 5.94
7.75 11.55 6.89 3.36
10.00 11.55 5.61 4.65
Mean (SD) 8.75 (1.15) 11.55 (0.00) 6.52 (0.79) 4.65(1.29)
1 3 47.25 89.52 60.39 68.18
45.25 90.07 63.18 70.43
44.25 84.29 53.71 69.30
Mean (SD) 45.58 (1.53) 87.96 (3.19) 59.09 (4.87) 69.30(1.13)
2 1 20.50 21.19 47.36 15.37
17.50 22.32 47.88 18.57
16.50 20.00 38.38 18.69
Mean (SD) 18.17(2.08) 21.17(1.16) 44.54 (5.34) 17.54(1.88)
2 2 13.00 18.09 39.88 14.08
N/A 15.29 42.72 12.65
N/A 16.74 37.29 12.15
Mean (SD) N/A 16.71 (1.40) 39.96 (2.72) 12.96(1.00)
2 3 30.75 27.76 19.27 24.71
29.50 30.24 27.74 32.65
23.00 25.48 40.48 33.68
Mean (SD) 27.75 (4.16) 27.83 (2.38) 29.16(10.68) 30.35 (4.91)
3 1 40.50 36.90 40.14 34.12
49.00 33.25 41.05 34.62
47.00 23.18 38.52 34.67
Mean (SD) 45.50 (4.44) 31.11 (7.11) 39.90(1.28) 34.37 (0.25)
3 2 52.75 42.59 40.14 44.12
51.75 40.15 41.05 32.97
51.50 37.94 21.87 33.54
Mean (SD) 52.00 (0.66) 40.23 (2.33) 34.35 (10.82) 36.88 (6.28)
3 3 84.00 40.22 58.77 44.12
81.00 34.03 53.96 22.97
79.75 32.52 59.05 33.54
Mean (SD) 81.58 (2.18) 35.59 (4.08) 57.26 (2.86) 33.54(10.58)
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Table 3.1 Results (DNA yield) o f  four Potential Quantification Methods (Continuation)
Subject Mouthwash DNA Yield (pg) measured by
Spectrophotometry Fluorometry Electrophoresis PCR
4 1 64.25 40.01 50.07 49.96
62.50 47.08 41.41 28.72
59.50 36.57 23.60 39.34
Mean (SD) 62.08 (2.40) 41.22 (5.36) 38.36(13.50) 39.34
(10.62)
4 2 9.50 10.71 19.04 9.42
N/A 9.78 23.38 16.67
N/A 10.06 17.39 9.95
Mean (SD) N/A 10.18(0.48) 19.94 (3.09) 12.01 (4.04)
4 3 29.00 54.20 25.50 68.43
21.00 46.50 21.57 74.23
21.75 63.48 35.50 58.30
Mean (SD) 23.92 (4.42) 54.73 (8.50) 27.52 (7.18) 66.99 (8.06)
5 1 60.00 45.33 37.19 24.75
55.00 49.02 25.72 41.26
54.25 46.85 13.16 33.01
Mean (SD) 56.42 (3.13) 47.07(1.85) 23.56(12.02) 33.01 (8.26)
5 2 78.50 36.86 36.59 37.99
76.50 37.45 33.60 36.26
94.25 49.49 28.16 31.91
Mean (SD) 83.08 (9.72) 41.27 (7.13) 32.78 (4.27) 35.39 (3.13)
5 3 26.50 15.23 17.73 18.16
27.50 15.45 32.09 38.01
23.50 15.16 24.91 28.08
Mean (SD) 25.83 (2.08) 15.28 (0.15) 24.91 (7.18) 28.08 (9.93)
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Compared to the amount of human DNA measured by qPCR, yields calculated by 
spectrophotometry, fluorometry and electrophoresis were overestimated by 33.64%, 7.7% 
and 4.08% respectively.
All groups of readings for each subject had no significant difference in their variability 
(Levene’s test p-value > 0.05, Table 3.2). ANOVA analysis revealed a significant 
difference between the groups of measurements for all five subjects (p < 0.05), except for 
the third mouthwash of subject two (Table 3.2). Post-Hoc analysis with Dunnett’s test 
showed no significant difference between fluorometry and PCR in 13 samples out of the 
15 examined (Table 3.2). This pattern was followed in 3 samples out of 13 for 
spectrophotometry, and in 9 samples out o f 15 for agarose gel electrophoresis (Table 3.2).
Table 3.2 Comparison o f human DNA quantification methods 
(ANOVA and Dunnett’s Tests Results)
ANOVA and Dunnet’s post-hoc test were used to test whether the measurements of four 
examined DNA quantification techniques were different from each other (non-significant 
result is highlited).
Note that the second mouthwash of subject two and the second mouthwash of subject four 
had only one acceptable (A260/A280 less than 1.79 or more than 2.10) spectrophotometry 
reading. Thus, Dunnett’s test was not performed for those samples. Levene’s statistic was 
calculated to test for homogeneity o f variances between groups of measurements.
Subject Mouthwash Levene’s ANOVA Dunnett’s Test p-value (PCR versus)
p-value p-value Spectrophotometry Florimetry Electrophoresis
1 1 0.123 0.001 0.002 0.112 0.772
1 2 0.871 0.000 0.001 0.000 0.078
1 3 0.121 0.000 0.000 0.000 0.000
2 1 0.267 0.000 0.976 0.143 0.000
2 2 0.866 0.000 N/A 0.100 0.000
2 3 0.270 0.961 0.942 0.934 0.977
3 1 0.108 0.010 0.023 0.609 0.284
3 2 0.161 0.013 0.019 0.761 0.841
3 3 0.200 0.000 0.000 0.886 0.001
4 1 0.438 0.013 0.015 0.971 0.986
4 2 0.598 0.001 N/A 0.556 0.002
4 3 0.509 0.000 0.000 0.152 0.000
5 1 0.352 0.003 0.011 0.105 0.425
5 2 0.971 0.000 0.000 0.451 0.872
5 3 0.396 0.025 0.973 0.017 0.719
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3.1.4 Discussion
Due to variety in the origins o f sample from which DNA can be extracted (e.g. buccal 
cells or blood) and in the method o f purification, low yields of DNA and/or the presence 
of contaminants are frequently encountered in molecular biology applications. This 
emphasizes the need and importance of a method capable of quantifying low levels of 
DNA, with (1) minimal consumption o f the total available sample, and (2) minimal 
influence of sample impurities on its accuracy. Precise quantification of DNA is crucial 
for efficient molecular procedures, such as genotyping, in order to maximize high- 
throughput completion rates, accuracy and reproducibility. It also enables good sample 
management and reduces unnecessary DNA consumption.
In this experiment, the performance o f four potential DNA quantification methods was 
compared. As expected from previous studies [293, 294], the amount of human DNA 
measured by spectrophotometry, fluorometry and electrophoresis was overestimated 
compared to the qPCR results that provided human-specific assessment.
Until recently, specrophotometry has been the traditional method of measuring DNA 
concentration as it does not require complicated equipment or multi step sample 
preparation. In addition, spectrophotometry has been proved to have small sample-to- 
sample variability [290]. In this experiment, its coefficient of variability (standard 
deviation divided by the mean of a sample) was the smallest (8.36% on average), 
confirming that it is indeed a reproducible method for DNA quantification. Nonetheless, 
non-specificity to DNA makes spectrophotometry readings not acceptable as a measure of 
human DNA concentration: the overestimation of spectrophotometry over qPCR was the 
largest at 33.64%, suggesting that more than 1/3 of what spectrophotometry quanitfies is 
not actually human DNA. Moreover, spectrophotometry is also the least sensitive method, 
requiring a relatively large amount o f sample DNA for its quantification.
In contrast to spectrophotometry, fluorometry and gel electrophoresis are both DNA 
specific and sensitive due to DNA-binding fluorophores applied in these techniques. 
Electrophoresis has an additional advantage of assuring of DNA quality (degraded or non­
degraded). However, because gel electrophoresis requires a number of sample preparation
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steps, its reproducibility is inferior to that of fluorometry (coefficient of variance: 20.5% 
versus 8.42%), whose sample preparation is simpler. DNA quantities measured by 
fluorometry, in this experiment, were not significantly different from those estimated by 
qPCR for the majority of DNA samples (87% concordance), at least in relative terms. This 
confirms the previously published results of fluorometry being useful as an accurate 
alternative to a qPCR for DNA quantification [293, 294]. Nonetheless, it does not give 
any measurement of purity (like an A260/A280 ratio of spectrophotometry), nor does it 
certify that DNA is not degraded (like gel electrophoresis) and requires more complicated 
and expensive equipment than either spectrophotometry or electrophoresis.
3.1.5 Conclusion
In light of the above, fluorometry has the potential to substitute for human-specific qPCR, 
provided that DNA is not degraded and is primarily of human-origin.
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3.2 Experiment 2: The quality of mouthwash-extracted, human DNA: effect of lag 
time between mouthwash rinse and DNA extraction on quality of the mouthwash- 
derived DNA
3.2.1 Introduction
Buccal cells are an important source o f DNA in epidemiological and genetic studies, and, 
thus, it is essential to determine how to maximize the amount and quality of DNA 
collected from this cellular material. Among several methods proposed for buccal cell 
collection [286, 287, 289, 295-297], mouthwash has proved to give the greater DNA yield 
and to be easier to perform than the others [286, 289]. However, the conditions of 
mouthwash performing/collection may affect the DNA extracted from it. The 
circumstances of mouthwash performance such as swish time and tooth 
brushing/eating/drinking before collection have already been examined [286], showing 
that for the best results a mouthwash should be performed before tooth brushing, eating or 
drinking; while swish time (30 seconds versus 1 minute) has no effect on DNA derived 
from buccal cells [217]. Lag time between mouthwash rinsing and processing, on the 
other hand, has been proposed as a possible cause o f poor DNA quality [217, 286, 296] 
extracted from buccal cells, but this issue has not been investigated in detail. As the 
Family Study of Myopia collects mouthwashes by post, in this experiment, the effect of 
delay of 0-3 days in the time between a mouthwash rinse being carried out and DNA 
extraction being completed (mimicking the delay that would be experienced by posted 
mouthwash samples) to find out whether such a time-delay had an effect on DNA 
degradation evaluated by agarose gel electrophoresis. In addition, the extend of 
association between DNA degradation and a subject was also assessed.
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3.2.2 Materials and Methods
3.2.2.1 Subjects and DNA samples
Ethical approval for this experiment was granted by the Cardiff University Human 
Sciences Research Ethics Committee. The experiment adhered to the tenants of the 
Declaration of Helsinki and all participants provided written informed consent.
Subjects of this experiment were university students, who each provided one mouthwash 
per day on 12 separate days. These volunteers brought their mouthwash samples to the 
laboratory on the day they were obtained. The single mouthwashes collected each day 
were assigned to one of the four groups A-D (with 3 mouthwashes per group), with 
samples being stored at room temperature for (A) zero, (B) one, (C) two, or (D) three days 
before being processed.
DNA was extracted as described in section 2.2.1.
3.2.2.2 UV Transilluminator Gel Imaging System
DNA degradation was examined with agarose gel electrophoresis as described in section 
3.1.2.4 of the previous experiment. Electrophoresed DNA was visualized using a digital 
imaging system.
DNA degradation appeared as an “all-or-nothing” phenomenon, making the effect 
straightforward to score by eye, and because existing automated image analysis systems 
for electrophoresis gels are not designed to score DNA degradation, it would have 
necessitated the development of a custom software to perform the task. Since (1) the time 
taken to score the gels by eye was shorter than the time required for software 
development, and (2) an automated system seemed unlikely to provide a greatly improved 
level of reproducibility over scoring by eye, it was decided that DNA degradation would 
be scored by visual inspection: samples showing a smear instead of a well-defined band 
were recorded as degraded.
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3.2.2.3 Statistical Analysis
To explore whether a delay prior to DNA extraction (0-3 days) influenced the proportion 
of DNA samples that were scored as being degraded, logistic regression (section 2.4.2.2) 
was carried out, with time (in days) as a predictor variable.
3.2.3 Results
3.2.3.1 Subjects and DNA samples
In total 6 volunteers agreed to participate in this experiment. All of them provided 12 
mouthwashes (72 samples in total) and DNA was successfully extracted after the 
appropriate 0-3 days delay.
3.2.3.2 Effect of lag time on DNA degradation assessed by gel electrophoresis
There was no obvious relationship between the amount of lag time a mouthwash sample 
was stored at room temperature (0-3 days) prior to extraction and the presence/absence of 
DNA degradation. Some subjects had degraded DNA in all samples (Figure 3.1), whilst 
for other subjects DNA degradation was sporadic (Figure 3.2). Statistically, lag time had 
no significant effect on DNA degradation in the logistic regression model (Wald test: Z = 
0.052, df = 1, P = 0.819).
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Figure 3.1 Gel electrophoresis o f 12 mouthwashes o f one the subjects examined 
(Degraded DNA in all samples)
The electrophoresed 12 mouthwash-extracted DNA samples were divided into 4 groups 
according to the number of days (0-3 days) they were left at a room temperature before 
further processing. DNA in all samples derived from this individual show signs of 
degradation.
NUMBER OF DAYS AFTER WHICH MOUTHWASH WAS PROCESSEC 
O O O I  I 1 2 2 2 3 3 3
Figure 3.2 Gel electrophoresis o f 12 mouthwashes o f one the subjects examined 
(Degraded DNA in some samples)
The electrophoresed 12 mouthwash-extracted DNA samples were divided into 4 groups 
according to the number of days (0-3 days) they were left at a room temperature before 
further processing. DNA is degraded in some samples (for example: lane 5) derived from 
this individual, but not in others (for example: lines 6).
NUMBER OF DAYS AFTER WHICH MOUTHWASH WAS PROCESSED
0 0 0 1 1 1 2 2 2 3 3 3
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3.2.4 Discussion
The effect of lag time between mouthwash rinsing and processing on the degradation of 
extracted DNA was examined in this experiment, as it has been suggested to be one of the 
potential causes for poor DNA quality derived from buccal cells [217, 286, 296].
Storage of unprocessed mouthwashes at room temperature for up to 1 week has been 
shown not to affect DNA yield or the efficiency with which the DNA can be amplified by 
PCR [217, 296]. Similarly, in this experiment there was no significant influence of the lag 
time on the degradation of DNA, suggesting that the possible delay in postage (up to 3 
days) would not affect the quality of mouthwash-extracted DNA.
Resistance of DNA to degradation over time is presumably influenced by the composition 
of the mouthwash solution itself (e.g. the presence or absence of alcohol). In this 
experiment mouthwashes were performed using sterile saline. DNA has been proved to be 
stable in saline at room temperature for up to 4 days [298], and, likewise, there was no 
pattern of increased degradation over 3 days time in this investigation.
3.2.5 Conclusion
Consistent with previous studies, this experiment showed DNA degradation being 
unrelated to the lag time (up to 3 days) between mouthwash rinse and DNA extraction, 
that samples spend at a room temperature. This finding suggests that mailing is an 
acceptable form of collection of mouthwash buccal cells.
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3.3 Experiment 3: Quality Assessment of Mouthwash-extracted DNA
3.3.1 Introduction
Buccal cell samples provide a valuable source of human DNA for genetic polymorphism 
analysis in molecular studies, especially if blood collection is not feasible (e.g. large 
“field” epidemiological study). The success of PCR reactions using mouthwash-derived 
DNA has been shown to be dependant on the size of the amplified fragment -  the 
amplification of long DNA fragments being more difficult presumably because of nucleic 
acid degradation [217, 299]. In addition, mouthwash-derived DNA shows a higher 
discordance rate than blood-derived DNA in genotyping and whole genome amplification 
[300].
Together, the above results suggest that buccal cell DNA is inferior to that obtained from 
blood. To address this issue in greater detail, this experiment evaluated the performance of 
gel electrophoresis and qPCR as DNA quality control procedures. After checking for 
degradation with agarose gel electrophoresis, “human-specific” qPCR was carried out to 
establish whether sufficient DNA of human-origin was present to perform efficient PCR 
(and to investigate whether degradation noticed with gel electrophoresis had any adverse 
effect on the outcome of qPCR). Finally, those samples that were judged to be non­
degraded by gel electrophoresis and to contain a supra threshold level of human DNA by 
qPCR were genotyped with Illumina 6k human bead array assay to assess if the quality 
control techniques were able to identify “high quality DNA” samples.
3.3.2. Materials and Methods 
3.3.2.1 Subjects and DNA samples
Recruitment of subjects, collection of their mouthwash samples and DNA extraction 
procedures are described in sections 2.1 and 2.2.1.
3.3.2.2 UV Transilluminator Gel Imaging System
The quality and quantity of mouthwash-extracted DNA was assessed by gel 
electrophoresis and gel imaging (section 2.2.23). Briefly, after extraction from a 
mouthwash, DNA was diluted 1:10 in TE and 10 pi of the dilution was electrophoresed on 
a 1% agarose gel with SYBR green I as a fluorophore.
DNA degradation appeared as an “all-or-nothing” phenomenon, making the effect 
straightforward to score by eye, and because existing automated image analysis systems 
for electrophoresis gels are not designed to score DNA degradation, it would have 
necessitated the development of a custom software to perform the task. Since (1) the time 
taken to score the gels by eye was shorter than the time required for software 
development, and (2) an automated system seemed unlikely to provide a greatly improved 
level of reproducibility over scoring by eye, it was decided that DNA degradation would 
be scored by visual inspection: samples showing a smear instead of a well-defined band 
were recorded as degraded.
3.3.2.3 Quantitative Polymerase Chain Reaction (qPCR)
“Human-specific” qPCR was also carried out to provide insight into the likely 
consequences of this degradation for downstream applications. A measure of the human 
DNA content of mouthwash-derived DNA samples was obtained in one of two ways: a 
conventional qPCR reaction followed by agarose gel and scanning densitometry, or a real­
time qPCR reaction (section 2.2.2.4.2).
For the standard reaction, samples were diluted with a known volume of TE to give an 
expected final DNA concentration in the range l-5ng/pl. The quantitative PCR reaction 
was performed as described in section 3.1.2.5.
For real-time qPCR, amplification was carried out using a Rotor-Gene 6000 thermal 
cycler, with SYBR-Green I (Molecular Probes-Invitrogen Ltd, Paisley, UK) as the 
fluorophore. Quantification of DNA was achieved by constructing a standard curve of 
calculated Ct versus concentration for a set of DNA standards that were included in each
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run (section 2.2.2A3). Reaction reagents were mixed to give final concentrations of 1.2 x 
HotStar PCR buffer (Qiagen Ltd, Crawley, UK), 3 mM MgCb, 0.24mM dNTPs mix, 1.2 
|iM of each primer (D7S3056) and 1:40 000 SYBR Green I. Each 10 pi reaction contained 
1U HotStar Taq polymerase (Qiagen Ltd) and mouthwash-extracted DNA diluted with a 
known volume of TE to an expected concentration of 0.5 -  2.5ng/pl. Amplification was 
achieved using 40 cycles of PCR (denaturation at 94°C for 1 minute, annealing at 60°C for 
1 minute and extension at 72°C for 1 minute) after a preliminary step of 10 minutes at 
95°C to activate the enzyme.
3.3.2.4 High-throughput SNP Array Genotyping
Mouthwash DNA from those participants that proved to contain sufficient human DNA to 
provide robust amplification of the test amplifier (D7S3056) and that were scored as non­
degraded by gel electrophoresis was sent to the Centre of Inherited Disease Research 
(CIDR) for genotyping on the Illumina 6k Human bead array [301]. Details of the 
genotyping procedures of CIDR are available at
http:Avww.cidr.jhmi.edu/human_snp.html. The proportion of mouthwash-derived DNA 
samples that were successfully genotyped by CIDR was compared to the results o f blood- 
derived DNA sent at the same time. Genotyping was deemed successful if the sample 
passed the quality control assessment carried out by CIDR. This was based on the use of 
Illumina’s BeadStudio software GenCall (GC) score (a GC score ranges from 0 to 1 and 
reflects the proximity within a cluster plot of intensities of that genotype to the centroid of 
the nearest cluster). All genotypes with GC score below 0.25 were considered as failures. 
DNA samples with >4% genotyping failures were judged as failed samples.
3.3.2.5 Statistical Analyses
Since DNA degradation appeared as an all-or-nothing event as judged from agarose gels, 
mouthwashes were scored as either intact or degraded using a binary code. Fisher’s exact 
test and odds ratio (sections 2.4.2.2 and 2.4.2.3) were calculated for a 2x2 table containing 
counts of the number o f first and second degraded DNA samples from the 2 consecutive 
mouthwashes provided by each subject.
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Analysis of qPCR results were based on binary coding as well: samples were scored as 
having “passed” or “failed” to amplify efficiently, depending on whether they reached a 
threshold level (this threshold being chosen as representative of the minimum level of 
PCR product required for successful microsatellite genotyping). Fisher’s exact test and 
odds ratio (sections 2A2.2  and 2.4.23) were computed for a 2x2 table comprising the 
number of successful qPCR reactions when template DNA was or was not degraded.
3.3.3 Results
3.3.3.1 Subjects and DNA samples
In total 500 subjects (1000 mouthwashes) were collected for this experiment, as a part of 
The Family Study of Myopia. DNA was successfully extracted from all mouthwashes and 
analyzed by gel electrophoresis and by qPCR.
3.3.3.2 Quality of DNA and Statistical Analyses
Degradation was observed in a proportion o f samples, evident as a broad smear of 
fluorescence in place of the usual single, sharp, high molecular weight band (Figure 3.3).
The frequency of DNA sample degradation was 8.9% (95% Cl: 7.1-10.7%; N = 1000). 
Among 52 subjects with degraded first mouthwashes, 37 second samples (71%) also 
contained degraded DNA (Table 3.3). The odds ratio for DNA degradation in the second 
sample given degradation of the first sample was 3.13 (95% Cl: 1.22 -  7.39), which was 
statistically significant (P=0.009, Fisher’s exact test).
Each DNA sample was also assessed using a qPCR assay with primers targeting a human 
microsatellite marker D7S3056. Figure 3.4 shows the amplification curve obtained for 
this qPCR reaction, while Figure 3.5 reflects the specificity of the reaction presenting the 
melting curve with one expected product, which was confirmed by agarose gel
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electrophoresis. The average efficiency of the real-time PCR reaction was 94.8%, while 
the average r2 value for the linear regression was 98%.
For the 1000 mouthwash-derived DNA samples tested in total, 85.4% of degraded 
samples passed the qPCR test, compared with 87.8% of non-degraded samples. Statistical 
analysis suggested that PCR amplification of degraded samples did not differ significantly 
from that of non-degraded ones (P = 0.5; Fisher’s exact test; Table 3.4). The presence of at 
least some high molecular weight DNA by gel electrophoresis was associated with 
successful qPCR amplification (Figure 3.6), although this was not investigated in detail.
Figure 3.3 Gel Electrophoresis o f Mouthwash-extracted DNA
Agarose gel electrophoresis of DNA extracted from mouthwashes of 8 subjects (2 samples 
per subject). Subjects are identified by the figures above lanes. DNA extracted from one 
of the mouthwashes provided by subject 4 and both mouthwashes provided by subject 5 
was found to be degraded.
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Table 3.3 DNA Degradation in a Subject ’s First Mouthwash Sample when Analyzed as a 
Risk-factor for DNA Degradation in their Second Mouthwashes.
DNA degraded in 2nd mouthwash? Total
Yes No
DNA degraded in Yes 9 43 52
1st mouthwash? No 28 420 448
Total 37 463 500
Figure 3.4 Real-time PCR Amplification Curve
Amplification of two DNA samples (yellow and purple lines) along with no-template- 
control (green line) is shown. Amplification starts its exponential growth at cycle number 
20 and reaches its plateau phase at cycle number 28.
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Figure 3.5 Real-time PCR Specificity
An indication of the specificity o f real-time PCR was the melting curve: the melting curve 
o f two DNA samples (A.) shows one specific melting point (yellow and purple lines), 
while the no-template-control has no product (green line). Normalized melting curve (B.) 
reveals the melting temperature o f the product: 82° C for DNA samples (yellow and purple 
lines) and none for no-template control (green line).
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Table 3.4 PCR Success in Degraded DNA Samples
Successful PCR? Total
Yes No
Degraded Yes 76 13 89
DNA? No 800 111 911
Total 876 124 1000
Figure 3.6 PCR Efficiency o f  Degraded DNA Samples
Eight mouthwash DNA samples (lower panels) were used as templates for PCR 
amplification (upper panels). Partially degraded DNA samples containing residual high 
molecular weight DNA typically permitted efficient PCR amplification (lanes 3 and 4). 
Severely degraded DNA typically failed to PCR amplify (lanes 5 and 6).
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3.3.3.3 High-throughput SNP Array Genotyping
Two hundred fifty three mouthwashes proved to provide sufficient human DNA for 
efficient qPCR and that was judged as non-degraded. These samples were genotyped 
using the Illumina 6k SNP array platform. There was only one sample (0.4%) that could 
not be genotyped. For DNA extracted from blood and sent for genotyping at the same 
time, between 0.6 - 5.3% DNA samples could not be genotyped by CIDR. For the 252 
buccal DNA samples that were successfully genotyped, the average number of SNPs that 
could be genotyped for each subject was 99.7% of the total, and the reliability of SNP 
genotyping “blind” duplicate mouthwash DNA samples was similarly high (>99.9% 
concordance).
3.3.4 Discussion
A major finding from this study was the discovery that ~ 10% of DNA samples obtained 
from saline mouthwashes contained degraded DNA. Furthermore, there was an 
approximately 3-fold increased risk of DNA degradation in a subject’s second mouthwash 
sample, given DNA degradation in their first. This finding suggests that DNA degradation 
may be due to one or more factors specific to individual subjects. Therefore, although in a 
genetic study, DNA derived from the majority o f participants (-90%) can score as non- 
degraded, there will also be individuals (-10%), whose DNA may always be degraded. If 
such degradation is not detected prior to downstream analyses, it is likely to lead to a 
failure rate o f -10% of samples. For high-throughput SNP genotyping and whole genome 
amplification reactions, this will result in reduced statistical power compared to that 
anticipated. For DNA pooling experiments it may lead to suboptimal results, since fewer 
individuals will contribute to the genotyping signals that expected.
Variability in the quality of DNA obtained from mouthwashes could arise due to 
dissimilarity in each individual’s oral flora, dietary or lifestyle habits, differences in 
desquamation of oral mucosa [299] or because of other reasons, such as how exactly the 
mouthwash rinsing protocol was performed, the composition of the mouthwash solution, 
and the lag time between mouthwash rinsing and processing. There is a highly diverse and
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subject-specific, bacterial flora in the healthy oral cavity [302, 303] that can be affected by 
smoking [304, 305] and diet [306], and which in turn can lead to DNA damage [307].
The way in which the mouthwash rinsing procedure is performed has been shown to 
significantly affect DNA yield [298, 308]. Furthermore, cells recovered in mouthwashes 
are likely to be superficial ones in the process o f apoptosis: about 30 % of buccal cells 
collected from persons with healthy, non-inflamatory oral mucosa show apoptotic signs 
[309]. Therefore, DNA from certain individuals may be more prone to the signs of DNA 
degradation noted here.
The lag time between mouthwash performance and DNA extraction from it can also be a 
possible cause of DNA degradation. However, this was not the case in this experiment as 
all mouthwashes were processed on the day o f their arrival to our laboratory, and delay in 
doing so up to 3 days was shown to have no significant effect on DNA quality (section 
3.2).
Approximately 12% of the DNA samples examined in this study failed to amplify with 
qPCR. Interestingly, this failure appeared to be independent of visible DNA degradation, 
suggesting that factors other than this were to blame [310]. It is likely, that carry-over of 
contaminating substances from DNA extraction played a major role in failure of qPCR in 
our mouthwash samples. During purification with phenol-chloroform, poor PCR 
performance [311] and relative loss o f human DNA [308] have been observed. In our 
experience, re-extraction improved PCR performance in approximately 50% of cases, 
supporting the possible presence of carry-over inhibitors. Nonetheless, since this study 
attempted to amplify a relatively small product (~200bp) of D7S3056 microsatellite 
marker (http://www.cephb.fr/cephdb) and previous studies have shown that amplification 
of long PCR products (>500 bp) is less successful for partially degraded DNA [217, 299], 
our results suggest that DNA degradation is likely to be more disruptive for demanding 
downstream analyses.
High-throughput genotyping of mouthwash-derived DNA samples that scored well with 
gel electrophoresis and qPCR showed high and reliable performance. Thus, this 2-step
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procedure may serve as a quality control for DNA of buccal origin collected in “field” 
conditions. Nonetheless, it is difficult to conclusively state how reliable the 2-step 
protocol would be since samples that were scored as “degraded” were not sent for 
genotyping, and, therefore, no comparison between the genotyping success of “degraded” 
versus “non-degraded” DNA samples was made.
3.3.5 Conclusion
Approximately 10% of mouthwash samples collected using a standardized protocol in our 
laboratory exhibited signs of DNA degradation. The phenomenon of DNA degradation 
was shown to be partially subject-specific, although further work will be required to trace 
the precise cause(s) involved. Therefore, planning a collection of buccal DNA for a large 
genome-wide study can be made more balanced and cost-effective by taking into the 
account that -10% of the collected DNA samples may not be intact.
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CHAPTER IV.
MYOCILIN POL YMORPH ISMS AND HIGH 
MYOPIA IN  EUROPEAN SUBJECTS
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4.1 Introduction
Several highly penetrant genetic loci for non-syndromic myopia have been mapped 
(section 1.4). However, none of the causative mutations has yet been found. Candidate 
gene association studies have led to the identification of a number of high myopia 
susceptibility genes (section 1.4), including the MYOC gene on chromosome 1. 
Nonetheless, replication of these findings is necessary in order to separate true positives 
from false positives.
The MYOC gene is best known for its role in glaucoma. Mutations in MYOC can cause 
both juvenile-onset and adult-onset open angle glaucoma [312, 313]. The MYOC gene 
consists of three exons (Figure 4.1), and it has been shown that an upstream stimulatory 
factor is critical for its basal promoter activity [314].
Myocilin (also known as trabecular meshwork inducible glucocorticoid response or 
TIGR), the protein product of the MYOC gene, was discovered during studies examining 
proteins that could be induced upon long-term treatment of human trabecular meshwork 
cells (TMC) with glucocorticoids [315]. In the human eye, myocilin is highly expressed in 
the TMC, sclera, ciliary body and iris, with considerably lower amounts in retina and optic 
nerve head. The secreted protein is present in aqueous humor [314]. Aside from 
glucocorticoid stimulation, the expression of myocilin in TMC is affected by the 
transcription protein transforming growth factor (3 (TGF p), mechanical stretch, basic 
fibroblast growth factor (bFGF) and oxidative stress [314, 316, 317]. Experimental studies 
show that mutant myocilin isoforms found in patients with juvenile-onset glaucoma are 
not secreted, but accumulate in the TMC where they are thought to interfere with cell 
functions. For example, mutant myocilin disturbs the mitochondrial membrane potential 
[318]. Despite intensive research efforts, however, the precise role of MYOC mutations in 
glaucoma is unclear.
In addition to glaucomatous involvement, genetic variants in the MYOC gene have also 
been implicated in causing susceptibility to high myopia [214, 319]. This involvement 
would be consistent with the possible link between intraocular pressure (IOP)/glaucoma 
and high myopia, that has been proposed and examined with mixed results in the
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literature.
An elevated frequency of glaucoma has been found in myopes: open-angle glaucoma 
occurs twice as often in the myopic eye as in the non-myopic one [7, 320]. It has also been 
shown that the probability of developing glaucoma for eyes without myopia is 1.5%, 
while for eyes with low or high myopia it is 4.2% and 4.4% respectively [321]. In 
addition, an increased frequency of myopia in patients with open angle glaucoma has been 
observed [320-322].
The relationship between high IOP and myopia has been suggested to be mediated 
through near work: there seems to be a general increase of IOP with accommodation and 
convergence to close distance [323]. In support of this assumption, an increase in 
intraocular fluid transfer was found during the emmetropisation (“recovery”) of previously 
form-deprived chicks [324]. Moreover, an elevation in IOP of at least 10 mmHg has been 
shown to lead to a significant increase in the axial length of the eye [325].
Experiments have shown that the growing eyes o f chickens elongate during the day and 
shorten during the night, which correlates with the IOP circadian rhythm (high during the 
daytime and low at night) [326]. Nonetheless, there appears to be a phase difference 
between the rhythms, with the IOP being phase-advanced with respect to the axial length 
diumal cycle. Therefore, Nickla et al. [327] proposed that the rhythm in IOP influences 
ocular elongation in ways other than by simply inflating the eye, for example, by 
influencing underlying rhythms in sclera extracellular matrix production.
As mentioned above, it has been observed that higher intraocular pressure (IOP) is 
associated with myopia [7, 274, 322, 328-330]. One interesting study claimed to have 
success in treating myopia with the IOP-lowering beta-blocker metipranolol [331], but 
other authors could not replicate this by using a different beta-blocker timolol [332]. It has 
also been stated that a higher IOP follows the onset o f myopia and does not cause it [7, 
333]. In addition, a number of studies have failed to establish any correlation between IOP 
and myopia [334, 335].
107
It is noteworthy, that some factors that stimulate myocilin expression in TMC have also 
been implicated in the regulation of postnatal eye growth and myopia, e.g. bFGF, TGFp 
and oxidative mitochondrial pathways [186, 210, 336]. In addition, significant genetic 
linkage has been identified close to the MYOC locus on chromosome 1 in families with 
myopia from the Beaver Dam Eye Study [183].
Association between MYOC and high myopia was first reported in a case-control study of 
Chinese subjects from Singapore [319]. An initial attempt to replicate this finding using a 
similar case-control design in Hong Kong Chinese subjects, however, did not support the 
association [337]. Later, a larger, family-based association study, also in Chinese subjects 
from Hong Kong, yielded a significant result [214]. In this latter study, association was 
found with two microsatellite polymorphisms (NGA17 at the promoter region and NGA19 
at the 3’ region) and two SNPs (rs2421853, rs235858 at the 3’ flanking region). Herein, 
association between myocilin polymorphisms and high myopia was examined in two 
independent Caucasian subject groups: a cohort from Cardiff University (UK) and a 
cohort from Duke University (USA).
Figure 4.1 MYOC gene position, structure and genotyped polymorphisms
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4.2.1 Subjects and DNA Samples
Subjects in the UK cohort were recruited as part of The Family Study of Myopia. 
Participants and their DNA samples were collected as described in sections 2.1 and 2.2.1. 
Individuals with known syndromic disorders or systemic condition that could predispose 
to myopia were excluded. All subjects were o f Caucasian ethnicity (self-reported “White 
Europeans”).
Subjects in the USA cohort were recruited by the Duke University’s Centre for Human 
Genetics. Genomic DNA was extracted from venous blood using the AutoPure LS® DNA 
Extractor and PUREGENE™ reagents (Gentra Systems Inc.). All subjects underwent a 
complete ophthalmic inspection, and individuals with syndromic conditions that could 
predispose to myopia were excluded. The study was approved by the Institutional review 
Board at the Duke University Medical Centre. The recruitment and ophthalmic 
examination of these subjects as well as DNA extraction was performed by Prof. Terri L. 
Young and her colleagues in Duke University, and did not involve any contribution from 
me.
4.2.2 Selection and Genotyping of Polymorphisms
The HapMap database lists 25 single nucleotide polymorphisms (SNPs) with minor allele 
frequencies (MAF) > 5% in the MYOC gene in subjects of European descent. The linkage 
disequilibrium (LD) structure of the gene in Europeans is shown in Figure 4.2.
In the Cardiff University (UK) cohort, tagging SNPs (sections 1.3.3.2 and 1.3.4.3.2) were 
selected using the Haploview program [338] conditional on LD (r2) >0.8 and MAF > 5% 
(Table 4.2). Genotyping was performed for 12 SNPs within and in the vicinity of MYOC 
and two microsatellites in the untranslated regions of the gene (NGA17 at 5’ and NGA19 
at 3’ end) including the significant SNPs from Tang et al. study [214]. SNP genotyping 
was carried out by Kbiosciences Ltd. Microsatellite genotyping was carried out using 
conventional methods [339]. Briefly, the PCR reaction mixture contained lx HotStar PCR 
buffer (Qiagen Ltd), 1.5 mM MgCU, 200pM each dNTP, 0.3pM of fluorescently-labelled 
forward primer, 0.3pM of reverse primer, 0.1 U HotStar Taq polymerase (Qiagen Ltd) and
109
~20ng genomic DNA. Amplification was achieved using 35 cycles of Hot Start PCR 
(denaturation at 94°C for 1 minute, annealing at 56°C for 1 minute and extension at 72°C 
for 1 minute) after a preliminary step of 15 minutes at 95°C to activate the enzyme. The 
primers are shown in Table 4.1. Amplicons were sized using an AB1 Prism 310 Genetic 
Analyzer® (section 2.3.1 in chapter two), run on program D with Genotyper® software 
(ABI) used to call the alleles.
The selection of tagging SNPs and their genotyping in the USA cohort was performed at 
Duke University and I was not involved. Tagging SNPs were selected using SNPSelector® 
conditional on r2 >0.8 and MAF > 5% in the CEU HapMap population. Genotyping was 
performed for 9 SNPs, including the significant SNPs from the Tang et al. study [214], 
using Taqman® allelic discrimination assays (section 2.3.2). SNP tagging and genotyping 
was carried out by our collaborators in Duke University’s Centre for Human Genetics. 
The SNP selection and genotyping performed by the genetic group in Duke University 
(USA) did not involve me.
The positions of the SNPs genotyped in this study are shown in Figure 4.1.
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Figure 4.2 Linkage Disequilibrium Patterns of MYOC SNPs in European Subjects in the 
HapMap database
The pairwise correlation of SNPs (based on D') is shown using red, white and blue 
squares. Red squares indicate statistically significant (LOD>2) allelic association (linkage 
disequilibrium, LD) between the pair of SNPs, as measured by the D’ statistic; darker 
colors of red indicate higher values of D’, up to a maximum of 1. White squares indicate 
pairwise D’ values of <1 with no statistically significant evidence of LD. Blue squares 
indicate pairwise D’ values of 1 but without statistical significance.
The number in each square is the multi-allelic D’ between SNPs.
SNPs are arranged in blocks (depicted here by the thick black triangles) using the "spine 
of LD" algorithm in Haploview, with adjacent blocks merged if they (1) have multiallelic 
D’ values of at least 0.9, indicating little recombination between blocks and (2) at least 
80% of the chromosomes in the resulting merged block are explained by 6 or fewer 
common haplotypes.
i l l
Figure 4.3 Linkage Disequilibrium Patterns of MYOC SNPs Han Chinese Subjects in the 
HapMap database
(See legend of Figure 4.2 for the explanation of LD diagram)
Table 4.1 MYOC Microsatellite Primer Sequences
Primer Name Primer Sequence
NGA17 forward GCA CAG TGC AGG TTC TCA A
NGA17 reverse CCG AGC TCC AGA GAG GTT TA
NGA19 forward CCA ACC ATC AGG TAA TTC CTT
NGA 19 reverse CCT CAA AAC CAG GCA CAA
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Table 4.2 TagSNPs in MYOC (Haploview Results)
A.) Pairwise LD measure for SNPs in MYOC
Only those SNPs are shown that exhibited LD of r2 > 0.8
SNP1 SNP2 r - value
rs2032555 rs235877 1.0
rs604864 rs235870 0.897
rs 183532 rs235870 0.899
rs 171001 rs235877 0.89
rs235868 rs235877 1.0
rs235869 rs235870 1.0
rs235876 rs235877 1.0
rs7523603 rs2236875 1.0
rs12035960 rs2236875 1.0
rs 171002 rs235877 1.0
rs 182907 rs235877 1.0
rs6425364 rs235877 1.0
rs235917 rs235918 0.961
rs2075648 rs2075648 1.0
B.) Chosen Tag SNPs based on Pairwise LD
TagSNP SNPs captured
rs235877 rs 171001, r s l82907, rs235876, rs6425364, rs!71002, rs2356868, rs2032555, 
rs235877
rs235870 rs235869, rs604864, r s l83532, rs235870
rs2236875 rs l2035960, rs7523603, rs2236875
rs235918 rs235917, rs235918
rs235875 Itself
rsl 1586716 Itself
rs 16864720 Itself
rs2075648 Itself
rs7545646 Itself
rsl 2076134 Itself
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Table 4.3 Allele Frequencies o f MYOC Markers
Comparison of allele frequencies in the two European cohorts examined in this study and 
in the Chinese cohort of Tang et al. [214]
A.) Allele frequencies o f microsatellites
Cardiff University Cohort Tang et al
Family Cases Controls Family
Founders Founders
NGA 17 alleles
12 repeats 0.000 0.033 0.028 -
13 repeats 0.597 0.637 0.550 0.501
14 repeats 0.184 0.156 0.170 0.184
15 repeats 0.219 0.174 0.252 0.312
16 repeats - - - 0.003
NGA 19 alleles
11 repeats - - - 0.0015
12 repeats 0.000 0.014 0.000 -
13 repeats 0.342 0.344 0.400 0.218
14 repeats 0.039 0.047 0.004 0.008
15 repeats 0.619 0.595 0.596 0.711
16 repeats - - - 0.060
17 repeats - - - 0.0015
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Table 4.3 A llele Frequencies o f  MYOC Markers (Continuation)
B.) Allele frequencies o f SNPs
SNP name SNP
allele
Cardiff University Cohort Duke University Cohort Tang et 
al
Family
Founders
Cases Controls Family
Founders
Cases Controls Family
Founders
rs235877 C 0.685 0.655 0.670 - - - -
T 0.315 0.345 0.330 - - - -
rs235870 A 0.560 0.556 0.551 - - - -
T 0.440 0.444 0.449 - - - -
rs2236875 G 0.920 0.940 0.930 - - - -
T 0.080 0.060 0.070 - - - -
rs235918 A 0.353 0.366 0.347 - - - -
T 0.647 0.634 0.653 - - - -
rsl 1586716 C 0.264 0.239 0.269 - - - -
T 0.736 0.761 0.731 - - - -
rs2075648 C 0.869 0.866 0.836 - - - -
T 0.131 0.134 0.164 - - - -
rs l6864720 A 0.131 0.118 0.115 0.121 0.116 - -
G 0.869 0.882 0.885 0.879 0.884 - -
rs7545646 C 0.087 0.074 0.078 0.100 0.116 - -
T 0.913 0.926 0.922 0.900 0.884 - -
rsl 2076134 G 0.210 0.202 0.232 0.272 0.232 - -
T 0.790 0.798 0.768 0.728 0.768 - -
rs235858 A 0.584 0.590 0.573 0.639 0.607 - 0.600
G 0.416 0.410 0.427 0.361 0.393 - 0.400
rs2421853 A 0.232 0.217 0.245 0.300 0.277 - 0.270
G 0.768 0.783 0.755 0.700 0.723 - 0.730
rs6425363 C - - - 0.886 0.900 - -
T - - - 0.114 0.100 - -
rs235917 A - - - 0.284 0.277 - -
G - - - 0.716 0.723 - -
rs235875 C - - - 0.792 0.815 - -
T - - - 0.208 0.185 - -
rs2032555 C - - - 0.239 0.277 - -
T - - - 0.761 0.723 - -
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4.2.3 Statistical Analysis
4.2.3.1 Hardy-Weinberg Equilibrium and Mendelian Consistency
The Pedstats package [340] was used to carry out an exact test for Hardy-Weinberg 
equilibrium (HWE) on unrelated subjects and to check for Mendelian consistency in 
pedigrees (section 2.3.3).
4.2.3.2 Test for Association (Unphased) and Correction for Multiple Testing
High myopia was examined as a dichotomous trait. Subjects with a spherical equivalent 
refractive error, averaged between eyes, of < -6.00 D were classified as affected [214]. All 
other subjects were classified as unaffected. Tests of association were performed using the 
Unphased program [147], which, in addition to family-based tests, is able to jointly 
examine pedigrees and case/control samples.
The analysis performed by the Unphased program is likelihood-based (section 2.4.3). The 
program defines separate association parameters in the parental and offspring components 
of the likelihood, allowing the introduction and conditioning on a so-called inheritance 
vector, which maintains robustness o f the test to linkage when there are multiple affected 
offspring present in a nuclear family. The final statistic is calculated from a likelihood 
ratio test, which compares a model “with” against a model “without” the SNP of interest.
Unrelated subjects are regarded as the children of two missing parents and are then 
included in the same formulation as nuclear families [147].
Unphased accounts for missing data by use of a score function (section 2.4.3) of the 
parental genotypes model [147].
A Bonferroni correction was applied to account for multiple testing (section 2.4.4). 
Importantly, the association test results for SNPs genotyped in both the Cardiff University 
and Duke University cohorts are only reported for combined analyses. The implications of 
this approach, with respect to potential population stratification between subjects from the
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UK and USA, are discussed in section 4.4.
4.3. Results
4.3.1 Subjects and Genotyping
The UK cohort comprised of 164 families with high myopia (604 subjects), along with an 
additional set of unrelated individuals comprised of 112 highly myopic cases and 114 
“emmetropic” controls (spherical equivalent refractive error in both eyes > -1 .0 0 D  and 
<+1.00 D).
The USA cohort comprised of 86 families with high myopia (358 subjects), along with an 
additional set of 56 highly myopic unrelated individuals.
The combined study population included a total o f 1251 subjects. Forty-nine subjects were 
excluded due to genotyping failure. This left 293 unrelated and 909 related individuals 
available for association analyses (Table 4.4): 788 subjects in the UK cohort (142 
families, 121 cases andl 16 controls) and 414 subjects in USA cohort (86 families and 56 
cases). Subjects for whom all relatives failed to pass our genotyping quality control 
threshold were classified as cases or controls if they met the necessary refractive criteria.
Genotyping of the two microsatellite markers NGA 17 and NGA 19 revealed four alleles 
for each. For both markers there were three common alleles and one rare allele. The 
observed allele frequencies of the microsatellite polymorphisms are shown in Table 4.3. 
Since the sample size was modest, the rare allele of each microsatellite marker was 
combined with the allele next in size to it (allele 1 with allele 2, for both markers).
Genotyping of SNPs had an average failure rate o f -7.5%  (see Table 4.5 for individual 
rates per SNP). Concordance was assessed based on 8 duplicate samples: genotypes of 2 
samples out of these 96 had discordant results. Genotyping for SNP marker rs235875 
failed.
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Table 4.4 Numbers o f Subjects in the Study o f Association Between High Myopia and 
Myocilin Gene _______________________________ ____________________________
Subjects (families) participating Subjects (families) analyzed
UK USA UK USA
Related 604(164) 358 (86) 551 (142) 358 (86)
Cases 112 56 121 56
Controls 114 0 116 0
Total 830 414 788 414
Table 4.5 Tests of Association between MYOC Polymorphisms and High Myopia
Polymorphism Failed genotypes (%) HWE Un phased p-value Un phased
p-value (corrected p-value) Odds Ratio (95% Cl)
Duke University Cohort
rs6425363 1.5 1.00 0.57 1.15(0.71-1.86)
rs235917 4.4 0.55 0.49 1.13 (0.79-1.59)
rs235875 2.7 0.20 0.36 1.20 (0.81-1.75)
rs2032555 3.5 0.01 Not tested due to HWE status
Cardiff University Cohort
rs235877 12.0 0.09 0.57 1.07 (0.84-1.37)
rs235870 9.0 0.27 0.53 0.93 (0.74-1.17)
rs2236875 10.0 0.01 Not tested due to HWE status
rs235918 8.0 0.19 0.53 1.07 (0.86-1.34)
r s l1586716 8.6 0.13 0.38 0.73 (0.84-1.44)
rs2075648 9.8 0.07 0.59 0.91 (0.64-1.28)
NGA 17 0.1 0.08 0.03 (0.39) 0.70 (0.55-0.92)
NGA 19 0.2 0.49 0.97 1.02 (0.82-1.26)
Combined Cohorts
rsl 6864720 7.9 0.85 0.04 (0.645) 1.30(1.004-1.73)
rs7545646 12.0 0.05 0.06 1.30 (0.98-1.8)
rsl 2076134 9.4 0.81 0.09 1.20 (0.97-1.48)
rs235858* 13.0 0.86 0.87 1.02 (0.84-1.22)
rs2421853* 13.0 0.18 0.25 1.13(0.91-1.39)
* These two SNPs were significantly associated with high myopia in the study of Tang et 
al. [214].
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4.3.2 Statistical Analysis
Tests for HWE showed that 2 SNPs, rs2236875 and rs2032555, were not in equilibrium in 
unrelated subjects (Table 4.5). Therefore, these two markers were dropped from further 
analyses, and association tests were performed for the remaining 15 variants: 13 SNPs and 
2 microsatellites.
There was no significant heterogeneity in genotype frequencies between families and 
singleton samples either within or between cohorts (Table 4.3). Thus, families and 
unrelated subjects were analyzed jointly [147]. Likewise, subjects recruited at Duke 
University and Cardiff University were analyzed jointly for those SNPs genotyped in 
common (i.e. ignoring potential population stratification issues). The association test 
results are shown in Table 4.5. Prior to correction for multiple testing, two variants 
showed significant association: r s l6864720 (p=0.043) and NGA 17 (p^O.026). However, 
neither association retained statistical significance after Bonferroni correction (Table 4.5). 
Evaluation of relative risk highlighted the same two polymorphisms, rs l6864720 and 
NGA 17, with 95% confidence intervals that did not include 1.0 (Table 4.5). The relative 
risk conferred by each of these variants, however, was low (RR < 1.5).
4.4 Discussion
A joint analysis of subjects from the UK and USA was carried out for those SNPs that 
were genotyped in both groups of subjects. This pooling of subjects could potentially have 
given rise to a “false positive” or “false negative” association due to population 
stratification. However, population stratification can only give rise to a significant 
association between a disease phenotype and a marker genotype if (a) the prevalence of 
the disease differs between the two subject groups, and (b) the marker of interest’s allele 
frequency differs between the two subject groups. For high myopia, exact figures on the 
prevalences in Caucasian subjects from the UK and USA are lacking, but estimates 
suggest these rates are similar [173, 341, 342]. Furthermore, the MYOC polymorphisms 
studied here had statistically similar allele frequencies in the UK and USA subjects (Table 
4.3B).
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In contrast to previously published significant associations between MYOC gene 
polymorphisms and high myopia [214, 319] in subjects of Chinese ethnicity, the present 
study suggested that there was no such relationship in subjects of Caucasian ethnicity. 
Indeed, the only polymorphisms that showed significant association before Bonferroni 
correction are situated at the 5’ end (NGA 17) and in the “middle” (rsl6864720) of the 
gene rather than towards the 3’ region implicated in the study of Tang et al. [214]. The 
ethnic difference of the respective study populations is an appealing explanation for these 
discrepant findings. Different populations may exhibit differences in allele frequencies 
and linkage disequilibrium patterns at specific loci (Figures 4.2, 4.3 and Table 4.3). Thus, 
the role of MYOC in high myopia in Chinese subjects may be dissimilar to that in 
Caucasians.
An alternative explanation could be the power of the analyses. The estimated relative risk 
o f the genetic variants examined here was less than 1.5, which suggests that the power of 
this study would be -75% [343]. Tang et al, on the other hand, investigated a smaller 
sample size (557 individuals, in 162 nuclear families) and reported a relative risk of >1.5 
for two significant SNPs (rs235858 and rs2421853). To gain 80% power, a family based 
association study of a variant with relative risk > 1.5 and allele frequency of 0.5, would 
need -200 families under an additive model and -1100 families under a dominant model 
[344].
The fact that MYOC polymorphisms are implicated in both myopia and glaucoma is 
intriguing, especially in light of the higher-than-chance co-occurrence of myopia and 
glaucoma seen in many studies [320-322]. Nonetheless, the high expression of myocilin in 
the TMC [345] is easier to reconcile with the role of MYOC polymorphisms in glaucoma 
than in myopia. Furthermore, the current evidence suggests that the MYOC gene variants 
which confer an increased risk of open angle glaucoma are different from those that may 
increase susceptibility to myopia. In this respect, the association of MYOC 
polymorphisms with both conditions may be coincidental.
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4.5 Conclusion
In conclusion, this study found no evidence to support a significant association between 
MYOC polymorphisms and high myopia in Caucasian subjects from the UK and USA.
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CHAPTER V
ASSOCIA H O N  BETWEEN SNPS IN  MYP 
REGIONS AND HIGH MYOPIA
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5.1 Introduction
MYP regions are chromosomal intervals linked to myopia (section 1.4). Therefore, these 
genetic loci include or harbour a number of possible myopia genes. Several association 
studies - fine-mapping of linkage loci as well as candidate-gene analysis -  have been 
carried out in attempt to identify genetic variants that confer susceptibility to myopia 
(section 1.4). To date, genes in the MYP 1, 2, 3, 5, 7 and 8 regions have been assessed. 
Some of the genes situated in these regions were only sequenced and screened for 
mutation, with no association test performed as such. The following genes have been 
investigated in detail: the TestisExpressed28 (TEX28) gene in MYP1 [195], the Lipin 2 
gene [200, 202] and the leucin-rich repeat protein genes in the MYP2 [200, 201] and 
MYP 3 [201] regions. These studies found only suggestive [195, 202] or no evidence 
[200, 201] of a relationship with myopia.
Association tests have also been performed for intervals of MYP 2, 3, 5, 7 and 8, for genes 
such as Transforming Growth (3-Induced Factor (TGIF), Lumican, Collagen type one 
alpha one (COL1A1), PairedBox6 (PAX6) and SexDeterminingRegionYBox 2 (SOX2). 
Apart from being situated within MYP loci, these genes also attracted myopia geneticists 
because of their biological role in embryonic development or, potentially, in myopic 
scleral remodelling. Although some o f these studies have shown significant association, 
replication analyses have been disappointing (section 1.4), suggesting that the candidate 
gene(s) remain to be discovered for the most part.
In this chapter, exploratory association analyses are described for SNPs in all o f the 
known MYP regions identified at the time o f the study.
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5.2 Materials and Methods
5.2.1 Subjects and DNA Samples
Recruitment of subjects and their DNA samples was accomplished within The 
International Myopia Consortium established in collaboration with myopia research 
centres in Denmark, Australia, France and USA [161]. DNA samples were collected in the 
form of mouthwash, blood and saliva. Objective or subjective measurements for spherical 
equivalent were obtained from each participating centre. The collection of high myopia 
pedigrees from Cardiff is described in sections 2.1 and 2.2.1.
5.2.2 Genotyping and Selection of SNPs
Whole genome genotyping was completed by the Center for Inherited Disease Research 
(ClDR; http://www.cidr.ihmi.edu/) using Illumina Linkage Panel IVb bead array system 
(http://www.illumina.com/pages.ilmn?ID=191). The average interpolated genetic map 
distance between all SNP loci was 0.62 cM.
For association analysis, SNPs were selected that are positioned within known genes in 
MYP regions or that are in high LD (r2 >0.8) with such genes (Table 5.1). LD information 
and minor allele frequency for each SNP was obtained from the FlapMap dataset for 
European (CEU) subjects. Those SNPs whose MAF in HapMap CEU subjects is less than 
5% were excluded from the analysis.
5.2.3 Statistical Analyses
5.2.3.1 Hardy-Weinberg Equilibrium and Mendelian Consistency
The Pedstats package [340] was used to carry out an exact test for Hardy-Weinberg 
equilibrium (HWE) on unrelated subjects and to check for Mendelian consistency in 
pedigrees (section 2.3.3).
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5.2.3.2 Association Tests (APL) and Correction for Multiple Testing
High myopia was examined as a dichotomous trait. Subjects with a spherical equivalent 
refractive error, averaged between eyes, of < -6.00 D were classified as affected [339]. All 
other subjects were classified as unaffected. Participants whose refractive error was not 
obtainable were coded as unknown.
Association tests were performed using the APL (Association in the Presence of Linkage) 
program, which calculates identity by descent (IBD -  the probability that two individuals 
in a pedigree possess the same allele inferred from a recent common ancestor) parameters, 
and which can account for the presence o f linkage when testing for association and/or 
inferring missing parental genotypes [149].
The basic concept of APL is that if there is no association, then the expected number of 
copies of alleles at the examined marker in siblings, given the genotypes of their parents, 
would be the number of copies o f the marker alleles in the parents. APL employs the 
standard likelihood theory (section 2.4.3) with additional parameters of probabilities that 
the affected siblings share 0, 1 or 2 alleles IBD respectively at the marker locus [149]. In 
addition, it has been demonstrated that under the null hypothesis of no association and in 
the presence of missing parental data, APL showed greater power than other family-based 
association tests [346]. A Bonferroni correction was applied to account for multiple 
testing (section 2.4.4).
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Table 5.1 Summary o f SNPs Chosen for the Exploration o f MYP Regions
Chosen
SNP
MYP
Region
Gene 
within 
which the 
chosen SNP 
is
Gene with 
which the 
chosen SNP is 
in high LD 
(r2 -value)
MAF Mendelian
errors
HWE
p-value
APL p- 
value 
(corrected 
p-value)
rsl 024694 MYP 1 FMR1NB FMR1 (0.89) 0.489 None 0.8791 0.9931
rsl 860929 MYP 1 AFF2 None 0.278 Corrected 0.5258 0.3144
rs758439 MYP 1 AFF2 None 0.278 Corrected 0.7135 0.1781
rs985595 MYP 1 AFF2 None 0.200 Many Excluded Excluded
rs222398 MYP 1 MTM1 None 0.389 None 0.7598 0.2336
rs6526192 MYP 1 MTMR1 HMGB3 (1.00) 0.167 Corrected 0.6688 0.6712
rs770238 MYP 2 LPIN2 None 0.325 Corrected 1.0000 0.8035
rs643015 MYP 2 LPIN2 None 0.308 Corrected 1.0000 0.9803
rsl 68206 MYP 2 DLGAP1 None 0.424 Corrected 0.8103 0.1006
rsl 565728 MYP 3 E2F7 None 0.475 None 0.7074 0.6612
rs998070 MYP 3 NAV3 None 0.483 None 0.3995 0.1612
rsl 351214 MYP 3 NAV3 None 0.417 None 0.6299 0.7881
rs2404772 MYP 3 None CART1 (0.95) 
LRRIQ1 (1.00)
0.250 None 0.0871 0.6896
rsl 508595 MYP 3 None KITLG (1.00) 
None
0.167 None 0.1344 0.8446
rsl 401982 MYP 3 ATP2B1 SYCP3 (1.00) 
GNPTAB
0.417 None 0.1306 0.1065
rsl 544921 MYP 3 CHPT1 (1.00) 
FLJ11259 
(0.88) 
None 
KIAA1033 
(0.96)
0.475 None 0.6260 0.5363
rs746035 MYP 3 CHST11 None 0.308 None 0.2459 0.8233
rs9143 MYP 3 DIP13B None 0.415 None 0.6300 0.7979
rsl 92243 8 MYP 3 RFX4 None 0.475 None 0.1018 0.8294
rs2873108 MYP 4 DPP6 None 0.161 None 0.8668 0.9694
rs306278 MYP 4 DPP6 None 0.450 None 0.1118 0.3038
rs2033108 MYP 5 None PCTP (1.00) 0.242 Corrected 0.7422 0.2009
rs759109 MYP 5 ANKFN1 None 0.425 Corrected 0.6281 0.6572
rsl 024819 MYP 5 MSI2 None 0.492 Corrected 0.3361 0.9228
rsl 974692 MYP 5 MSI2 None 0.195 Corrected 0.8511 0.3547
rsl 3137 MYP 5 None TMEM49
(1.00)
0.212 Corrected 0.1076 0.3472
rsl881441 MYP 5 CLTC None 0.117 Corrected 0.0230 Excluded
rsl 557720 MYP 5 BRIP1 None 0.458 Corrected 0.2190 0.3326
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Table 5.1 Summary o f SNPs Chosen fo r  the Exploration o f MYP Regions (Continuation)
Chosen
SNP
MYP
Region
Gene 
within 
which the 
chosen SNP 
is
Gene with 
which the 
chosen SNP 
is in high LD 
(r2-value)
MAF Mendelian
errors
HWE
P-
value
APL p- 
value 
(corrected 
p-value)
rsl 997719 MYP 6 EMID1 None 0.367 Corrected 0.6249 0.8585
rsl 40062 MYP 6 EWSR1 None 0.317 Corrected 0.4567 0.0563
rs715494 MYP 6 AP1B1 EWSR1
(0-95)
GAS2L1
0.367 Corrected 0.5449 0.2604
rs714027 MYP 6 HORMAD2 (0.95) 0.433 None 0.5439 0.5232
rs737805 MYP 6 None None 
TBCIDIOA 
(1.00) 
SF3A1 (1.00) 
LOC550631 
(1.00) 
LOC200312 
(0.90) 
SEC14L2
0.358 Corrected 0.0043 Excluded
rs4444 MYP 6 OSBP2 (0.96) 0.442 Corrected 0.4672 0.1321
rsl 36488 MYP 6 RFPL2 None
SLC5A4
0.475 Corrected 0.9048 0.8280
rs762883 MYP 6 SYN3 (0.96) 0.400 Corrected 0.3958 0.8603
rs9862 MYP 6 SYN3 None 0.467 Corrected 0.0537 0.9840
rsl 38777 MYP 6 TOM1 None
HMG2L1
0.333 Corrected 0.6203 0.7873
rs739096 MYP 6 MYH9 (1.00) 0.458 Corrected 0.2786 0.4960
rs933224 MYP 6 MYH9 None 0.358 Corrected 0.6809 0.3662
rs2413411 MYP 6 CACNG2 None 0.325 Corrected 0.6926 0.2305
rs760519 MYP 6 NCF4 None
FLJ90680
(0.94)
0.258 Corrected 0.0665 0.6827
rsl 534880 MYP 6 CSF2RB None 0.492 Corrected 0.9035 0.4905
rs4348874 MYP 7 PTPNS None 0.274 Corrected 0.7657 0.7621
rs730348 MYP 7 NAV2 None 0.408 Corrected 0.6237 0.2601
rsl 470251 MYP 7 NAV2 None 0.183 Corrected 0.7583 0.6671
rsl 374719 MYP 7 SLC17A6 None 0.306 Corrected 0.3385 0.9208
rs2928345 MYP 7 GAS2 None 0.192 Corrected 0.5741 0.4831
rsl 491846 MYP 7 None KIF18A 0.167 None 0.2289 0.7189
rsl 032090 MYP 7 METT5D1 (0.81) 0.375 Corrected 0.4733 0.6738
rsl 564745 MYP 7 METT5D1 None 0.375 Corrected 0.4023 0.3121
rs524373 MYP 7 None None
KCNA4
(1.00)
0.317 None 0.3416 0.8939
rs2273544 MYP 7 PCI 1 LI None 0.280 Corrected 0.1383 0.6214
rs373499 MYP 7 CSTF3 None 0.423 Corrected 1.0000 0.0607
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Table 5.1. Summary o f SNPs Chosen For the Exploration o f MYP Regions (Continuation)
Chosen
SNP
MYP
Region
Gene within 
which the 
chosen SNP is
Gene with 
which the 
chosen SNP 
is in high LD 
(r2-value)
MAF Mendelian
errors
HWE
p-value
APL p- 
value 
(corrected 
p-value)
rs765695 MYP 8 None C30RF58
(1.00)
0.442 Corrected 0.3323 0.4568
rs723490 MYP 8 None C30RF58
(1.00)
0.460 None 0.3959 0.4818
rsl 707465 MYP 8 PLOD2 None 0.397 Corrected 0.2822 0.2893
rsl 027695 MYP 8 None Z1C4 (0.93) 0.494 None 0.3872 0.7378
rsl 450344 MYP 8 None TSC22D2
(1.00)
0.392 Corrected 0.1012 0.5613
rsl 920395 MYP 8 P2RY14 None 0.325 Corrected 0.2795 0.5471
rs3863100 MYP 8 MDS1 None 0.075 Corrected 1.0000 0.7210
rs755763 MYP 8 MBNL1 None 0.25 Corrected 1.0000 0.8707
rs701265 MYP 8 P2RY1 None 0.217 Corrected 0.2470 0.6686
rs9438 MYP 8 DHX36DEAH None 0.350 Corrected 0.7140 0.6188
rsl 025192 MYP 8 MME None 0.492 Corrected 0.7180 0.9215
rs359573 MYP 8 None PLCH1 (1.00) 0.307 Corrected 0.6025 0.8617
rs986963 MYP 8 KCNAB1 None 0.317 Corrected 0.2895 0.6517
rsl 384542 MYP 8 FLJ16641 None 0.333 Corrected 0.2654 0.0737
rsl074864 MYP 8 VEPH1 None 0.492 Corrected 0.9044 0.0274
rsl 515628 MYP 8 SCHIP1 None 0.475 Corrected 0.6304 0.6792
rsl599386 MYP 8 None PPM 1L (1.00) 
NMD3 (0.83) 
SLITRK3 
(1.00)
0.467 Many Excluded Excluded
rs920417 MYP 8 None GOLPH4
(1.00)
0.458 Corrected 0.7181 0.8865
rs953834 MYP 8 None None 0.065 None 0.6954 0.7665
rs877439 MYP 8 GOLPH4 None 0.500 Many Excluded Excluded
rs905129 MYP 8 TNIK None 0.442 Corrected 1.0000 0.7908
rsl 285082 MYP 8 FNDC313 None 0.458 Corrected 0.0685 0.4897
rs623021 MYP 8 AADACL1 None 0.450 Corrected 0.1101 0.9169
rs649695 MYP 8 NLGN1 None 0.275 Corrected 0.8830 0.6408
rs2046718 MYP 8 NLGN1 None 0.308 Corrected 0.5261 0.2334
rs753293 MYP 8 NAALADL2 None 0.267 Corrected 0.6062 0.7077
rsl549114 MYP 8 NAALADL2 None 0.358 Many Excluded Excluded
rsl 468924 MYP 8 KCNMB3 None 0.342 Corrected 0.8967 0.1137
rs2049769 MYP 8 PEX5L None 0.200 Corrected 0.4109 0.4009
rsl 973738 MYP 8 KLHL6 None 0.375 Corrected 1.000 0.7779
rs2054172 MYP 8 KLHL24 None 0.233 Corrected 0.3788 0.1480
rsl 401999 MYP 8 ABCC5 None 0.408 Corrected 0.4633 0.8593
rs869417 MYP 8 ABCC5 None 0.408 Corrected 0.3921 0.6833
rs4432622 MYP 8 VPS8 None 0.356 Corrected 0.7906 0.9974
rs3332 MYP 8 VPS8 None 0.390 None 1.0000 0.8922
rs6769709 MYP 8 LOC285382 None 0.075 Corrected 0.5273 0.7566
rsl 837882 MYP 8 L1PH None 0.458 Corrected 0.7151 0.2946
rs6808013 MYP 8 DGKG None 0.208 Corrected 0.5077 0.1911
rl561026 MYP 8 None 0.267 Corrected 0.0297 Excluded
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Table 5.1. Summary o f SNPs Chosen For the Exploration o f MYP Regions (Continuation)
Chosen
SNP
MYP
Region
Gene within 
which the 
chosen SNP 
is
Gene with 
which the 
chosen SNP 
is in high LD 
(r2-value)
MAF Mendelian
errors
HWE
p-value
APL p- 
value 
(corrected 
p-value)
rsl 039559 MYP 9 TMEM156 None 0.458 Corrected 0.6305 0.2245
rs974734 MYP 9 None TMEM156
(1.00)
0.500 Corrected 0.5473 0.2270
rsl 046655 MYP 9 None KLHL5 (1.00) 
WDR19 
(1.00) 
RFC1 (1.00)
0.433 Corrected 1.0000 0.4620
rs2035383 MYP 9 APBB2 None 0.492 Corrected 0.8112 0.8105
rs790142 MYP 9 APBB2 None 0.308 Corrected 0.1018 0.5961
rsl565114 MYP 9 ATP8A1 None 0.331 Corrected 1.0000 0.0164
(2.296)
rsl 504491 MYP 9 None GABRG1
(1.00)
0.500 Corrected 0.1034 0.4311
rsl866989 MYP 9 GABRB1 None 0.467 Corrected 0.0096 Excluded
rs225160 MYP 9 None SPATA18
(1.00)
0.417 Corrected 0.1175 0.2173
rs751266 MYP 9 FIP1L1 SCFD2 (1.00) 
CLOCK
0.408 Corrected 0.3924 0.3961
rs2538 MYP 9 None (1.00)
None
0.300 Corrected 0.4295 0.2472
rsl 40643 MYP 9 AASDH2 IGFBP7 0.431 Corrected 0.4699 0.1705
rs899631 MYP 9 POLR2B (1.00)
None
0.400 Corrected 0.4549 0.8055
rsl 456860 MYP 9 LPHN3 SRD5A2L2 0.308 Corrected 0.7818 0.9528
rsl 879323 MYP 9 None (1.00)
None
0.433 Corrected 0.5262 0.8729
rsl 483720 MYP 9 SRD5A2L2 CENPC1 0.433 Corrected 0.3992 0.0622
rs 1899 30 MYP 9 None (1.00)
SULT1B1
0.333 Corrected 0.4976 0.2119
rsl 560605 MYP 9 None (1.00)
C40RF7
0.142 Corrected 0.1365 0.0228
(3.192)
rs2063749 MYP 9 None (1.00) 
CSN3 (1.00)
0.325 Corrected 0.8003 0.6123
rs9131 MYP 9 MTHFD2L None 0.350 Corrected 0.4574 0.8693
rs717239 MYP 9 FLJ25770 None 0.408 Corrected 0.2292 0.7715
rs 1511817 MYP 9 SHROOM3 None 0.276 Corrected 0.8900 0.0511
rsl 566485 MYP 9 SNOT6L None 0.425 Corrected 1.0000 0.2050
rsl 426138 MYP 9 None BMP2K
(0.93)
0.175 None 0.2465 0.2975
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Table 5.1 Summary o f SNPs Chosen for the Exploration o f MYP Regions (Continuation)
Chosen
SNP
MYP
Region
Gene within 
which the 
chosen SNP 
is
Gene with 
which the 
chosen SNP 
is in high 
LD 
(r2-value)
MAF Mendelian
errors
HWE
p-value
APL p- 
value 
(corrected 
p-value)
rsl3429 MYP 10 None C80RF42
(1.00)
0.417 Corrected 0.4026 0.0180
(2.520)
rs935559 MYP 10 C80RF42 None 0.127 Corrected 0.7915 0.4968
rs922798 MYP 10 CSMD1 None 0.433 Corrected 0.9013 0.8315
rs732299 MYP 11 None RAP1GDS1
(1.00)
0.358 None 1.0000 0.3646
rs501110 MYP 11 RAP1GDS1 None 0.342 None 0.4506 0.0454
(6.356)
rs749407 MYP 11 MTTP None 0.358 None 0.6958 0.1277
rs716556 MYP 11 DNAJB14 None 0.450 None 1.0000 0.0249
(3.486)
rs871061 MYP 11 BANK1 None 0.317 Corrected 0.4546 0.5292
rs230490 MYP 11 NFKB1 None 0.375 Corrected 0.2579 0.0985
rs747559 MYP 11 None MANBA
(1.00)
0.458 Corrected 0.4449 0.1244
rs228617 MYP 11 UBE2D3 None 0.450 Corrected 0.7193 0.0151
(2.114)
rs223383 MYP 11 LOCI 50159 None 0.483 None 0.7192 0.0168
(2.352)
rs223334 MYP 11 OC150159 None 0.483 None 0.8105 0.2866
rs995387 MYP 11 DC2 None 0.392 Corrected 1.0000 0.5572
rsl 865845 MYP 11 AGXT2L1 None 0.314 Corrected 0.2327 0.1640
rs243985 MYP 11 ENPEP None 0.425 Corrected 0.0633 0.5970
rsl 354680 MYP 11 ANK2 None 0.258 Corrected 0.8851 0.1733
rs967099 MYP 11 ANK2 None 0.350 Corrected 0.2051 0.1982
rsl 380931 MYP 11 UGT8 None 0.442 Corrected 0.3360 0.0460
(6.440)
rsl 459062 MYP 11 USP53 None 0.467 Corrected 0.8100 0.7152
rs537111 MYP 13 GUCY2F None 0.467 None 0.5440 0.6793
rs697829 MYP 13 NXT2 None 0.378 Corrected 0.3341 0.4114
rs926412 MYP 13 PAK3 None 0.000 None Excluded Excluded
rsl 016231 MYP 13 OCX None 0.221 None 0.0080 Excluded
rs3027802 MYP 13 GLT28D1 None 0.189 Corrected 0.0174 Excluded
rs7049660 MYP 13 ZCCHC16 None 0.189 Corrected 1.0000 0.8756
rs2040497 MYP 13 ZCCHC16 None 0.200 Corrected 0.0806 0.2821
rs583430 MYP 13 None LHFPL1
(1.00)
0.167 Corrected 0.0255 Excluded
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Table 5.1 Summary o f SNPs Chosen fo r  the Exploration o f MYP Regions (Continuation)
Chosen
SNP
MYP
Region
Gene within 
which the 
chosen SNP 
is
Gene with 
which the 
chosen SNP 
is in high 
LD 
(r2 -value)
MAF Mendelian
errors
HWE
p-value
APLp-
value
(corrected
p-value)
rsl 577454 MYP 13 HTR2C None 0.156 Corrected 0.5717 0.1441
rs7056311 MYP 13 LRCH2 None 0.211 Corrected 0.3285 0.5906
rs2231 MYP 13 None LUZP4 0.178 Corrected 0.1171 0.9725
rs988457 MYP 13 None (1.00)
SLC6A14
0.478 Corrected 0.1196 0.5118
rsl 716758 MYP 13 None (1.00)
WDR44
0.211 Corrected 0.0898 0.4427
rs929590 MYP 13 None (0.93) 
IL13RA1 
(0.90) 
DOCK 11 
(0.80)
0.133 Corrected 1.0000 0.3165
rs2227098 MYP 13 GRIA3 None 0.467 Corrected 0.8795 0.6008
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5.3 Results
5.3.1 Subjects and Genotyping
In total 1462 subjects were recruited by the five myopia centres. As phenotypic data and 
trio parental information were not obtainable for some subjects, 786 participants were 
available for the association tests. After checking for Mendelian errors, a further 3 
pedigrees (15 subjects) were excluded, leaving 771 subjects for the final analysis: 101 
subjects from Denmark (22 pedigrees), 3 subjects from Australia (1 pedigree), 299 
subjects from USA (58 pedigrees), 204 subjects from the UK (46 pedigrees) and 164 
subjects from France (36 pedigrees).
Genotyping had a reproducibility rate o f 99.99% and a failure rate of 0.20% (based on 81 
blind duplicates and assessed in the total cohort of 1462 subjects).
5.3.2 Statistical Analyses
Out of 152 chosen SNPs, 12 were excluded from the analysis: 4 SNPs were not Mendelian 
consistent, 7 SNPs were out of HWE (P < 0.05) and 1 SNP had a MAF less than 5% 
(Table 4.5).
Prior to correction for multiple testing, nine variants showed significant association: 
rs l074864 in MYP 8; rs l565114, r s l560605 and r s l511817 in MYP 9; r s l3429 in MYP 
10; rs501110, rs716556, rs228617, rs223383 and rsl380931 in MYP 11. However, none 
of them retained its statistical significance after Bonferroni correction (Table 4.5).
5.4 Discussion
A combined analysis of subjects from the UK, USA, Denmark, France and Australia was 
carried out for SNPs in MYP regions. Since family-based tests are robust against potential 
population stratification, this joining o f subjects could not have given rise to a false 
positive result. If, on the other hand, a SNP was associated with high myopia in some 
population, but not in others, this joint analysis could have diluted the association signal.
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Previously, several attempts have been made to find a relationship between high myopia 
and genes in MYP intervals [163, 167-169, 177, 185, 186, 198, 199, 203-208]. Despite 
some encouraging, positive findings in MYPs 3 [203, 204], 5 [205], 6 [206, 208] and 8 
[186], replication of most o f these results has failed [163, 167, 168, 177, 185, 198, 199, 
203, 205, 207, 347]. Likewise, the association tests described in this chapter, revealed no 
significant relationship with high myopia in any of the 12 MYP regions examined. 
Nonetheless, these analyses did not permit the evaluation of any of the genes tested in the 
previous studies mentioned above.
The present study was performed using APL [149], whereas the assessment of an 
association between high myopia and myocilin (described in the previous chapter) was 
carried out with Unphased [147]. APL has been shown to be the most powerful test for 
association for family-based analyses in the presence of linkage [346], hence this method 
was applied to test for a relationship between MYP regions and high myopia. Analyzing 
myocillin as a candidate gene for high myopia, however, involved not only families, but 
also cases and controls, making APL unsuitable as it cannot accommodate both types of 
subjects.
One likely explanation for the high rate of unsuccessful association studies in general, and 
the present study in particular, is a lack of power. Assuming myopia is a multifactorial 
disease, the polymorphisms responsible for it would likely be o f low effect (genotype 
relative risk < 1.5), requiring a large sample size for their detection (section 1.3.4.3.1). 
Most of the studies performed to date (including this one) had a sample size o f 1000 
subjects or less (an exception is Andrew and colleagues study [186] with 1430 
participants), while to achieve -80%  power at alpha 0.001 level, a relative risk o f 1.3 and 
an allele frequency of 20%, one would need -6000 people [122].
Another factor that could have led to the failure of the present study is poor genome 
coverage: the detection of a genetic variant with an effect on disease susceptibility will 
suffer if genetic markers with only low LD with the variant of interest are genotyped. In 
my analyses of MYP regions, the genotyped SNPs were widely spaced (~0.62cM), and as 
such poorly suitable for fine scale association analysis and candidate gene association
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studies. From the International HapMap Project, it has been determined that the vast 
majority o f SNPs with MAF of at least 5% can be reduced to -550,000 LD bins for 
individuals of European and Asian ancestry. By genotyping at least one tagging SNP from 
each bin (-550,000 SNPs), -80%  o f SNPs present at a frequency above 5% across the 
genome can be covered [348, 349]. Thus, the 140 SNPs examined here -  although having 
a high prior probability of association due to their location within MYP regions -  
represent a massively limited panel of markers.
An important aspect of attempting to fine map or replicate different association results is 
the population on which the relationship was originally tested. Previous significant 
findings have been mostly reported in Asian populations [197, 199, 204, 206]. Therefore, 
the replication of such results in Caucasian population may fail due to the genetic 
discrepancies between different populations (section 1.3.3.2).
The specification of myopia as a phenotype varies among studies: some o f those reporting 
significant finding have categorised myopia affectation as < - 10.00 D [199] or as < - 9.25 
D [204]. Thus, analyses defining myopia as < - 6.00 D may find no association.
An alternative explanation for my negative Findings could also be that common variants 
do not explain a substantial proportion o f the phenotypic variation in refractive error. For 
example, there are 18 common variants that have been associated with type 2 diabetes, 
with MAFs ranging from 0.073 to 0.50 and relative risk ranging from 1.05 to 1.37. 
Together, however, these 18 polymorphisms explain less than 4% of the total liability of 
the trait [116]. Under the “common disease, rare variant” hypothesis, the large levels of 
heritability could reflect the aggregate effects of very many, very rare variants: each 
potentially o f moderate effect but accounting for virtually none of the variation at the 
population level [350]. Such polymorphisms could be analyzed using different approaches 
that do not assume that common variant underlies a disease: if multiple rare disease 
variants exist within the same genomic region, then, instead of a standard association test, 
a linkage analysis-like approach of examining ancestral sharing at a locus performed in 
population-based samples of unrelated individuals may be considered [260].
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It is also important to highlight, that in contrast to case/control studies, family-based tests 
of association are confounded with tests of linkage: marker/disease association will only 
be detected if the marker and causative allele are in strong LD and, in addition, are linked 
[351]. Moreover, in large genome-wide studies, the case/control design has been proved to 
be a more powerful tool of testing for association than a family-based method [352]. 
Therefore, this analysis of association between MYP regions and high myopia could have 
been more beneficial if performed in a case/control dataset rather than in families.
5.5 Conclusion
This study failed to find a significant relationship between high myopia and SNPs in 12 
MYP intervals, most probably due to the lack of statistical power and poor genome 
coverage of the SNP panel.
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CHAPTER VI.
ASSOCIA HON BETWEEN HIGH MYOPIA AND
COLLA GEN GENES
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6.1 Introduction
The human eye contains a wide diversity of connective tissues, including the cornea, 
sclera, trabecular meshwork and vitreous, that function in a coordinated manner to ensure 
clear vision [353]. Genetic disorders involving connective tissues generally have a 
profound effect on the eye: such conditions as Marfan or Stickler syndromes have severe 
myopia as a consistent phenotype. It is, therefore, anticipated that abnormalities of the 
eye’s connective tissue will result in impaired vision.
The connective tissues of the eye consist mostly o f a collagenous extracellular matrix 
(ECM) network, the major part o f which is composed of bundles of collagen fibres, 
surrounded by a complex matrix of proteoglycans and glycoproteins [354]. The lamellar 
collagen fibril bundlesare secreted and maintained by so-called fibroblast cells [354, 355]. 
Fibroblasts are thought to be able to differentiate to myofibroblasts through either stress or 
stimulation with signalling growth factors such as the cytokine transforming growth factor 
beta (TGFP) [356]. Facilitated by direct cell-matrix interactions, myofibroblasts are able 
to modify their surrounding ECM both by contraction and the production of collagen, 
proteoglycans and many other constituents and regulatory molecules [357].
As myopia is mostly due to the elongation of vitreous chamber of the eye (section 
1.2.1.2), in this chapter associations between variants in the major collagen types found in 
the sclera (COL1A1) and the vitreous (COL2A1) with high myopia were examined.
The relationship between the sclera and myopia is not clear. However, being significantly 
thinner in myopic than in non-myopic eyes, the sclera is considered to be an important 
component in myopic eye growth [355, 358-360]. Generally, loss of collagen and 
proteoglycans in ECM is thought to be responsible for myopic scleral thinning [358-360]. 
Studies examining scleral changes in myopia development highlight the altered expression 
of various fibrillar collagens (types I, III and V) [361-363]and the involvement of matrix- 
degrading enzymes (e.g. matrix metalloproteinases).
In sclera, collagen accounts for 80% of the dry weight, and is responsible for the strength 
and resilience of the tissue; 90% of the scleral collagen is of type I [364]. Animal studies 
have reported that mRNA expression of type 1 collagen in the sclera is reduced during
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myopia development [361, 365]. Moreover, mutations in the collagen type-I gene 
(COL1A1) that encodes alpha one chains have been reported in clinical conditions 
associated with myopia, such as type-I osteogenesis imperfecta and the Ehlers-Danlos 
syndrome [366]. COL1A1 is located on chromosome 17 and consists of 51 exons (Figure 
6.1). Its position within the MYP5 region further suggests a possible link with high 
myopia. In addition, significant association between two COL1A1 polymorphisms and 
myopia was found in a Japanese case/control study [205]. However, this initial positive 
finding failed to replicate in a different Japanese cohort and in a Chinese cohort [169, 
347].
The vitreous body plays an important role in emmetropization and, thus, in the 
development of myopia. There is a rapid increase of the length of the vitreous chamber 
during the first year of life up to the age of 3 years, followed by a comparatively slow 
increase from the age of 3 to 12 years [367].
The vitreous body consists of the vitreous cortex and the central vitreous. The vitreous 
cortex is a thin layer of dense collagen fibrils, running parallel to the retina and attached to 
its internal membrane. The major constituent o f the central vitreous (also known as 
vitreous humor) is water, although it exists in the form of gel. The pivotal role in 
maintaining this gel structure is played by a low concentration of collagen fibrils [368]. It 
has been proven that removal of these collagen fibrils results in the conversion of the gel 
into a viscous liquid [367]. Liquefaction o f vitreous gel, however, occurs physiologically 
during aging [369]. In patients with high myopia this process begins at younger age than 
in non-myopic eyes and progresses with axial elongation, thus, resulting in a frequent 
occurrence of posterior vitreous detachment and, consequently, can lead to blindness 
[370].
Collagen fibrils of the vitreous are mostly of type II [353] and polymorphisms in the 
collagen type two alpha one (COL2A1) gene have been found to be associated with low 
grade myopia in a Caucasian population [163]. In addition, COL2A1 mutations are 
associated with Stickler syndrome, a condition that has severe myopia as a consistent 
phenotype [371]. The COL2A1 gene is located on chromosome 12 and consists of 54
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exons (Figure 6.2).
In this chapter, replication of the previous significant association between COL1A1 and 
COL2A1 and high myopia was attempted in families and cases/controls recruited as part 
of the Family Study of Myopia. Analyses were performed by our group as well as by the 
research team of Prof. T.L. Young in Duke University (USA).
6.2 Materials and Methods
6.2.1 Subjects and DNA Samples
Subjects were recruited and DNA samples collected as described in sections 2.1 and 2.2.1. 
Apart from pedigrees with high myopia, unrelated cases and controls were also collected 
for these analyses. Whilst the ascertainment of pedigrees was carried out via 
optometrists/ophthalmologists throughout UK (section 2.1), cases and controls were 
recruited from the Cardiff University Eye Clinic’s database only.
Individuals with known syndromic disorders or a systemic condition that could predispose 
to myopia were excluded. All subjects were o f Caucasian ethnicity (self-reported “White 
Europeans”).
6.2.2 Selection and Genotyping of SNPs
Being a SNP replication study, the SNPs examined were those found to be associated with 
myopia in previous studies: rs2075555 and rs2269336 in COL1A1 [205]; rsl635529 in 
COL2A1 [163] and rs 1034762 and rs 1793933 in COL2A1 by the group of 
Prof.T.L.Young in Duke University (USA).
Diagrams of positions of the selected SNPs in COL1A1 and COL2A1 genes are shown in 
figures 6.1 and 6.2. SNP genotyping was carried out by Kbiosciences Ltd.
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6.2.3 Statistical Analyses
6.2.3.1 Hardy-Weinberg Equilibrium and Mendelian Consistency
The Pedstats package [340] was used to carry out an exact test for Hardy-Weinberg 
equilibrium (HWE) on unrelated subjects and to check for Mendelian consistency in 
pedigrees (section 2.3.3).
6.2.3.2 Association Analysis and Correction for Multiple Testing
Association analyses were carried out by two researchers: one from the group o f Prof. 
Terri L. Young in Duke University (USA) and myself at Cardiff University. Both teams 
analyzed the same cohort collected as a part o f The Family Study o f Myopia. Analyses 
completed in Duke University did not involve me.
Duke University Analysis: High myopia was examined as a dichotomous trait. Subjects 
with a spherical equivalent refractive error, averaged between eyes, of < -5.00 D were 
classified as affected [172]. All other subjects were classified as unaffected, while subjects 
whose refractive error was unobtainable were coded as unknown. The researcher in this 
group chose to perform the genetic analysis using PDT (Pedigree Disequilibrium Test 
[372]) and to analyze pedigrees only to avoid issues related to population stratification.
Cardiff University Analysis: High myopia was examined as a dichotomous trait. Subjects 
with a spherical equivalent refractive error, averaged between eyes, of < -6.00 D were 
classified as affected [339]. All other subjects were classified as unaffected, while subjects 
whose refractive error was unobtainable were coded as unknown. Due to the expected 
modest size of samples that comprises pedigrees only, I carried out association tests on a 
combined cohort of families and cases/controls using the Unphased genetic program 
(section 4.2.3.2).
A Bonferroni correction was applied to correct for multiple testing in the analyses of both 
groups. The correction was performed for 10 tests: 5 SNPs examined in families only and 
an additional 5 tests for the same SNPs performed in the combined dataset.
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Figure 6.1 COL1A1 gene position, structure, LD patterns and genotyped SNPs
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6.3 Results
6.3.1. Subjects and Genotyping
Genotyping o f SNPs had an average failure rate o f ~7.5 %. Genotyping concordance was 
assessed to be 99.38% based on 8 duplicate samples. Allele frequencies of the genotyped 
SNPs are shown in Table 6.1.
The Duke University researchers analyzed 130 multiplex families (582 individuals), while 
our group examined 164 families with high myopia (604 subjects) and an additional set of 
unrelated individuals, comprising o f 112 highly myopic cases and 114 “emmetropic” 
controls (spherical equivalent refractive error in both eyes > -1 .0 0 D  and <+1.00D ). 
(Note that the multiplex pedigrees analysed by both groups were largely identical — the 
difference in the number o f pedigrees/subjects examined differed only because of me 
choosing to include cases/controls as well as some additionally recruited pedigrees into 
my analysis.)
6.3.2 Association Analysis
All SNPs were Mendelian consistent and in HWE (Table 6.2).
Duke University Analysis: The PDT analysis performed in families-only by the Duke 
team revealed a significant association between rs 1635529 in COL2A1 and high myopia 
(Table 6.2). The initial p-value o f 0.0044 remained statistically significant at the 0.05 level 
after Bonferroni correction (p=0.044). There was no significant association between any 
of the COL 1A 1 SNPs and high myopia.
Cardiff University Analysis: In contrast to the significant PDT result of Prof. T.L. 
Young’s group, my analysis o f the joint family-plus-case/control sample, using the 
Unphased program, failed to show an association with high myopia and any SNP in either 
COL1A1 or COL2A1 (Table 6.3).
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Table 6.1 Allele frequencies o f  the genotyped SNPs in COL1A1 and COL2A1
Gene SNP Allele Frequency among 
founders in families
Frequency 
among cases
Frequency 
among controls
CO LlA l rs2075555 T 0.1321 0.1351 0.1538
G 0.8679 0.8649 0.8462
rs2269336 C 0.1215 0.1327 0.1415
G 0.8785 0.8673 0.8585
COL2A1 rs 1635529 T 0.1611 0.1589 0.1727
G 0.8389 0.8411 0.8273
rs 1034762 A
C
0.1722
0.8278
0.1500
0.8500
0.1698
0.8302
rs1793933 G 0.1770 0.1606 0.1847
T 0.8230 0.8394 0.8153
Table 6.2 Results o f the Replication Study between High Myopia and COL1A1 and 
COL2A1 polymorphisms performed by the group o f  Prof T.L. Young in Duke University 
(USA)
Gene SNP HWE p-value PDT p-value 
(corrected p-value)
CO LlA l rs2075555 0.4053 p>0.05
rs2269336 0.3916 p>0.05
COL2A1 rs 1635529 0.481 1 0.0044 (0.044)
rs 1034762 0.7247 0.0629
rs 1793933 0.4042 0.1175
Table 6.3 Results o f the Replication Study between High Myopia and COLlAl and 
COL2A1 polymorphisms performed by m yself All p-values are uncorrected.
Gene SNP HWE
p-value
Unphased p-value Odds
Ratio
95%
Confidence
Interval
C O LlA l rs2075555 0.4053 0.4067 0.88 0 .66-1 .18
rs2269336 0.3916 0.1022 1.29 0 .95-1 .75
COL2A1 rs 1635529 0.481 1 0.0640 0.76 0 .56-1 .02
rs 1034762 0.7247 0.2043 1.20 0 .90-1 .60
rs 1793933 0.4042 0.1521 1.22 0.93-1.61
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6.4 Discussion
The replication o f  previously established significant association of myopia with 
polymorphisms in the collagen genes C O LlA l and COL2A1 was attempted in a 
Caucasian cohort. The association was examined in families only (performed by 
researchers in the Human Genetic Centre at Duke University, USA), and in a combined 
sample of families and unrelated cases/controls (performed by m yself). Although the 
family-based analysis revealed a significant result for COL2A1, this was not confirmed in 
the combined dataset.
A likely explanation for the discrepant results is the different methods applied in these two 
analyses. The Duke University group examined families only and used the PDT program, 
while I analyzed families jointly with an additional case/control set o f subjects and used 
the Unphased program for the calculation of association statistics. Although it has been 
shown that PDT (Pedigree Disequilibrium Test) has approximately the same power as 
Unphased under the null hypothesis o f no association and in the presence of missing 
parental data [346], for a rare disease such as high myopia (prevalence ~ 2% in the 
European population), a trio-based design is sometimes more powerful than a case/control 
design [139], suggesting that examining families alone may be beneficial. In addition, I 
have used a different criterion for affectation status (more or equal to -6.0 Dioptres) 
compared to that o f  the team of Prof. T. Young (more or equal to -5.0 Dioptres). Because 
the analyses performed by me and by the Duke University group diverge at more than one 
point (number and type of participants, statistical software, affectation status threshold), it 
is difficult to pinpoint with certainty which one may be the reason for the observed 
opposition in these results.
The lack o f consistency in the results o f PDT and Unphased, suggests the possibility that 
the apparent COL2A1 replication, observed by the team of Duke University, may be a 
false positive result. According to the results I observed, the relative risk of the variant 
found significant by Duke group (rs 1635529) is 0.76 (Table 6.3) and its minor allele 
frequency among founders is 0.16 (Table 6.1), suggesting that at a 0.05 significance level, 
the respective analyses had ~67% power when performed by the Prof.T.L.Young’s team
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and -75%  power when performed by myself [373], Thus, a more powerful, larger sample 
size would be needed in order to confidently recognize a true association, if present.
Mutti and co-workers [163] established a significant association between rs 1635529 in 
COL2A1 and myopia. Their study comprised o f 123 families (517 individuals) and 
included subjects of varying ethnicity: Caucasian (62%), East Asian (13%), Hispanic 
(8%), African-American (7%), Indian/Pakistani (4%) and mixed or other ethnicity (6%). 
The group does not report an effect size for rs 1635529, but calculates the minor allele 
frequency among the founders of examined families to be 0.21. Assuming the same effect 
as estimated in our study, the power o f Mutti et al.’s analyses would be -65%  [373]. 
Although none of the analyses (performed on the families o f The Family Study of Myopia 
or on the families collected by Mutti et al) have power of -80%  or more, the power of the 
test carried out by our group is 10% greater than that o f Mutti et al’s.
It is also important to point out that Mutti et al. established a positive relationship between 
COL2A1 and short-sightedness using an analysis model with myopia classified as < -0.75 
D, suggesting that COL2A1 is linked to common myopia rather than to high myopia. The 
present study defined myopia as < -5.00 D (Prof.T.L.Young’s group) or as < -6.00D (our 
group) and, thus, concentrated on a different phenotype. Therefore, this would not 
constitute true replication in a strict sense, because the phenotypes concerned were not 
identical.
Considering the arguments above, it is presumable that COL2A1 is associated with lower 
degrees of myopia; and/or the study o f Mutti et al [163] suffers from a small power 
relative to that carried out here. In addition, because o f the negative replication in the joint 
family and case/control analysis performed by our group, it is difficult to state 
conclusively that this replication was successful.
Another collagen gene examined in this study was C O L lA l. Variants genotyped in this 
gene showed no significant association with high myopia independently o f whether the 
team of Prof. Young or I performed the test (Tables 6.2 and 6.3). One of the explanations 
for this negative result could have been an ethnicity difference: the original report of
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significant association between two C O LlA l SNPs and high myopia was found in the 
Japanese population [205], while we examined subjects of Caucasian background. SNPs 
which would be in strong LD with a disease-causing polymorphism in the COLlAl gene 
in Japanese subjects would not necessarily be in strong LD with the disease-causing 
polymorphism in Caucasian subjects, due to the differing LD structure of COLlAl in the 
two races (Figure 6.1). This racial difference in LD structure may also have been 
responsible for the significantly different minor allele frequencies (in Japanese versus 
Caucasian subjects) of the two SNPs that were originally implicated as disease causing 
(p=0.004 for rs2075555 and p=0.0004 for rs2269336; Fisher’s test) as shown in Table 6.4. 
Thus, it was not entirely surprising that assessing the same genetic variants in these two 
different ethnic groups led to different results. Instead o f a strict SNP replication study, a 
more thorough analysis of the C O LlA l gene, such as with tag SNPs chosen based on the 
LD pattern of the Caucasian population, would have been an option, which would have 
overcome this potential problem. Flowever, the large size o f the COLlAl gene precluded 
this, as it would have been prohibitively expensive.
Comparing the genotype relative risks o f the two significant SNPs (rs2075555 and 
rs2269336) of the Japanese study [205] and this one, rs2075555 has a slightly smaller 
effect (1.14 versus 1.30 in Japanese) in the results of our group, while rs2269336 has 
approximately the same odds ratio o f 1.30 in both studies. The Japanese analysis involved 
660 subjects in total (330 cases and 330 controls), while the test performed by our team 
was carried out on 830 participants (604 individuals in families, 112 cases and 114 
controls). Given, that the relative risk o f two examined SNPs is similar in two populations, 
it may be that the Japanese significant result established with a smaller sample size does 
not reflect a true association, but a type I error. This assumption is supported by two other, 
independent studies in the literature [169, 347] that also failed to replicate the original 
finding of association between C O LlA l and high myopia. Moreover, both of these 
negative replications were carried out on Asian population: one o f them [347] involved 
Japanese participants (847 unrelated individuals) like the initial, positive test of Inamori et 
al [205]; and the other comprised of 1094 Han Chinese cases and controls [169].
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Table 6.4 Allele Frequencies o f  C O LlA l polymorphisms in Japanese (JPT) and 
Caucasian (CEU) populations o f  HapMap
SNP Allele Frequency
JPT CEU
rs2075555 T 0.367 0.183
G 0.633 0.817
rs2269336 G 0.393 0.164
C 0.607 0.836
Despite substantial research, contradictory results in genetic association analyses of 
candidate genes for such common, complex diseases as myopia are not rare. Explanations 
for this are the difficulty in recruiting very large sample sizes and poor genomic coverage. 
With modem whole-genome association studies examining a large number of SNPs, the 
later disadvantage can be overcome. However, from a set of hundreds of thousands of 
tests, many highly significant results are expected by chance alone, making it hard to 
distinguish a true signal from noise. This latter problem can only be solved by increases in 
sample size: fortunately, maintaining the same power when performing an exponentially 
larger number of Bonferroni-corrected tests requires only a linear increase in sample size. 
For example, if 500 individuals are needed to test a single SNP with an adequate power, 
then -2,000 subjects would be suitable for testing 500,000 SNPs even after Bonferroni 
correction [260].
6.5 Conclusion
This study revealed a suggestive relationship between COL2A1 and high myopia. 
However, further, statistically more powerful analyses are needed to confirm this finding 
as a true positive association.
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CHAPTER VII.
A TEST OF IMPRINTING IN HIGHLY MYOPIC
CASE-PARENT TRIOS
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7.1. Introduction
A gene is imprinted when its level o f expression is dependent on the sex of the parent 
from whom it was inherited (section 1.3.1.3). Such gene expression contributes to 
resemblance between siblings as well as between parents and offspring [374], introducing 
a sex-specific element to the genetic mechanism of complex disorders.
The correlation of refractive error between relatives in families with high myopia has been 
well established [323, 375-377]. The between-sibling correlation has been estimated to 
vary from 0.31 [375] to 0.77 [376] in different populations. In addition, sister-sister 
correlation proved to be stronger than brother-brother or brother-sister correlations [323, 
377], suggesting a potential sex (parent-of-origin) effect on refractive error. This effect is 
also supported by the observation that a female child tends to mirror the refractive error of 
her mother, while a male child mirrors the refractive error of his father [378].
In this study the possible effect of imprinting was examined in highly myopic offspring 
and their parents.
7.2 Materials and Methods
7.2.1 Subjects and DNA Samples
Trios (an offspring and its two parents) were selected from the families collected within 
The International Myopia Consortium (section 5.2.1). Complex families were reduced to 
trios in two steps: (1) first smaller, nuclear families with both parents genotyped were 
chosen; and then (2) one of the affected offspring from each family was randomly selected 
to form a trio. Only trios that had no missing data (both parents were available for 
recruitment) and had a highly myopic offspring were included in the analyses.
7.2.2 SNP selection and Genotyping
As described previously (section 5.2.2), a panel of SNPs was genotyped using the Illumina 
Linkage Panel IVb bead array system (http://www.illumina.com/ pages.ilmn?ID-l91),
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completed by the Center for Inherited Disease Research (CIDR; 
http://www.cidr.ihmi.edu/). From the approximately 6000 SNPs genotyped by CIDR, 
SNPs for the present analysis were selected in two stages: firstly, SNPs related to genes 
within established MYP regions were short listed (as described in section 5.2.2 and shown 
in Table 5.1); and secondly, SNPs with any missing genotype calls were excluded (this 
was done because the software used to perform the test of imprinting effect can not handle 
any missing data).
7.2.3 Statistical Analysis 
7.2.3.1 Hardy-Weinberg Equilibrium and Mendelian Consistency
The Pedstats package [340] was used to carry out an exact test for Hardy-Weinberg 
equilibrium (HWE) on unrelated subjects and to check for Mendelian consistency in 
pedigrees (section 2.3.3).
7.2.3.2 Test of Imprinting (TRIMM) and Correction for Multiple Testing
High myopia was examined as a dichotomous trait. Subjects with a spherical equivalent 
refractive error, averaged between eyes, of < -6.00 D were classified as affected [339]. All 
other subjects were classified as unaffected, while subjects whose refractive error was 
unobtainable were coded as unknown.
The analyses were performed with the TRIMM package. This software was developed for 
testing for parent-of-origin effects in case-parent trios [379]. TRIMM first examines the 
transmission of alleles from parents to offspring by constructing, for each trio, a so-called 
“complementary sibling” who carries the two alleles not transmitted to the (real) affected 
child. It then computes a “difference vector” between the alleles transmitted to the 
affected offspring cases and to the complementary siblings. Under the null hypothesis that 
the set of markers is not associated with disease status within families, the genotype 
distributions of cases and their complements are the same, and, consequently, the expected 
value of the difference vector is zero. (Thus, this first step assesses transmission distortion,
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reflecting the intuition that any set o f alleles jointly related to risk will have been 
transmitted to the affected offspring more often than to the complement). The test 
computes a z-statistic (the value o f a vector divided by its standard error) for each SNP in 
turn and identifies the maximum z-score (“Z m a x ”) across all examined loci. The 
statistical significance is assessed using the permutation distribution of squared Z max 
over random re-assignments of the labels “case” and “complement”. In addition to z- 
statistics, a so-called T2 -  statistic is also calculated. The latter is used to exploit the 
correlation structure produced by LD and is expected to be beneficial when the causative 
SNP is not genotyped or, alternatively, the increased susceptibility is due to a particular 
set of SNPs. Statistical significance is assessed using the permutation distribution of T2.
As a result o f the first step, TRIMM produces two p-values for the possible transmission 
disequilibrium (Z max and T -  statistic) and, thereby, identifies a set of SNPs transmitted 
from parents to offspring that potentially could play a role in susceptibility to the 
examined phenotype. Under the default settings, TRIMM assumes that SNPs are 
“potentially” over- or under-transmitted if the Z max p-value is less than 0.1.
For its second step, TRIMM examines if there is a parent-of-origin effect. This is achieved 
by calculating another difference vector: in this case, the “SNP-count difference” between 
mothers and fathers. Assuming that one of the parental (maternal or paternal) alleles alone 
conferred the risk, then one of the parents would be more likely than the other to carry that 
risk allele, producing an asymmetry in maternal and paternal SNP-allele counts. Similarly, 
Z-statistic calculation and permutation testing is applied to nominate a parental set o f risk 
SNPs for effects mediated through each parent. Before performing these calculations, 
however, the trios are stratified into two groups: one group consisting of trios whose 
offspring possess the set of risk alleles identified in TRIMM’s first step, and another 
group who do not. The reason for this is that, if imprinting were present, the parents of 
possible carriers should show a SNP-allele count difference for that set of risk alleles, 
whereas parents of the definite non-carriers should not [379].
Figure 7.1 represents the two steps of TRIMM’s algorithm.
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Figure 7.1 Schematic Representation o f TRIMM's Algorithm
Consider biallelic SNP with alleles 1 and 2. The four trios represent some possible 
combinations of genotypes for such SNP.
Stage One Analysis: Transmission distortion test performed on the offspring, resulting in 
the identification of the set of “offspring risk alleles”. The difference vector D for this 
stage is calculated as 2C-(M+F), where C, M and F are the number of copies of designated 
allele at the SNP examined. This figure shows D vectors for each trio assuming allele 1 is 
the analyzed one. Z-statistic is determined as Davcragc/SE, where Daverage is the average D 
among informative families (the D vector is not zero) and SE is the corresponding 
standard error.
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Figure 7.1 Schematic Representation o f  TRIMM’s Algorithm (Continuation)
Stage Two Analysis: Test for SNP-allele counts in parents, resulting in the nomination of 
the set of “parental risk alleles”. The difference vector D for this stage is calculated as M- 
F, where M and F are the same counts as in the stage one analysis. Trios are stratified 
according to whether the child possesses at least one copy of each nominated “offspring 
risk alleles” or not, creating a risk group and a non-risk group. Assuming that allele 1 of 
the SNP represented in this figure is nominated as the “offspring risk allele”, risk group 
would consist of trios 2 and 4, while non-risk group would be trios 1 and 5. If the parental 
test of this stage is significant in the risk group only, the data supports a parent-of-origin 
effect. If, however, the test is significant in both groups, the data supports the presence of 
a maternal effect rather than a parent-of-origin effect.
Non-risk Group Risk group
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7.3 Results
7.3.1 Subjects and Genotyping
The initial collection o f pedigrees ascertained by the International Myopia Genetics 
Consortium comprised 1462 subjects. After the exclusion of subjects for whom 
phenotypic and/or parental data was not available, and of pedigrees that were not 
Mendelian consistent, there were 771 individuals in 264 pedigrees (section 5.3.1). An 
additional 498 participants were excluded as a result of (1) pedigrees being trimmed to 
trios; (2) trios not having an affected child; and (3) both parents not having been 
genotyped. Finally, 91 trios (273 subjects) were included in the dataset selected for 
TRIMM analysis.
As described in Chapter 5 (section 5.3.2), o f the -6000 SNPs genotyped in the Illumina 
panel, 140 SNPs were information with respect to genes within myopia MYP regions, 
passed the HWE quality control test (p>0.05) and were Mendelian consistent. Because 
TRIMM handles X-chromosome genotypes by stratifying the trios according to the sex of 
the offspring, SNPs on the X-chromosome were also excluded (because the small sample 
size would not allow enough power for such an analysis). In addition, as the T -statistic is 
not able to handle any missing data, SNPs with any failed genotypes were also excluded. 
This left 86 SNPs available for the TRIMM analyses.
7.3.2 Statistical Analyses
The first step of TRIMM showed little/borderline evidence of transmission distortion 
among affected offspring according to the Z max statistic (p=0.053), and proved to be 
even less convincing after performing the T2 — test (p=0.163). Nonetheless, individual tests 
of each SNP nominated a set of 6 “offspring risk SNPs” that potentially could confer an 
increased risk of high myopia (Table 7.1).
Trios were stratified according to whether the offspring carried at least one copy of the 
potential susceptibility allele o f each SNP in the “offspring risk set”. This resulted in 20 
trios being assigned to the “risk group” and the remaining 71 trios being assigned to the
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"‘non-risk group”. After performing the second TRIMM analysis step -  the test for a 
difference in SNP-allele count amongst parents -  the z-score statistic showed no evidence 
o f asymmetry in the “risk group” (p=0.256) but did suggest a significant result in the 
“non-risk group” (p=0.005). The T2 -  test, on the other hand, revealed a significant 
difference in both groups (p=0.035 in the risk group and p=0.012 in the non-risk group). 
TRIMM did not identify a “parental set o f  risk SNPs” for the risk group, since the overall 
z-statistic p-value did not reach the program’s threshold p-value of 0.1 (Table 7.2). In the 
non-risk group, however, TRIMM identified a set of 4 “parental risk SNPs” (Table 7.3). 
The 6 “offspring risk SNPs” nominated in step one and the 4 “parental risk SNPs” 
nominated in step two consisted o f different variants (i.e. there was no overlap in the list 
o f risk SNPs identified).
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Table 7.1 Test o f  Imprinting Results (Step One): Transmission Distortion to Affected
Offspring
SNP MYP
Region
Gene within 
which the 
chosen SNP is
Gene with which 
the chosen SNP is 
in high LD 
(r2-value)
MAF p-value
(z-statistic)
rs770238 MYP 2 LPIN2 None 0.325 0.920
rs 168206 MYP 2 DLGAP1 None 0.424 0.100
rs 1565728 MYP 3 E2F7 None 0.475 1.000
rs998070 MYP 3 NAV3 None 0.483 1.000
rs2404772 MYP 3 None CART1 (0.95) 
LRRIQ1 (1.00)
0.250 0.110
rs 1508595 MYP 3 None KITLG (1.00) 0.167 0.660
rs 1401982 MYP 3 ATP2B1 None 0.417 0.450
rs 1544921 MYP 3 CHPT1 SYCP3 (1.00) 
GNPTAB (1.00) 
FLJ11259 (0.88)
0.475 0.162
rs 1922438 MYP 3 RFX4 None 0.475 0.095 (1.793)
rs2873108 MYP 4 DPP6 None 0.161 0.268
rs306278 MYP 4 DPP6 None 0.450 0.326
rs2033108 MYP 5 None PCTP (1.00) 0.242 0.505
rs 1024819 MYP 5 MSI2 None 0.492 0.527
rs 1974692 MYP 5 MSI2 None 0.195 0.303
rsl 881441 MYP 5 CLTC None 0.117 1.000
rs 1557720 MYP 5 BRIP1 None 0.458 0.466
rs715494 MYP 6 AP1B1 EWSR1 (0.95) 
GAS2L1 (0.95)
0.367 0.934
rs714027 MYP 6 HORMAD2 None 0.433 0.661
rs4444 MYP 6 OSBP2 None 0.442 0.085 (-1.906)
rs762883 MYP 6 SYN3 None 0.400 0.578
rs9862 MYP 6 SYN3 None 0.467 0.380
rs739096 MYP 6 MYH9 None 0.458 0.671
rs2413411 MYP 6 CACNG2 None 0.325 0.705
rs760519 MYP 6 NCF4 FLJ90680 (0.94) 0.258 0.597
rsl 534880 MYP 6 CSF2RB None 0.492 0.157
rs4348874 MYP 7 PTPNS None 0.274 1.000
rs730348 MYP 7 NAV2 None 0.408 0.002 (3.764)
rsl 470251 MYP 7 NAV2 None 0.183 0.410
rsl 374719 MYP 7 SLC17A6 None 0.306 0.230
rs2928345 MYP 7 GAS2 None 0.192 0.830
rsl 491846 MYP 7 None KIF18A (0.81) 0.167 0.160
rsl 032090 MYP 7 METT5D1 None 0.375 0.740
rsl 564745 MYP 7 METT5D1 None 0.375 0.670
rs524373 MYP 7 None KCNA4 (1.00) 0.317 0.660
rs2273544 MYP 7 TPC11 LI None 0.280 0.610
rs373499 MYP 7 CSTF3 None 0.423 0.520
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Table 7.1 Test o f  Imprinting Results (Step One): Transmission Distortion to Affected
Offspring (Continuation)
SNP MYP
Region
Gene within 
which the 
chosen SNP is
Gene with which 
the chosen SNP is 
in high LD 
(r2 -value)
MAF p-value
(z-statistic)
rs765695 MYP 8 None C30RF58 (1.00) 0.442 0.140
rs723490 MYP 8 None C30RF58 (1.00) 0.460 0.140
rsl 027695 MYP 8 None ZIC4 (0.93) 0.494 0.250
rsl 920395 MYP 8 P2RY14 None 0.325 0.570
rs755763 MYP 8 MBNL1 None 0.25 0.710
rs701265 MYP 8 P2RY1 None 0.217 0.600
rs9438 MYP 8 DHX36DEAH None 0.350 0.900
rsl 025192 MYP 8 MME None 0.492 0.440
rs359573 MYP 8 None PLCH1 (1.00) 0.307 0.560
rs986963 MYP 8 KCNAB1 None 0.317 0.210
rsl 384542 MYP 8 FLJ16641 None 0.333 0.930
rs920417 MYP 8 None SLITRK3 (1.00) 0.458 0.707
rs953834 MYP 8 None GOLPH4 (1.00) 0.065 0.684
rs3863100 MYP 8 MDS1 None 0.075 0.869
rs905129 MYP 8 TNIK None 0.442 0.846
rsl 285082 MYP 8 FNDC313 None 0.458 0.815
rs2046718 MYP 8 NLGN1 None 0.308 0.910
rs753293 MYP 8 NAALADL2 None 0.267 0.094 (-1.879)
rsl 468924 MYP 8 KCNMB3 None 0.342 0.241
rs2049769 MYP 8 PEX5L None 0.200 0.727
rs l973738 MYP 8 KLHL6 None 0.375 1.000
rsl 401999 MYP 8 ABCC5 None 0.408 1.000
rs869417 MYP 8 ABCC5 None 0.408 0.895
rs4432622 MYP 8 VPS8 None 0.356 0.324
rs3332 MYP 8 VPS8 None 0.390 0.288
rsl837882 MYP 8 LIPH None 0.458 0.026 (2.372)
rs6808013 MYP 8 DGKG None 0.208 0.471
rsl 039559 MYP 9 TMEM156 None 0.458 0.177
rs974734 MYP 9 None TMEM156 
(1.00) 
KLHL5 (1.00)
0.500 0.151
rs2035383 MYP 9 APBB2 None 0.492 0.776
rs790142 MYP 9 APBB2 None 0.308 0.499
rsl 565114 MYP 9 ATP8A1 None 0.331 0.920
rsl 504491 MYP 9 None GABRG1 (1.00) 0.500 0.370
rs225160 MYP 9 None SPATA18 (1.00) 0.417 0.140
rs751266 MYP 9 FIP1L1 SCFD2 (1.00) 0.408 0.280
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Table 7.1 Test o f  Imprinting Results (Step One): Transmission Distortion to Affected
Offspring (Continuation)
SNP MYP
Region
Gene within 
which the 
chosen SNP is
Gene with which 
the chosen SNP is 
in high LD 
(r2-value)
MAF p-value
(z-statistic)
rs2538 MYP 9 None CLOCK (1.00) 0.300 0.290
rs899631 MYP 9 POLR2B IGFBP7 (1.00) 0.400 0.740
rsl 456860 MYP 9 LPHN3 None 0.308 0.830
rsl 879323 MYP 9 None SRD5A2L2
(1.00)
0.433 0.130
rsl 483720 MYP 9 SRD5A2L2 None 0.433 0.370
rsl 899130 MYP 9 None CENPC1 (1.00) 0.333 0.570
rsl560605 MYP 9 None SULT1B1 (1.00) 0.142 0.078 (-1.944)
rs2063749 MYP 9 None C40RF7 (1.00) 
CSN3 (1.00)
0.325 0.999
rs9131 MYP 9 MTHFD2L None 0.350 1.000
rs717239 MYP 9 FLJ25770 None 0.408 1.000
rs 1511817 MYP 9 SHROOM3 None 0.276 0.252
rsl 566485 MYP 9 SNOT6L None 0.425 0.150
rsl 3429 MYP 10 None C80RF42 (1.00) 0.417 1.000
rs935559 MYP 10 C80RF42 None 0.127 0.780
rs922798 MYP 10 CSMD1 None 0.433 0.920
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Table 7.2 Test o f  Imprinting Results (Step Two): SNP-allele count Asymmetry in Parents
in the Risk Group
SNP MYP
Region
Gene within 
which the 
chosen SNP 
is
Gene with 
which the 
chosen SNP is in 
high LD 
(r2 -value)
MAF p-value
(z-statistic)
rs770238 MYP 2 LP1N2 None 0.325 0.229
rsl 68206 MYP 2 DLGAP1 None 0.424 0.139
rs l565728 MYP 3 E2F7 None 0.475 0.054
rs998070 MYP 3 NAV3 None 0.483 0.219
rs2404772 MYP 3 None CART1 (0.95) 
LRRIQ1 (1.00)
0.250 1.000
rsl 508595 MYP 3 None KITLG (1.00) 0.167 0.780
rsl 401982 MYP 3 ATP2B1 None 0.417 0.007
rsl 544921 MYP 3 CHPT1 SYCP3 (1.00) 
GNPTAB (1.00) 
FLJ11259 (0.88)
0.475 1.000
rsl 922438 MYP 3 RFX4 None 0.475 0.450
rs2873108 MYP 4 DPP6 None 0.161 0.370
rs306278 MYP 4 DPP6 None 0.450 1.000
rs2033108 MYP 5 None PCTP(l.OO) 0.242 0.530
rsl 024819 MYP 5 MS12 None 0.492 0.510
rsl 974692 MYP 5 MSI2 None 0.195 0.630
rs 1881441 MYP 5 CLTC None 0.117 0.450
rsl 557720 MYP 5 BRIP1 None 0.458 0.410
rs715494 MYP 6 AP1B1 EWSR1 (0.95) 
GAS2L1 (0.95)
0.367 0.260
rs714027 MYP 6 HORMAD2 None 0.433 0.819
rs4444 MYP 6 OSBP2 None 0.442 0.092
rs762883 MYP 6 SYN3 None 0.400 1.000
rs9862 MYP 6 SYN3 None 0.467 1.000
rs739096 MYP 6 MYH9 None 0.458 1.000
rs2413411 MYP 6 CACNG2 None 0.325 0.826
rs760519 MYP 6 NCF4 FLJ90680 (0.94) 0.258 1.000
rsl 534880 MYP 6 CSF2RB None 0.492 1.000
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Table 7.2 Test o f  Imprinting Results (Step Two): SNP-allele count Asymmetry in Parents
in the Risk Group (Continuation)
SNP MYP
Region
Gene within 
which the 
chosen SNP is
Gene with which 
the chosen SNP is 
in high LD 
(r2-value)
MAF p-value
(z-statistic)
rs4348874 MYP 7 PTPNS None 0.274 1.000
rs730348 MYP 7 NAV2 None 0.408 0.229
rsl 470251 MYP 7 NAV2 None 0.183 0.600
rsl 374719 MYP 7 SLC17A6 None 0.306 1.000
rs2928345 MYP 7 GAS2 None 0.192 0.490
rsl 491846 MYP 7 None KIF18A (0.81) 0.167 1.000
rs l032090 MYP 7 METT5D1 None 0.375 1.000
rsl 564745 MYP 7 METT5D1 None 0.375 0.860
rs524373 MYP 7 None KCNA4 (1.00) 0.317 0.410
rs2273544 MYP 7 TPC11L1 None 0.280 0.820
rs373499 MYP 7 CSTF3 None 0.423 1.000
rsl 027695 MYP 8 None ZIC4 (0.93) 0.494 0.811
rs765695 MYP 8 None C30RF58 (1.00) 0.442 0.170
rs723490 MYP 8 None C30RF58 (1.00) 0.460 0.167
rs l920395 MYP 8 P2RY14 None 0.325 0.802
rs755763 MYP 8 MBNL1 None 0.25 0.283
rs701265 MYP 8 P2RY1 None 0.217 1.000
rs9438 MYP 8 DHX36DEAH None 0.350 1.000
rsl 025192 MYP 8 MME None 0.492 1.000
rs359573 MYP 8 None PLCH1 (1.00) 0.307 0.098
rs986963 MYP 8 KCNAB1 None 0.317 1.000
r s l384542 MYP 8 FLJ16641 None 0.333 0.046
rs920417 MYP 8 None SLITRK3 (1.00) 0.458 0.390
rs953834 MYP 8 None GOLPH4 (1.00) 0.065 1.000
rs3863100 MYP 8 MDS1 None 0.075 1.000
rs905129 MYP 8 TNIK None 0.442 0.170
rsl 285082 MYP 8 FNDC313 None 0.458 0.300
rs2046718 MYP 8 NLGN1 None 0.308 1.000
rs753293 MYP 8 NAALADL2 None 0.267 1.000
rsl 468924 MYP 8 KCNMB3 None 0.342 0.650
rs2049769 MYP 8 PEX5L None 0.200 1.000
rsl973738 MYP 8 KLHL6 None 0.375 0.350
rsl 401999 MYP 8 ABCC5 None 0.408 0.852
rs869417 MYP 8 ABCC5 None 0.408 0.852
rs4432622 MYP 8 VPS8 None 0.356 0.192
rs3332 MYP 8 VPS8 None 0.390 0.201
rsl 837882 MYP 8 LIPH None 0.458 1.000
rs6808013 MYP 8 DGKG None 0.208 1.000
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Table 7.2 Test o f  Imprinting Results (Step Two): SNP-allele count Asymmetry in Parents
in the Risk Group (Continuation)
SNP MYP
Region
Gene within 
which the 
chosen SNP is
Gene with which 
the chosen SNP is 
in high LD 
(r2-value)
MAF p-value
(z-statistic)
rsl 039559 MYP 9 TMEM156 None 0.458 0.116
rs974734 MYP 9 None TMEM156 
(1.00) 
KLHL5 (1.00)
0.500 0.042
rs2035383 MYP 9 APBB2 None 0.492 0.128
rs790142 MYP 9 APBB2 None 0.308 0.214
rsl 565114 MYP 9 ATP8A1 None 0.331 0.690
rsl 504491 MYP 9 None GABRG1 (1.00) 0.500 0.820
rs225160 MYP 9 None SPATA18 (1.00) 0.417 0.720
rs751266 MYP 9 FIP1L1 SCFD2 (1.00) 0.408 0.190
rs2538 MYP 9 None CLOCK (1.00) 0.300 1.000
rs899631 MYP 9 POLR2B IGFBP7 (1.00) 0.400 0.630
rsl 456860 MYP 9 LPHN3 None 0.308 0.770
rsl 879323 MYP 9 None SRD5A2L2
(1.00)
0.433 0.130
rsl 3429 MYP 10 None C80RF42 (1.00) 0.417 0.845
rs935559 MYP 10 C80RF42 None 0.127 1.000
rs922798 MYP 10 CSMD1 None 0.433 1.000
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Table 7.3 Test o f  Imprinting Results (Step Two): SNP-allele count Asymmetry in Parents
in the Non-Risk Group
SNP MYP
Region
Gene within 
which the 
chosen SNP is
Gene with which 
the chosen SNP is 
in high LD 
(r2-value)
MAF p-value
(z-statistic)
rs770238 MYP 2 LPIN2 None 0.325 0.192
rs 168206 MYP 2 DLGAP1 None 0.424 0.358
rs 1565728 MYP 3 E2F7 None 0.475 0.477
rs998070 MYP 3 NAV3 None 0.483 0.807
rs2404772 MYP 3 None CART1 (0.95) 
LRRIQ1 (1.00)
0.250 0.782
rs 1508595 MYP 3 None KITLG (1.00) 0.167 0.423
rs 1401982 MYP 3 ATP2B1 None 0.417 0.243
rs 1544921 MYP 3 CHPT1 SYCP3 (1.00) 
GNPTAB (1.00) 
FLJ11259 (0.88)
0.475 0.906
rs 1922438 MYP 3 RFX4 None 0.475 0.906
rs2873108 MYP 4 DPP6 None 0.161 0.642
rs306278 MYP 4 DPP6 None 0.450 0.617
rs2033108 MYP 5 None PCTP (1.00) 0.242 0.661
rs 1024819 MYP 5 MSI2 None 0.492 0.640
rs 1974692 MYP 5 MSI2 None 0.195 0.764
rs 1881441 MYP 5 CLTC None 0.117 1.000
r s l557720 MYP 5 BRIP1 None 0.458 0.188
rs715494 MYP 6 AP1B1 EWSR1 (0.95) 
GAS2L1 (0.95)
0.367 0.001 (5.054)
0.660
rs714027 MYP 6 HORMAD2 None 0.433 0.300
rs4444 MYP 6 OSBP2 None 0.442 1.000
rs762883 MYP 6 SYN3 None 0.400 0.910
rs9862 MYP 6 SYN3 None 0.467 0.200
rs739096 MYP 6 MYH9 None 0.458 0.790
rs2413411 MYP 6 CACNG2 None 0.325 0.880
rs760519 MYP 6 NCF4 FLJ90680 (0.94) 0.258 0.130
rsl 534880 MYP 6 CSF2RB None 0.492
rs4348874 MYP 7 PTPNS None 0.274 0.770
rs730348 MYP 7 NAV2 None 0.408 0.520
rsl 470251 MYP 7 NAV2 None 0.183 0.550
rsl 374719 MYP 7 SLC17A6 None 0.306 0.590
rs2928345 MYP 7 GAS2 None 0.192 1.000
rsl 491846 MYP 7 None KIF18A (0.81) 0.167 0.870
rsl 032090 MYP 7 METT5D1 None 0.375 0.280
rs l564745 MYP 7 METT5D1 None 0.375 0.280
rs524373 MYP 7 None KCNA4 (1.00) 0.317 0.220
rs2273544 MYP 7 TPC11L1 None 0.280 1.000
rs373499 MYP 7 CSTF3 None 0.423 0.220
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Table 7.3 Test o f  Imprinting Results (Step Two): SNP-allele count Asymmetry in Parents
in the Non-Risk Group (Continuation)
SNP MYP
Region
Gene within 
which the 
chosen SNP is
Gene with which 
the chosen SNP is 
in high LD 
(r2 -value)
MAF p-value
(z-statistic)
rs765695 MYP 8 None C30RF58 (1.00) 0.442 0.420
rs723490 MYP 8 None C30RF58 (1.00) 0.460 0.424
rsl027695 MYP 8 None ZIC4 (0.93) 0.494 0.021 (2.681)
rsl 920395 MYP 8 P2RY14 None 0.325 0.291
rs755763 MYP 8 MBNL1 None 0.25 0.488
rs701265 MYP 8 P2RY1 None 0.217 0.866
rs9438 MYP 8 DHX36DEAH None 0.350 0.727
rsl 025192 MYP 8 MME None 0.492 0.355
rs359573 MYP 8 None PLCH1 (1.00) 0.307 0.893
rs986963 MYP 8 KCNAB1 None 0.317 0.369
rsl 384542 MYP 8 FLJ16641 None 0.333 0.338
rs920417 MYP 8 None SLITRK3 (1.00) 0.458 0.901
rs953834 MYP 8 None GOLPH4 (1.00) 0.065 0.674
rs3863100 MYP 8 MDS1 None 0.075 0.488
rs905129 MYP 8 TNIK None 0.442 0.039 (2.218)
rsl 285082 MYP 8 FNDC313 None 0.458 0.844
rs2046718 MYP 8 NLGN1 None 0.308 1.000
rs753293 MYP 8 NAALADL2 None 0.267 0.413
rsl 468924 MYP 8 KCNMB3 None 0.342 0.595
rs2049769 MYP 8 PEX5L None 0.200 0.008 (3.090)
rsl 973738 MYP 8 KLHL6 None 0.375 0.246
rsl 401999 MYP 8 ABCC5 None 0.408 0.750
rs869417 MYP 8 ABCC5 None 0.408 0.920
rs4432622 MYP 8 VPS8 None 0.356 0.680
rs3332 MYP 8 VPS8 None 0.390 1.000
rsl 837882 MYP 8 LIPH None 0.458 0.910
rs6808013 MYP 8 DGKG None 0.208 1.000
rsl 039559 MYP 9 TMEM156 None 0.458 0.620
rs974734 MYP 9 None TMEM156 
(1.00) 
KLHL5 (1.00)
0.500 1.000
rs2035383 MYP 9 APBB2 None 0.492 0.520
rs790142 MYP 9 APBB2 None 0.308 0.150
rsl 565114 MYP 9 ATP8A1 None 0.331 1.000
rsl 504491 MYP 9 None GABRG1 (1.00) 0.500 0.270
rs225160 MYP 9 None SPATA18 (1.00) 0.417 0.820
rs751266 MYP 9 FIP1L1 SCFD2 (1.00) 0.408 0.800
rs2538 MYP 9 None CLOCK (1.00) 0.300 0.800
rs899631 MYP 9 POLR2B IGFBP7 (1.00) 0.400 1.000
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Table 7.3 Test o f  Imprinting Results (Step Two): SNP-allele count Asymmetry in Parents
in the Non-Risk Group (Continuation)
SNP MYP
Region
Gene within 
which the 
chosen SNP is
Gene with which 
the chosen SNP is 
in high LD 
(r2-value)
MAF p-value
(z-statistic)
rsl 456860 MYP 9 LPHN3 None 0.308 0.790
rsl 879323 MYP 9 None SRD5A2L2
(1.00)
0.433 0.810
rsl 483720 MYP 9 SRD5A2L2 None 0.433 1.000
rsl 899130 MYP 9 None CENPC1 (1.00) 0.333 0.290
rsl 560605 MYP 9 None SULT1B1 (1.00) 0.142 1.000
rs2063749 MYP 9 None C40RF7 (1.00) 
CSN3 (1.00)
0.325 0.780
rs9131 MYP 9 MTHFD2L None 0.350 1.000
rs717239 MYP 9 FLJ25770 None 0.408 0.920
rs 1511817 MYP 9 SHROOM3 None 0.276 0.680
rs l566485 MYP 9 SNOT6L None 0.425 0.690
rsl 3429 MYP 10 None C80RF42 (1.00) 0.417 0.518
rs935559 MYP 10 C80RF42 None 0.127 0.079 (2.017)
rs922798 MYP 10 CSMD1 None 0.433 0.476
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7.4 Discussion
The effect of imprinting was examined in 91 trios with highly myopic offspring. This 
resulted in identification of 6 “offspring risk SNPs” and 4 “parental risk SNPs”.
The first step of the TRIMM analysis addressed the issue o f transmission distortion to 
affected offspring. With a borderline significant result, this test nominated a set o f 6 
“offspring risk SNPs” (rs l922438, rs4444, rs730348, rs753293, r s l837882, r s l560605) 
situated on 5 different chromosomes (Table 7.1). Some alleles o f these SNPs were found 
to be over-transmitted (rsl922438, rs730348 and r s l837882), while others were under­
transmitted, i.e. protective (rs4444, rs753293 and r s l560605) (Table 7.1). This finding fits 
well with the assumption of myopia being a complex disease with several loci affecting its 
susceptibility (the common disease, common variant theory). It is indeed possible that the 
over-transmission as well as simultaneous under-transmission o f certain alleles would lead 
to myopia, explaining why the single candidate gene analyses carried out to date have 
been disappointing in identifying strong, reproducible genetic effects.
The second stage o f the analysis was a test for imprinting, which comprised o f two 
separate tests of SNP-count asymmetry among parents o f highly myopic offspring: one 
performed in the group of trios whose offspring carried at least one copy o f the set o f risk 
alleles identified in step one (the risk group) and another in the group of trios whose 
offspring did not carry the nominated susceptibility alleles (the non-risk group). In the 
presence of an imprinting (parent-of-origin) effect, this test was expected to be significant 
in the risk group [379]. The results o f this study, however, are equivocal, because the 
program produced two p-values for the overall test, one of which suggested statistical 
significance and the other which did not.
One of the calculated statistics, the z-score proved to be significant only in the non-risk 
group (p=0.005), showing no evidence (p=0.256) of SNP-count distortion in the parents of 
those offspring who carried at least one copy of the risk alleles identified in the first step 
of the study. One of the explanations for such a finding is that the nominated set o f SNPs 
is protective and not disease causing (thus, a parental effect showed up only in the group 
with the opposite alleles- namely, those in the non-risk group).
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Another explanation would be that there is a maternal effect rather than an imprinting 
effect. Maternal effects arise when the genetic and environmental characteristics o f the 
mother influence the phenotype of her offspring, beyond the direct inheritance o f alleles 
[374]. The mother plays crucial role not only as genetic parent, but also as a fetal 
environment. A maternal allele may, for example, damage a fetus through effects on the 
intrauterine milieu, regardless of whether the allele is passed to the offspring or not [380]. 
In the case of the imprinting, however, an allele must be transmitted to the offspring in 
order for it to exert its effect in an offspring. Therefore, finding a significant effect in the 
non-risk group only, may suggest the presence of maternal influence because the offspring 
o f that group did not inherit the actual risk allele. In addition, the set of the “parental risk 
SNPs” identified as being “asymmetric” in parents differed from the set o f the “offspring 
risk SNPs”, again pointing towards a maternal effect, which is consistent with the absence 
of any transmission distortion to the affected offspring (in the case of imprinting the 
“offspring” and “parental” sets of risk SNPs should be identical or partly the same).
An additional test for SNP-allele count asymmetry in parents was also performed for the 
whole dataset without stratifying the trios. Reassuringly, this time both statistics (z-score 
and T2) showed a highly significant result (p=0.003 for z-score and p=0.006 for T2) and 
appointed a set of 8 “parental risk SNPs” (rs93559, rs770238, r s l401982, r s l557720, 
r s l384542, rs905129 and rs2049769). When comparing the 4 “parental risk SNPs” 
identified in the stratified analyses in the non-risk group (Table 7.3) and the 8 “parental 
risk SNPs” identified above, there were 3 SNPs common to both sets.
An asymmetry in SNP-counts between parents cannot by itself distinguish whether the 
mother or the father is responsible for the observed imbalance. However, because the only 
possible effect the father can have is via the genes he passes to the fetus (i.e. fetal effects) 
and there was no significant fetal effect (no transmission distortion) for the set of “parental 
risk SNPs”, the data suggest that the set of “parental risk SNPs” is over-represented in the 
mothers and, thus, is exerting an effect via a maternally-mediated genetic influence.
When T2-statistics were used to test for imprinting (instead of z-statistics) there was 
evidence of a parental SNP-allele count imbalance in both the risk group and the non-risk
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group, suggesting the presence o f a true imprinting (parent-of-origin) effect. Nonetheless, 
since the z-score revealed no statistical evidence in favour of such effect, it is difficult to 
confidently state that imprinting was present rather simply a maternal effect.
More generally, it should be noted that the present study was performed on a modestly 
sized sample and, thus, may have had insufficient power to detect imprinting (if present) 
with high confidence. In addition, a possible bias of selection might have been introduced 
because some trios included in these analyses were partial nuclear families from which an 
affected offspring was randomly chosen to form a trio with his/her parents, who in turn 
were selected based on their genotyping success as well as availability for recruitment.
The first step yielded a borderline significant set of “offspring risk SNPs”, which makes it 
difficult to decide between a true and a false positive result. It would be desirable to 
perform these analyses on a larger dataset, that hopefully could reveal a more significant, 
convincing set of risk SNPs, leading to a more clearer identification o the presence or 
absence of the parent-of-origin effects.
7.5 Conclusion
In summary, the performed test for imprinting revealed an ambiguous result, leading to 
uncertainty whether or not myopia is affected by parent-of-origin effects and/or by 
maternal effects. Further analyses on a larger sample size are needed to resolve this 
question.
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CHAPTER VIII.
GENERAL DISCUSSION AND FUTURE WORK
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8.1 General Discussion
This study focused on the exploration o f the genetic background of high myopia classified 
as equal or more severe than -6.00 D as this type of myopia threatens with permanent 
degradation of vision or even blindness.
All the analyses o f this study were carried out on families with high myopia and 
cases/controls collected within the Family Study of Myopia. DNA samples were obtained 
in the form of posted mouthwashes.
As the source o f DNA in this study was buccal cells, a series o f tests were performed to 
ensure that DNA scheduled for further analyses was o f good quality, to avoid unnecessary 
failure or false-positive genotyping. Firstly, the accuracy of human DNA quantification 
was assessed with four methods: spectrophotometry, fluorometry, gel electrophoresis and 
qPCR. Due to its specific primers, qPCR is the only approach that quantifies human DNA 
and, thus, it was considered as a reference in the experiment. In agreement with the 
literature, it was established that the traditional and most widely used method o f 
spectrophotometry overestimated the amount of the human DNA by approximately 33% 
(compared to qPCR), but that fluorometry had the potential to substitute for human- 
specific qPCR, provided that the DNA sample was not degraded and was primarily of 
human origin. Nonetheless, spectrophotometry proved to be the most reproducible 
measure with the smallest coefficient of variability and, unlike fluorometry, it provided a 
measure of DNA purity (A260M 280 ratio).
Further analyses performed on mouthwash-derived genetic material concerned the quality 
of DNA. The effect of lag time between mouthwash rinsing and the actual DNA extraction 
was examined, with regards to the quality o f the extracted DNA. Given that mouthwashes 
were collected by post and assuming that the maximum mailing delay would be 3 days, 
mouthwashes collected for this experiment were processed on the same day or within one, 
two or three days of the mouth rinse procedure. DNA quality was evaluated with qPCR 
(as it provides information on the amount of human DNA in a sample and on the 
amplification ability of DNA needed for genotyping) and with agarose gel electrophoresis 
(as it gives insight into the degradation state of the DNA). Although no obvious
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relationship between the amount o f lag time and the presence/absence of degradation was 
revealed, it was established that, statistically, there was no effect of lag time on the quality 
of DNA, suggesting that mailing is an acceptable form of collection of mouthwash buccal 
cells. This observation was in agreement with previously published results of no such 
relationship [298].
In addition to the effect of lag time (up to 3 days) between mouthwash rinse and DNA 
extraction, the quality of DNA derived from mouthwashes collected for the study was also 
assessed in 500 subjects (1000 mouthwashes, as each participant provided two samples). 
As in the previous experiment, the quality o f DNA was analyzed by gel electrophoresis 
and qPCR. To ensure that the quality o f DNA screened by these two techniques was good 
enough for successful genotyping, a selection o f those samples that proved to contain 
sufficient human DNA to provide robust amplification with qPCR and that were scored as 
non-degraded by gel electrophoresis were genotyped on an Illumina 6k Human bead array. 
A major finding from the experiment was that -10%  of DNA samples obtained from 
mouthwashes contained degraded DNA. Furthermore, there was an -3-fold increased risk 
o f DNA degradation in a participant’s second mouthwash sample, given DNA degradation 
in their first, suggesting that DNA degradation may be due to factors specific to an 
individual subject. This finding may help the planning of mouthwash collection for large 
genome-wide analyses to be more cost-effective as it can be assumed beforehand that 10% 
of the samples may not be intact.
The average number of SNPs that could be genotyped on an Illumina array for each 
subject was 99.7% of the total, and the reliability o f SNP genotyping “blind” duplicate 
mouthwash DNA samples was similarly high (>99.9% concordance). Nonetheless, it has 
to be mentioned that degraded samples were not sent out for genotyping and, thus, no 
comparison can be made between the genotyping success of “poor” and “good” quality of 
mouthwash-derived DNA.
Apart from investigating the quantity and quality o f DNA extracted from mouthwashes, I 
also examined myopia candidate genes: analyses were performed to test for association
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between myopia and polymorphisms in the myocilin gene (MYOC). the collagen type I 
alpha-1 gene (COL1A1). the collagen type II alpha-1 gene (COL2A1) and several genes 
located in MYP regions.
The myocilin gene is best known for its role in glaucoma (313, 314]. Genetic variants of 
MYOC'. however, have also been implicated in causing susceptibility to high myopia 
[214, 321]. I his study analyzed MYOC' jointly with the research group of Prof.
I .I .Young in Duke University (USA) and examined 250 nuclear families along with 1 12 
highly myopic cases and 1 14 emmetropic controls. There was no significant heterogeneity 
in allele frequencies o f genotyped variants between the families of USA and UK cohorts, 
or between founders o f the families and cases/controls. Therefore, the pooling of subjects 
was “safe" from population stratification.
In contrast to the significant association between MYOC gene polymorphisms and high 
myopia found in Asian populations [214. 3 2 1 j. the Duke-CardifT study suggested that 
there is no such relationship in subjects o f Caucasian origin. Apart from the ethnic 
difference, another appealing explanation for this discrepancy is the smaller sample size 
and. thus, power o f the studies examining Asian populations. Counter-intuitively, low- 
powered studies are more likely to give rise to false-positive associations than highly- 
powered ones, furthermore, the MYOC gene variants which confer an increased risk of 
open angle glaucoma are different from those that may increase susceptibility to myopia. 
In this respect, the association of MYOC polymorphisms with both conditions may be 
coincidental.
MYP regions are chromosomal intervals linked to myopia o f different grades and, 
consequently, genes within these loci are considered to be candidate genes for myopia 
susceptibility, following this assumption. SNPs within those genes were tested for 
association with high grade myopia. Previously, several attempts have been made to find 
such a relationship and some have reported significant findings [179, 195, 207J, but 
replication o f most o f these positive findings has failed [ 177, 185, 189, 193, 194, 199, 200, 
204. 206, 208], C ontinuing this line of disappointing replications, my study revealed no 
connection between the genes in MYP regions that were examined and high myopia.
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I here arc several factors which could have been responsible for the negative result: 
modest sample size (low power), poor genome coverage (only 140 SNPs were examined) 
and different ethnicity to that o f the original, positive studies (most o f significant 
associations were found in Asian populations).
1 xcessive elongation of the eye is thought to be responsible for myopia development. 
Ihus, collagen genes that occur in the eye's connective tissues (sclera and vitreous) were 
analyzed. Specific variants in the Collagen type I alpha-1 (COL1A1) and collagen type II 
alpha-1 (COI.2A1) genes have been found to confer an increased risk to high myopia 
(163. 205J. f urthermore, both genes are responsible for connective tissue syndromes 
(Marfan and Stickler syndromes) with high myopia as a consistent phenotype. 
Nonetheless, this study found no convincing association between high myopia and the 
variants in COLl A 1 or CO L2A 1 that were previously postulated to be myopia related.
Analysis o f COLl A 1 was performed on subjects of the same ethnicity as the original, 
positive study. The power of my study, however, was ~I0%  greater than that o f the one 
with significant findings by Mutti et al (163]. However, Mutti et al defined myopia as <- 
0.75 I), while my investigation concentrated on high myopia only, classified as < -6.00 D.
I hus. it is likely that COLl A 1 is associated with lower degrees of myopia, or that the 
study o f Mutti et al suffers from low power, which may have led to a false positive 
finding.
My analy sis o f the COL2A1 gene was performed on subjects o f different ethnicity to that 
o f the original, positive finding in a Japanese population [205] as the subjects examined 
here were o f C aucasian origin. According to HapMap, the two populations (Caucasian and 
Japanese) exhibit dissimilar LD patterns in COLl A 1. and the minor allele frequencies of 
the tested SNPs are significantly different. Aside from the discrepancies in ethnicities, the 
study o f Inamori et al. (205] had lower power that that o f the current study, suggesting 
that its positive finding may also represent a type I error. This assumption is supported by 
another two failed COLl A I replications in Asian populations 1169, 347].
In addition to the association analyses, this project examined the possibility of genetic 
imprinting in high myopia. It has already been observed that the correlation of retractive
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error between siblings, and between mothers and offspring. is high, suggesting that the 
expression of only one parental allele (known as imprinting) may be behind this similarity. 
Driven by this idea, parents with an affected offspring (trios) were tested for allele-count 
disequilibrium. The results o f this analysis did not convincingly support the presence of 
imprinting, but did show signs of a maternal effect. As the distinction between maternal 
efleets and imprinting effects can be subtle (if present at all) and the analyzed sample size 
was rather modest (91 trios), it is not possible to state conclusively whether this study 
revealed any imprinting or maternal efleet on high myopia, but the possibility is 
intriguing.
8.2 Future Work
The major drawback o f this study is the lack o f power due to the small sample size. I hus. 
one o f the most important tasks for the future work would be to collect more participants 
to be able to perform more powerful and. consequently, more conclusive analyses. When 
my research project began, sample sizes o f -100 cases and 100 controls were considered 
large enough to allow the identification o f susceptibility genes for complex disorders such 
as myopia. However, with the advent o f genome-wide association studies researches now 
have realized that most genetic effects caused by commonly-occurring risk alleles have a 
much lower impact than was initially assumed, e.g. most risk-conferring alleles increase 
the chances o f affectation by only -20% . Rather than sample sizes of a few hundred 
participants, subject cohorts of several thousands are required to detect such genetic 
effects.
Recruitment o f new subjects may target unrelated individuals (cases/controls) as well as 
families with highly myopic members. As it is still not clear whether association or 
linkage-like analyses would benefit myopia research best, collection of both types of 
subjects would be advantageous.
Another approach to increase the power of tests to dissect the genetic basis of high myopia 
would be to perform meta-analyses. I he International Myopia C onsortium has already
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analyses on the existing collection o f pedigrees.
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APPENDIX 1.
THE INFORMATION PACK FOR 
PROVISIONAL PARTICIPANTS OF THE 
FAMILY STUDY OF MYOPIA
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The information pack sent out to the provisional participants of The Family Study of 
Myopia consisted of the following:
1. Information sheet about the research project 
Information about the research project
We would like to invite you to take part in The Family Study of Myopia, a research 
project investigating the genetic factors that lead to the development of high myopia (also 
known as short-sightedness).
What is the purpose of the study?
The study is investigating how myopia is inherited from one generation to the next. Our 
aim is to discover the genes that make some people more likely to become short-sighted 
than others. This will help our understanding of why myopia occurs, and in the future may 
aid the development of treatments for the condition.
Why have I been chosen?
We are seeking the participation of families from across the U.K. and Ireland in which 
there are one or more individuals with high myopia. We are looking for the help of about 
200 such families in total.
Who is organising the study?
The study is organised by researchers from the Department of Optometry and Vision 
Sciences at Cardiff University and the Medical Genetics Department at the University of 
Wales College of Medicine. The research is funded by two eye research charities, the 
National Eye Research Centre and the College of Optometrists.
What would it involve if I take part?
• We would ask you to fill in a short questionnaire about your eyesight and your 
general health, and also to identify other members of your family who might be 
prepared to take part in the study (the more members of your family who are willing 
to take part in the study the better, even if these relatives are not short sighted 
themselves).
• To enable us to trace myopia genes in your family, we would ask you to provide two 
mouthwash samples. These mouthwashes are easily done by swishing some saline 
around in your mouth for 30 seconds. The equipment and instructions will be posted 
to you if you agree to take part. We can assure you that these samples will only be 
used for studying myopia genes, and that all samples will be coded in order to protect 
your anonymity
• We would ask for your permission to contact your Optometrist/Optician for details of 
your spectacle or contact lens prescription and your ocular health.
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Will my confidentiality be maintained?
We take great care to ensure that the confidentiality of participating families is 
maintained. All personal details are kept securely, and the findings from this research will 
not identify individuals.
How do I participate?
If you would like to take part, please fill in the enclosed questionnaire and consent form 
and return them to us in the Freepost envelope provided. We will contact you with details 
about the mouthwash samples at a later date.
Contact for further information
If you have any further questions then we would be very happy to answer them either by 
telephone on 029 20875063, by post at the address overleaf or via email at 
myopia@cardiff.ac. uk.
Many thanks,
The Family Study of Myopia
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2. Consent Form
Consent Form for the Family Study o f Myopia Please tick boxes
I agree that my Optometrist/Optician can be contacted for further details about 
my eyes and health.
□
I agree that other members of my family may be asked to take part in this study.
I agree to provide mouthwash samples, which will be used to trace the passage 
of myopia genes through my family.
I have been given an information sheet and have been given an opportunity to 
discuss the research.
□
□
□
I understand that my participation is voluntary and that I am free to withdraw at 
any time without my legal rights being affected.
I agree to take part in this study.
□
□
Name Date Signature
Name of parent/guardian 
(if applicable)
Date Signature
Researcher’s name Date Signature
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3. Study Questionnaire
Study Questionnaire
Title □  Mr. □  Mrs. G Ms. □  Miss □  Other (Please specify)
Surname ...........................................................................................
First names ............................................................................................
Date of birth ............................................................................................
Address ...........................................................................................
Tel. Number ..............................................................................
Please tick the box which you feel best describes your ethnic group:
□  White European
□  Other European
□  African
□  Asian
□  American
□  Afro-Caribbean
□  Australasian
□  Other (please specify)
1. At what age did you begin to wear spectacles?
................... Yrs
2. Did you have any eye condition or eye disease at birth or in childhood?
Yes □  No □  Don’t know □
If Yes, please give
details.......................................................................................................
3. Do you currently suffer from any eye condition or disease?
Yes □  No □  Don’t know □
If Yes, please give
details.......................................................................................................
4. Have you had any eye surgery?
Yes □  No □  Don’t know □
If Yes, please give
details.......................................................................................................
5. Do you take any medication for your eyes?
Yes □  No □  Don’t know □
If Yes, please give
details.......................................................................................................
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6. Were you bom prematurely?
Yes □  No □  Don’t know □
7. Do you take any medication for any other health condition?
Yes □  No □  Don’t know □
If Yes, please give
details...........................................................................................................................
Please supply the names and addresses of any relatives who you think might be willing to 
participate in the research project. The participation of relatives who are not short-sighted 
is just as valuable as those that are. Similarly, the participation of your spouse would be 
very helpful, if appropriate.
Title □  Mr. □  Mrs. □  Ms. □  Miss □  Other (Please specify)
Surname ....................................................................................................
First names ...........................................................................................
Date of birth ...........................................................................................
Address ....................................................................................................
Tel. number ...................................................................................................
Is this relative short-sighted? □  Yes □  No □  Don’t know
Please indicate their relationship to you:
□  Sister □  Brother □  Mother □  Father □  Daughter □  Son
□  Uncle □  Aunt □  Husband □  Wife □  Grandfather
□  Grandmother
□  Other (please specify):..................................................................
Many thanks for your help
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THE PROTOCOL FOR D N A EXTRACTION  
FROM MOUTHWASHES
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PROTOCOL FOR DNA EXRACTION -  PROTEINASE K FOR BUCCAL CELLS
Proteinase K solution: 1 x proteinase K buffer
10 mM Tris-HCL, pH 8.0 
1 mM EDTA
0.5 % SDS
0.5 mg/ml proteinase K
1. Refrigerate mouthwashes (—15 ml) for at least 30 min, then centrifuge at 3500 rpm for 5 
min.
2. Pour off the supernatant - ensuring you do not lose the pellet of buccal cells.
3. Add 380 pi 1 x Proteinase K buffer solution using a filter pipette tip. Pipette up-and-down to 
resuspend the cells, and transfer to a labelled 1.5 ml screw-cap vial. Freeze at -20°C until ready 
to process further.
4. Remove samples from freezer, thaw at 37°C, mix and spin.
5. Add 20 pi Proteinase K 10 mg/ml to each tube and incubate at 37°C for 2 hours, in a 
waterbath with continuous shaking (-100 rpm).
6. Centrifuge at 14000 rpm x 3 min to pellet insoluble material and transfer supernatant to a
I.5 ml silicon grease Eppendorf tube (use a syringe to instil -100 pi silicon grease into a 1.5 
Eppendorf tube, just underneath the hinge; centrifuge at 3000 rpm for 4 seconds with the hinge 
pointing outwards, to create a smear of grease down the side of the tube).
7. Add 470 pi of phenol/chlorophorm to the sample (phenolxhlorophomv.isoamyl alcohol -  
25:24:1) and vortex vigorously for 30 seconds. Then centrifuge at 14000 rpm for 2 mintues.
9. If debris remains in the supernatant, transfer it to the second 1.5 ml silicon grease Eppendorf 
tube and repeat the phenol-chlorophorm extraction (steps 7-8).
10. When no debris remains in the supernatant, transfer it to a 1.5 ml screw-cap vial and add 
19 pi of 5M NaCl. Mix and spin.
II. Add 1 ml of 100 % ethanol. Mix and spin. Then leave to precipitate at -20°C overnight.
13. Remove samples from freezer, invert a few times to mix, and then centrifuge at 14000 rpm 
for 10 minutes.
14. Discard the supernatant and add 1 ml of ice cold 70 % ethanol. Centrifuge at 14000 rpm 
for 2 minutes.
15. Remove the majority of supernatant, then use a narrow pipette tip to remove the last traces 
of ethanol, taking care not to lose the pellet.
16. Air-dry the tube in an inverted position for 3 minutes.
17. Resuspend the pellet in 50 pi of TE and incubate for 15 minutes at 37°C with periodic 
gentle vortexing to ensure that the pellet is fully dissolved.
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